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Coeliac Disease 
History 
The first description of coeliac disease dates back to 1888, when Gee described a disease 
with onset usually between one and five years of age with diarrhoea, abdominal 
distension and failure to thrive as the most important symptoms.1 In 1908 Herter 
extended this description with delay in vertical growth.2 The cause of coeliac disease was 
unknown at that time, but by the end of the 1920’s it was generally agreed that the disease 
should be treated by rest and diet. Many diets have been recommended, from the banana 
diet, the carbohydrate diet (fruit, tomatoes and mashed potatoes), beefsteak therapy, and 
the milk diet (2-2.5 litres/day).3 But it was not until 1941 that the famous Dutch 
paediatrician Willem Dicke published his findings about the benefits of a wheat-free diet.4 
At that time, the banana diet and the fruit and vegetables diet were regarded as the best 
diets for treating coeliac disease. However, during World War II, bananas, fruit and 
vegetables were not easily available, but Dicke’s patients were doing well on a simple diet 
without bread or rusks. In his thesis, published in 1950, he describes the growth curves 
and symptoms of five children who clinically improved when wheat, rye and oats flour 
were omitted from their diet, and who relapsed when these flours were added to the diet 
again, thereby proving that components from these grains cause coeliac disease.5  
It is now well established that one of the major protein components of wheat, the 
storage proteins named gluten, are the toxic components that cause coeliac disease. 
Gluten proteins contain high percentages of glutamine and proline residues, hence the 
name “gluten”. Wheat gluten can be divided into two groups, the gliadins which are 
alcohol-soluble and the glutenins which are insoluble. Similar storage proteins are present 
in barley, rye and oats, and are called hordeins, secalins and avenins, respectively. Wheat 
is the most toxic for coeliac disease patients. Barley and rye, closely related in 
evolutionary terms, are also harmful but more distantly related grains like corn and rice 
are non-toxic.6 Oats are evolutionary categorised between these groups and have long 
been regarded as harmful. Recent studies however, have shown that oats can be tolerated 
well by coeliac disease patients, when they are not contaminated by gluten proteins from 
wheat, barley or rye.7 Coeliac disease is still treated with a life-long gluten-free diet, a diet 
without wheat, barley or rye products. 
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Clinical aspects 
Ingestion of gluten by coeliac disease patients results in lesions of the proximal small 
intestine. The range of abnormalities in the small intestinal mucosa can be classified 
according the modified Marsh classification.6 Marsh I comprises normal mucosal 
architecture with a marked infiltration of the villous epithelium by lymphocytes. Marsh II 
includes intraepithelial lymphocytosis and crypt hyperplasia with branching and 
elongation of crypts. And Marsh III comprises villous atrophy with lymphocytic 
infiltration of the epithelium and crypt hyperplasia. This category has been modified into 
three subtypes, with MIIIa representing partial, MIIIb subtotal and MIIIc total villous 
atrophy, respectively.8 Histological identification of the small-intestinal lesion by a biopsy 
of the duodenum is still the only accepted basis for diagnosing coeliac disease.9 However, 
in recent years, serological tests have become available to screen for this disorder. The 
best screening test available at the moment is the determination of anti-endomysium 
(Ema) IgA antibodies, with a high sensitivity (85-98%) and specificity (97-100%) in 
detecting untreated coeliac disease patients.9 A few years ago, the enzyme tissue 
transglutaminase (tTG) was identified as being the autoantigen recognized in the 
endomysium.10 The sensitivity of the anti-tTG IgA antibody test seems to be as high as 
that of the IgA-anti-endomysium antibody test (90-98%), but its specificity is slightly 
lower (94-97%).9 However, the sensitivity of both antibody tests was shown to be lower 
in patients with only partial villous atrophy.8,11 
 The clinical presentation of coeliac disease comprises a wide spectrum of 
symptoms, most of them related to malabsorption of nutrients from food.9 Typical 
symptoms of childhood coeliac disease include chronic diarrhoea, abdominal distension 
and a failure to thrive. However, the occurrence of the classic presentation of coeliac 
disease in infancy has decreased. Nowadays, children with coeliac disease may present at 
a later age with isolated short stature, recurrent abdominal pain or with delayed puberty. 
Recurrent aphthous lesions in the mouth, dental enamel defects, fatigue, isolated iron 
deficiency anaemia, or dermatitis herpetiformis, characterized by itching skin lesions, may 
also be manifestations of coeliac disease, both in children and adults. Moreover, infertility 
or recurrent abortions have been observed in women with coeliac disease. Severe 
complications, like osteoporosis, autoimmune disorders or intestinal malignancies, may 
occur in patients with untreated coeliac disease.12-15 Besides the paucisymptomatic 
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presentation of coeliac disease, some patients are even asymptomatic. Strict adherence to 
the gluten-free diet results in complete restoration of the small intestine and 
disappearance of the clinical symptoms. 
 In addition, coeliac disease is associated with other autoimmune disorders. Coeliac 
disease is diagnosed in ~4.5% of patients with type 1 diabetes mellitus.16 Moreover, an 
apparent association exists between thyroid disease and coeliac disease, as approximately 
5% of patients with autoimmune thyroiditis are found to be positive for coeliac disease 
after screening. Similarly, about 5% of patients with coeliac disease suffer from 
autoimmune thyroid disease.17 Coeliac disease also has an increased prevalence in patients 
with autoimmune liver diseases18 and certain chromosomal abnormalities like Down 
syndrome (3-17%)19-22 and in women with Turner syndrome (4-6%).23,24  
 
Epidemiology 
Coeliac disease occurs largely in Caucasians. Although the disease has been well 
documented in Asians from India25 and Turkey26, it is rare or nonexistent among native 
Africans, Japanese and Chinese. The disease is less common in men than in women, with 
a male to female ratio of 1:3. Up to only a few years ago, coeliac disease was thought to 
be rare; most patients were not recognized since they did not have the symptoms 
associated with classical coeliac disease. In the Netherlands, the incidence of recognized 
childhood coeliac disease has increased from 0.18/1000 live births in the period 1975-
1990, to 0.54/1000 live births in 1994.27 In 1998, two large population screenings were 
conducted in the Netherlands. Over 6000 children28 and 1000 blood donors29 were 
screened for the presence of Ema-antibodies. Coeliac disease was confirmed by small-
bowel biopsy in Ema-positive individuals. These studies revealed that the prevalence of 
coeliac disease is 1 in 200-300, which is much higher than was previously thought. 
Furthermore, it was estimated that for every child recognized with coeliac disease, 14 
affected children go unrecognized.28 The disease prevalence in the Netherlands is 
comparable with that seen in other European countries30-32, Australia33, South 
America34,35 and the USA.36 Coeliac disease is, with an average disease prevalence of 
approximately 0.4%, one of the most common forms of food intolerance in the world. 
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Genetics 
The development of coeliac disease is influenced by both genetic and environmental 
factors. It has long been known that coeliac disease runs in families. The sibling 
recurrence risk is approximately 10%.6,37-44 So, based on a population prevalence of 0.4%, 
the sibling relative risk (λs) for development of coeliac disease is 25. Evidence for a 
genetic contribution to coeliac disease was also shown by a recent twin study.45 Disease 
concordance rates for coeliac disease were 86% in monozygous (MZ) twins and 20% in 
dizygous (DZ) twins. Although the large difference between MZ twins and DZ twins 
indicates a strong genetic component in the development of coeliac disease, 
environmental factors are also of vital importance as can be concluded from the less than 
100% concordance rate in MZ twins. 
To date only one genetic factor involved in coeliac disease is known, namely the 
HLA-DQ protein. The HLA-DQ molecule consists of two different peptides, HLA-
DQα1 and HLA-DQβ1. These peptides are encoded by the highly polymorphic HLA-
DQA1 and HLA-DQB1 genes respectively, localized in the major histocompatibility 
complex (MHC) on chromosome region 6q21.3 (Figure 1a). The high degree of 
polymorphism in both genes and the combination of the two peptides in the heterodimer 
HLA-DQ result in a large number of possible different DQ molecules. This mechanism 
is used by the immune system to maximize the number of peptides that can be presented 
to the T cells. The HLA-DQ2 molecule, encoded by the HLA-DQA1*05 and HLA-
DQB1*02 alleles in either the cis or the trans configuration (Figure 1b), is expressed by 
more than 90% of coeliac disease patients. This is in strong contrast to the frequency of 
HLA-DQ2 carriers in the general population, which is 20-30%. Almost all coeliac disease 
patients carry the alleles encoding HLA-DQ2 on the extended HLA-B8-DR3-DQ2 
haplotype. This haplotype includes many other genes that play a role in the immune 
response and it cannot be excluded that another MHC gene also confers increased risk to 
coeliac disease development. Almost all the DQ2-negative coeliac disease patients carry 
the HLA-DQA1*0301 and HLA-DQB1*0302 alleles, which combine into the 
heterodimer HLA-DQ8.46  
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Figure 1. The MHC gene complex and HLA association in coeliac disease.  
a. Overview of the most important loci in the MHC complex. The MHC complex contains in total 224 
genes, of which 96 are pseudogenes. b. The HLA-DQ heterodimer is encoded by the DQA1 and DQB1 
genes. Coeliac disease is associated with HLA-DQ2, which is encoded by the HLA-DQA1*05 and HLA-
DQB1*02 alleles. These two alleles can be present either in cis on the DR3 haplotype or in trans on the 
DR5 and DR7 haplotypes. Both situations result in expression of the HLA-DQ2 molecule. 
 
Coeliac disease is a typical example of a multifactorial disorder, i.e. a disease caused 
by the combined action of several genes and environmental factors. The genetic 
predisposition cannot be derived from one single gene. There are several reasons to 
assume this. First, there is no Mendelian inheritance of the disease in families. 
Consequently, the recurrence risk of 10% is much lower than would be expected for a 
recessive or dominant disease (25% or 50%, respectively). Second, the frequency of 
HLA-DQ2 carriers in the population (20-30%) is much higher than the prevalence of 
coeliac disease (0.4%), implying that most HLA-DQ2 positive individuals do not develop 
coeliac disease. And third, the disease concordance rate between HLA identical siblings is 
approximately 30%,47 which is much lower than the 86% concordance rate in MZ twins. 
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Since the HLA identical siblings share at least part of their environment, this difference 
must be explained by the presence of other susceptibility genes.  
 
Environmental factors 
In addition to the genetic contribution, several non-genetic factors play a role in the 
aetiology of coeliac disease too. The most important environmental factor is gluten. 
When a coeliac disease patient does not ingest gluten, the disease process is absent and 
the gut of the patient is completely normal. The effect of gluten intake on coeliac disease 
development became clear from a recent study on incidence rates in Sweden.48 The 
annual incidence rate of coeliac disease was 50-60 cases per 100,000 person years in 
children under the age of two from 1973 to 1984. In the years from 1985 to 1987, this 
incidence increased dramatically to 200-240 cases per 100,000 person years. After 1995, 
the incidence dropped to the same level as before 1985. This sudden increase in coeliac 
disease incidence was thought to be caused in part by a higher intake of gluten during the 
years with high incidence rates, compared to the years with low incidence rates. In 
addition, at the end of 1982 the national recommendation for introduction of gluten at 
the age of 4 months was postponed to 6 months of age. In 1996, this recommendation 
was changed to introducing small amounts of gluten at 4 months, preferably while the 
child is still being breastfed. A new study was performed during the peak years of the 
Swedish coeliac disease epidemic.49 The risk of coeliac disease in children under two years 
of age was reduced when small amounts of gluten were introduced during the 
breastfeeding period. This risk was even smaller when breast-feeding was continued after 
introduction of gluten. A higher risk was observed when large amounts of gluten were 
introduced. These studies suggest that the amount of gluten consumption, breastfeeding 
habits and timing of gluten introduction can all influence the development of the disease.  
Although gluten is essential for the expression of coeliac disease, there must be 
other environmental factors that influence the development of the disease. The 14% 
discordance rate in MZ twins cannot be explained by the presence of gluten, as twins are 
likely to consume comparable diets. The identity of the other environmental factors is 
not known yet, but infections or the occurrence of other autoimmune diseases are 
thought to be able to trigger coeliac disease development. Furthermore, children born in 
the summer seem to have an increased risk for coeliac disease compared to children born 
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in other seasons.50 But before the environmental contribution to coeliac disease can be 
completely unravelled, the genetic contribution and the pathogenesis of the disease must 
be known. 
 
Pathogenesis 
In the last few years, great progress has been made in understanding the pathogenesis of 
coeliac disease. It has become clear that ingestion of gluten by coeliac disease patients 
results in an improper T cell mediated immune response. Gluten peptides are not 
completely digested by the enzymes of the stomach and small-intestinal brush border.51 
The partially digested gluten peptides cross the gut epithelium by an unknown 
mechanism and arrive in the lamina propria (Figure 2). These peptides are bound by 
HLA-DQ2 and DQ8 proteins on the cell surface of antigen presenting cells (APCs) and 
presented to the T cells in the lamina propia.52 Other HLA-DQ molecules have different 
binding motifs and are probably incapable of binding these peptides. Interaction between 
gluten peptides and HLA-DQ2 and DQ8 is greatly enhanced by the action of the enzyme 
tissue transglutaminase (tTG).53,54 This enzyme is expressed at the epithelial brush border 
and is also excreted in the subepithelial region in active coeliac disease.54 An important 
function of tTG is to catalyse protein cross linking by the formation of isopeptide bonds 
between lysine and glutamine residues, resulting in a dense protein network necessary for 
repair of tissue damage. Alternatively, the tTG enzyme specifically deamidates certain 
glutamine residues from gluten peptides into glutamic acid. This results in peptides which 
match perfectly to the binding motif of HLA-DQ2 and DQ8, because these molecules 
prefer negative charges in the bound peptides (i.e. glutamic acid).55 Recently, the 
specificity of tTG was elucidated.56 It was shown that the amino acid composition 
following the glutamine residues determines which of these residues will be converted to 
glutamic acid. From this pattern it could be predicted that glutamine residues from 
gluten-related peptides derived from oats would not be a target for tTG. This would 
explain the non-toxicity of oats for coeliac disease patients. 
  
 
General Introduction 
17 
Figure 2. Pathogenesis of coeliac disease.  
Gluten peptides are partially digested by the enzymes of the stomach and small-intestinal brush border. 
The gluten-derived peptides cross the epithelium of the gut and are deamidated by tissue transglutaminase 
(tTG). These deamidated gluten-derived peptides are presented to T cells by antigen presenting cells 
(APCs) via HLA-DQ2 or DQ8. 
 
Searching for susceptibility genes underlying multifactorial disorders 
The identification of genes that predispose to multifactorial diseases is hampered by 
multigenic inheritance and genetic heterogeneity.57 Multifactorial diseases are caused by 
variants in multiple genes. Certain combinations of these variants will lead to disease, but 
the variant by itself is not sufficient to cause the disease. Hence, these variants may occur 
frequently in the population, and many gene-carriers will not suffer from disease. 
Furthermore, identical phenotypes can arise that are caused by variants in different genes. 
This genetic heterogeneity implies that a certain gene variant causing disease in some 
patients may be absent in other patients. To complicate matters even more, allelic 
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heterogeneity must also be taken into account. Different variants in the same gene can 
cause the same phenotype. The HLA-DQ involvement in coeliac disease is a good 
example of this, since both DQ2 and DQ8 confer risk. All these considerations must be 
taken into account when searching for susceptibility genes in multifactorial diseases. 
There are two major approaches for finding these genes: linkage analysis and association 
studies.58 Both approaches are widely used and are discussed in more detail below. 
 
Linkage analysis 
Linkage analysis is used to localize susceptibility genes within the genome. In general, 
families with multiple patients are collected, and a genome-wide screen with microsatellite 
markers, evenly spaced on all chromosomes, is performed. Markers that co-segregate 
with the disease indicate the regions in the genome that contain disease susceptibility 
genes. Knowledge about the disease process is not required, which makes linkage analysis 
applicable for all inherited disorders and traits. For some disorders it is possible to make 
assumptions about the mode of inheritance of the disease. These disorders can be studied 
by parametric linkage analysis, in which a genetic model is defined based on disease 
segregation and recurrence risks in families. Parametric linkage analysis has been very 
successful in localizing genes causing monogenic disorders. By the end of 2001, 1336 
genes had been identified in which mutations cause a Mendelian disorder. In contrast, 
only seven genes involved in multifactorial diseases have been identified so far.57 In 
multifactorial diseases there is no Mendelian inheritance of the disease as multiple genes 
are involved. Each gene can act in a dominant, recessive or X-linked fashion but its mode 
of inheritance cannot be recognized in families. It is therefore not possible to define a 
genetic model for parametric linkage analysis. These disorders can be studied by non-
parametric linkage analysis, in which no assumptions are made about the mode of 
inheritance. This approach is based on allele sharing between affected individuals from 
one family. Regions with increased sharing of marker alleles identical-by-descent (IBD), 
when compared to the expected sharing based on the familial relationship between the 
patients, may contain the disease genes. Susceptibility genes for multifactorial diseases are 
most often mapped in affected sibling pairs (ASPs) because they are relatively easy to 
collect. Siblings already share 50% of their DNA on average, so that large numbers of 
ASPs are needed to detect linkage.59 For example, approximately 115 ASPs are needed to 
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detect with 90% probability a locus with a locus-specific λs of 2. But to detect loci with 
small effects, much larger sample sizes are required. In coeliac disease, with a total λs of 
20, there is a higher probability that some of the loci have moderate or strong effects (λs 
≥ 2), which reduces the number of ASPs needed to detect them. As well as ASPs, other 
affected relative pairs can also be used, except for the parent-child relations since they 
share 50% of their DNA by definition. 
Some practical considerations must be taken into account when designing a 
linkage study. Firstly, families with multiple affected individuals must be collected, which 
can be difficult. Also, when the patients attend different clinics, homogeneity in diagnosis 
must be ensured. Secondly, a whole genome screen comprises about 400 microsatellite 
markers, which must be available. Usually at least 100 ASPs are necessary to give a 
linkage analysis sufficient power to detect at least one locus, and parents or healthy 
siblings must also be included to determine whether the alleles are shared IBD. So, with 
one ASP comprising four individuals that have to be genotyped, at least 160,000 
genotypes have to be created for an initial screening of the genome. Many laboratories do 
not have the resources to carry out these large-scale studies. And thirdly, a genome-wide 
screen is just the beginning of the search for disease-causing genes. Candidate regions 
obtained by linkage analysis are usually quite large and contain many genes. The disease-
causing gene must be identified by testing variants in the positional candidate genes by 
association studies. 
 
Association studies 
Association analysis is used to test polymorphisms for association with a disease. There 
are three main applications: testing of functional or positional candidate genes and 
genome-wide association analysis. Functional candidate genes are selected based on their 
function and expression profile. This strategy implies knowledge of the disease process 
and can only be applied to genes with a known function, which includes about one-third 
of all genes. Positional candidate genes are located within a region of linkage or 
association. Genes with a function compatible with the disease will have highest priority, 
but genes with an unknown function also become serious candidates. For whole-genome 
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association studies no a priori knowledge about the disease is needed as SNPs spaced 
approximately every 10 kb on all chromosomes are tested for association with a disease.  
To implicate a gene as disease causing, one or more variants in this gene must be 
shown to be associated with the disease. The most widely used approach is to test a 
variant in a number of cases and controls and determine whether allele or genotype 
frequencies are significantly different between the groups. Independent patients are 
required for case-control studies, and these can be collected easily, for example via one 
clinic. However, sometimes the control individuals are harder to collect. Healthy blood 
donors or samples collected for other purposes are most easily obtained and they are 
frequently used. It is most important to match the ethnic background of the controls to 
that of the patients. Allele frequencies can differ between populations and this may lead 
to false-positive associations. This matter raised strong concerns in the past, but it is now 
relatively easy to test for the presence of stratification by typing a number of unlinked 
microsatellite markers.60 Stratification can be excluded when no significant differences 
between patients and controls are present. 
Large numbers of patients are also needed in association analysis to detect loci 
with small effects, just as in linkage analysis. Furthermore, when no prior risk alleles are 
known (for example from other studies or based on the functional characteristics of a 
certain allele), multiple variants must be tested in one gene. To reduce the number of 
genotypings, a DNA pooling strategy can be used.61 Identical amounts of DNA from all 
patients and controls are pooled together in a patient-pool and a control-pool. Allele 
frequencies are estimated from these pools and tested for the presence of significant 
differences. Even when the DNA pools are included in triplicate, together with a few 
individual samples for correcting PCR artefacts, the total number of genotypings for one 
variant does not exceed ~25, compared to 400 genotypings for 200 patients and 200 
controls for example. Positive associations have to be verified by individual genotyping, 
as frequencies of some alleles can be over- or underestimated in DNA pools due to PCR 
artefacts. DNA pooling is particularly useful for large-scale screening studies, in which 
many microsatellite markers or single nucleotide polymorphisms (SNPs) have to be 
tested for association. In practice, DNA pooling is applied for whole genome association 
analysis, refining of candidate regions obtained by linkage analysis, and typing of many 
SNPs in multiple candidate genes. 
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The transmission/disequilibrium test (TDT) can be used to avoid effects due to 
population stratification, but only if both parents of the patients are available.62 
Transmission of variants are scored from heterozygous parents to the patients and 
compared to a random transmission of 50%, which would be expected if the variant is 
not associated with the disease. So the non-transmitted alleles serve as control alleles and 
the possibility of stratification is eliminated. The major problem with TDT is that only 
heterozygous parents are informative, which greatly reduces the power to detect 
association. Furthermore, the workload is increased compared to a case-control design, as 
three individuals must be typed for each patient. Besides, TDT is not suitable for late-
onset disorders, as most parents of patients are no longer available. A major advantage of 
TDT is that phase-known haplotypes of several variants can be determined. 
 
Aims and outline of this thesis 
In the past few years, great progress has been made in understanding the pathogenesis of 
coeliac disease. However, little is yet known about the genes involved in the disease 
process. For a better understanding of coeliac disease, it is of vital importance to identify 
and characterize the predisposing genes. The aim of the project described in this thesis 
was to localize and identify the genes that cause coeliac disease in the Dutch population. 
Two different approaches were used to achieve this goal: linkage analysis for the 
localization of the disease genes and association analysis for their identification. Part I of 
this thesis describes the results of the linkage analysis. A genome-wide screen was 
performed in Dutch sibpairs affected with coeliac disease and two regions, both 
conferring a considerable risk to coeliac disease development, were identified (Chapter 2). 
An exceptionally large number of coeliac disease patients was present in one family and 
the major gene in this family was mapped to a third region (Chapter 3). Part II describes 
the association analysis of candidate regions and candidate genes. The most promising 
candidate region obtained by the linkage analysis was subjected to systematic fine-
mapping using a DNA pooling strategy. Positional candidate genes in this region were 
subsequently tested for association with coeliac disease (Chapter 4). Polymorphisms in 
three functional candidate genes, located outside regions with linkage to coeliac disease, 
were also tested for association (Chapters 5-7). Finally, an extensive scan of the MHC 
region was performed in search for additional HLA susceptibility genes, by comparing 
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DQ2-positive haplotypes from patients to control DQ2 haplotypes (Chapter 8). The 
implications of the results described in this thesis are discussed within the context of the 
current knowledge of coeliac disease (Chapter 9). 
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Summary 
Background & Aims: The pathogenesis of coeliac disease is still unknown, despite its well-
known association with HLA-DQ2 and DQ8. It is clear that non-HLA genes contribute 
to coeliac disease development as well, but none of the previous genome-wide screens in 
coeliac disease have resulted in identification of these genes. Methods: We therefore 
performed a two-stage genome-wide screen in 101 affected sibpairs from 82 Dutch 
families that met strict diagnostic criteria. The small intestinal biopsy samples, on which 
the original coeliac disease diagnoses had been based, showed a Marsh III lesion in all 
patients on re-evaluation by one pathologist. For association analysis of markers in 
regions linked to coeliac disease, 216 independent MIII patients and 216 age and sex-
matched controls were available. Results: As expected, highly significant linkage to the 
HLA-region was detected (multipoint maximum lod score (MMLS) = 8.14). More 
importantly, significant linkage was also present at 19p13.1 (MMLS = 4.31), with the 
peak at marker D19S899. Moreover, this marker was also significantly associated with 
coeliac disease in the case-control study (corrected p = 0.016). Furthermore, we identified 
suggestive linkage to 6q21-22, which is ~70 cM downstream from the HLA-region 
(MMLS = 3.10). Conclusions: Significant linkage of coeliac disease to chromosome region 
19p13.1 was detected in our genome-wide screen. These results were confirmed by the 
association of D19S899 to coeliac disease in an independent case-control cohort. 
Furthermore, we identified a possible second coeliac disease locus on chromosome 
region 6q21-22.  
 
Introduction 
Coeliac disease is one of the most common forms of food intolerance in the Western 
world, with an estimated prevalence as high as 0.3-1%.1 Coeliac disease is considered to 
be an autoimmune disorder, and it is strongly associated with the Human Leukocyte 
Antigen (HLA) region. Coeliac disease patients are unable to tolerate gluten from wheat, 
barley and rye. The gluten peptides that arrive in the small intestine of a coeliac disease 
patient are presented to T-cells and this process leads to the characteristic coeliac disease 
lesion in the gut, with villous atrophy, hyperplastic crypts and large infiltrates of 
lymphocytes into the epithelium and the lamina propria.2 The presence of the small 
intestinal lesion can lead to a broad variety of symptoms, varying from diarrhoea and 
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abdominal distension to fatigue, anaemia, osteoporosis and short stature due to 
inefficient uptake of nutrients from food.1 
Coeliac disease is a strongly inheritable disorder, with a ~10% recurrence risk for 
siblings of a patient.3 Recently, it was shown that the disease concordance rates are 86% 
in monozygous twins and 20% in dizygous twins, indicating a strong genetic contribution 
to coeliac disease development.4 The association between coeliac disease and the HLA-
region is well known. Over 90% of coeliac disease patients express the HLA-DQ2 
protein, encoded by the DQA1*0501 and DQB1*02 alleles. The majority of the DQ2-
negative patients carry the DQA1*0301 and DQB1*0302 alleles, which combine to form 
the DQ8 molecule.5 HLA-DQ2 and DQ8 have been shown to bind gluten-derived 
peptides, which provokes a T-cell response, thereby explaining the genetic association.3,6 
However, the genetic contribution of coeliac disease cannot be explained by HLA solely. 
The concordance rate in monozygous twins is much higher than in HLA-identical 
siblings (~30%), indicating the action of non-HLA genes. This is compatible with the 
fact that the prevalence of DQ2 in the general population is ~25%, which is much higher 
than the prevalence of coeliac disease.5 
Since coeliac disease is the only autoimmune disorder in which both an important 
genetic (HLA-DQ) and environmental (gluten) factor are known, this disease presents a 
unique paradigm for studying complex autoimmune diseases. Elucidation of the genes 
involved in coeliac disease pathogenesis will therefore not only contribute to our 
knowledge about coeliac disease pathogenesis, but may also provide a beginning to 
understanding the destructive processes in other autoimmune disorders. So far, eight 
whole genome screens have been performed to identify the non-HLA genes causing 
coeliac disease. Unfortunately, none were able to identify genome-wide statistically 
significant linkage outside the HLA-region except in a population isolate7 and 
chromosomal regions showing evidence for linkage differed markedly between the 
studies. 
We set out to perform a genome-wide scan in Dutch sibpairs affected with coeliac 
disease that met strict diagnostic criteria. We attempted to retrieve the small intestinal 
biopsies of all patients initially selected for this study. Only those sibpairs whose biopsies 
could be re-examined and which showed the characteristic coeliac disease lesion on re-
evaluation by one experienced pathologist were included in this genome-wide screen. 
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This strategy is expected to lead to a smaller, but more homogeneous set of affected 
sibpairs, thereby increasing the chance of detecting significant linkage. 
 
Materials and Methods 
Study subjects 
Families with two or more siblings affected with coeliac disease were invited to 
participate in our study through an advertisement in the Dutch Coeliac Society’s 
newsletter. Several families were also referred by their medical specialists. Blood was 
collected from those families in which the affected siblings were diagnosed by a small 
bowel biopsy. All biopsy samples on which the original coeliac disease diagnosis had been 
established were collected and sent to an experienced pathologist (JWRM) for re-
evaluation and Marsh classification. This procedure ensured homogeneity in the 
evaluation of the biopsy samples, since the patients were originally diagnosed in more 
than 50 different hospitals over the past 30 years. Only families with at least two siblings 
with coeliac disease grade Marsh IIIa, Marsh IIIb or Marsh IIIc (i.e. partial, subtotal or 
total villous atrophy respectively, with the presence of crypt hyperplasia and an increased 
number of intraepithelial lymphocytes (>30 per 100 enterocytes))8 were included in our 
genome-wide screen. Patients with Marsh II or Marsh I biopsy samples, or whose biopsy 
samples were too damaged to classify or unavailable were excluded from this study. This 
procedure resulted in exclusion of 23 affected sibpairs from the study. In total, 67 
families with two or more Marsh III siblings were included in the whole genome screen. 
They comprised 60 families with two affected siblings, six families with three affected 
siblings and one family with four affected siblings. Additional siblings from families with 
missing parents were included to determine the parental genotypes. The composition of 
the families, who came from all parts of the Netherlands and were of Dutch origin, is 
shown in Table 1. 
For the follow-up study of the chromosome regions showing evidence for linkage, 
15 more families were recruited, 14 with two affected siblings and one with three affected 
siblings. These families met the same criteria as the first-stage families, i.e. all affected 
siblings had a Marsh III lesion. The composition of the families is also shown in Table 1. 
Thirteen of these families were of Dutch origin and the other two were from the Dutch-
speaking part of Belgium.  
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In total, 74 families with two affected siblings, seven families with three affected 
siblings and one family with four affected siblings were included in this study. This 
resulted in 101 affected sibpairs, consisting of both children as well as adults. The 
affected siblings were typed at the HLA-DQA1 and DQB1 loci by SSCP based methods.9 
The patients could be divided into two groups based on their age at the time of diagnosis. 
The childhood-onset group consisted of 47 families with 55 affected sibpairs who were 
diagnosed before the age of 11. The adult-onset group consisted of 33 families with 42 
affected sibpairs who were diagnosed after the age of 20. Two families fell between these 
categories. 
For association analysis in the regions with evidence for linkage, 216 independent 
Dutch coeliac disease patients were available. Of these patients, 141 were female (65%) 
and 75 were male (35%). The age ranged from 4-91 years with a mean age of 39 years. 
These patients met the same strict diagnostic criteria as those selected for the genome-
wide screen; all showed a Marsh III lesion upon re-evaluation of their initial biopsy 
specimens by the same pathologist (JWRM). Control individuals were age and sex-
matched to the coeliac disease patients and consisted of random hospital controls. The 
study was approved by the Medical Ethics Committee of the University Medical Centre 
Utrecht and written informed consent was obtained from all the participants. 
 
 
 
 
 
 
 
Table 1. Composition of the families with 2 or more siblings affected with coeliac disease. 
Stage Family type Number 
Initial genome-wide screen 2 parents 43 
(N = 67) 1 parent  
       + 1 additional sibling 9 
       + 0 additional siblings 2 
 0 parents  
       + 2 additional siblings 11 
       + 1 additional sibling 1 
       + 0 additional siblings 1 
   
Follow-up 2 parents 12 
(N = 15) 1 parent  
       + 1 additional sibling 1 
 0 parents  
       + 2 additional siblings 2 
   
 Total 82 
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Genotyping the microsatellite markers 
A total of 326 microsatellite markers were genotyped in the 67 families in the initial 
genome-wide screen. Genotypes were obtained for 270 subjects, including the parents of 
the affected siblings to gain more information about the number of alleles shared 
identical by descent at the marker loci. If the parents were unavailable, a maximum of 
two additional siblings were included to reconstruct the missing parental genotypes. Our 
marker set consisted mainly of screening set 6 from the Marshfield Centre for Medical 
Genetics, complemented with markers selected from the Marshfield genetic map 
(http://research.marshfieldclinic.org/genetics/). The markers were evenly spread over all 
22 autosomes and the X chromosome, with an average spacing of 12 cM. A denser 
marker map was used for the CELIAC1 region (HLA), the CELIAC2 region on 
chromosome 5q31-q33 and the CELIAC3 region on chromosome 2 (CTLA4/CD28), 
since these regions had been previously implicated as candidate regions in other genome 
scans.10-16  
Forty-three additional markers were typed in six non-HLA regions that showed 
evidence for linkage in the initial genome-wide screen at a nominal significance level 
≤0.01 (lod score >1.3). The additional 15 families were also typed for these regions, as 
well as for the CELIAC1 and CELIAC2 regions. The CELIAC3 region was not typed in 
these families because no evidence for linkage to this region was present in the initial 
genome-wide screen.  
The markers were amplified in multiplex PCR reactions in 96-well plates. Each 
plate contained DNA from the coeliac disease families, a negative control, three CEPH 
reference samples (1331-01, 1331-02 and 1347-02) and four blind control samples that 
were duplicates of samples in one of the other plates. The reaction volume of 10 µl 
contained 25 ng of DNA, 0.2 mM dNTPs, 2.5 mM MgCl2, 50 ng fluorescence-labelled 
primer and 0.4 U AmpiTaq Gold (PE Applied Biosystems, Foster City). The PCR 
products were pooled and separated on a 3700 DNA sequencer (PE Applied Biosystems) 
and analysed by Genescan 3.5 and Genotyper 2.0 software (PE Applied Biosystems). All 
genotypes were checked independently by two researchers (MJvB and AFJB). 
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Statistical analysis 
The power to detect linkage to a coeliac disease susceptibility locus in our data set was 
estimated according to Risch.17 Probabilities were calculated for detecting loci with 
different sibling relative risks (λs): 1.5, 2, 2.5 and 3. For these calculations we aimed at a 
p-value of 0.0007, which corresponds to the genome-wide threshold for suggestive 
linkage.18 
The genotype data of the genome-wide screen were analysed using the 
MAPMAKER/SIBS program,19 which is based on allele sharing between the affected 
siblings. This program performs a non-parametric linkage analysis, which is preferred 
since the mode of inheritance of the coeliac disease susceptibility genes is unknown. The 
identical by descent allele sharing between pairs of affected siblings (0, 1 or 2 alleles) is 
determined at the marker loci and the observed frequencies are compared to the expected 
allele sharing of 0.25, 0.5 and 0.25 identical by descent under the null hypothesis of no 
linkage. Single and multipoint analyses were performed, both allowing for dominance 
variance (possible triangle method). Multiple affected sibpairs from the same family were 
treated as independent sibpairs, by calculating the number of alleles shared identical by 
descent of all possible pairs in the unweighted mode. Allele frequencies were calculated 
from the data set, since population frequencies of the markers were unknown in our 
population. The order and location of the markers on the chromosomes was based on 
the Marshfield genetic map (http://research.marshfieldclinic.org/genetics/). 
Several quality checks were performed on the markers before inclusion in the 
linkage analysis. Firstly, the genotypes of the CEPH reference samples were compared to 
the CEPH genotype database (http://www.cephb.fr/) to check that the intended marker 
was amplified. Secondly, the blind controls were checked by an independent investigator 
and markers with more than one discrepancy were re-analysed. The marker was excluded 
from the linkage analysis if the discrepancies remained. Thirdly, a Mendelian inheritance 
check was performed and markers with more than two Mendelian errors were also 
excluded from the linkage analysis to ensure the quality of the marker set. New alleles are 
frequently observed in microsatellite markers, since they mutate easily. Therefore, when a 
new allele was observed in one or two families, only those families were excluded for that 
marker, but it was included in the other families. In contrast, markers with null-alleles 
were excluded in all families. A null-allele is an allele that is segregating in a family, but it 
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is not amplified by PCR due to polymorphisms in the primer-binding site. This can be 
observed in families in which non-paternity has been excluded, but where one parent is 
homozygous for a certain allele and a child is homozygous for another allele transmitted 
by the other parent. Fifteen markers were excluded due to these quality checks, resulting 
in 311 markers that were used for the linkage analysis. 
The initial genome-wide screen was analysed in the 67 families typed for all 311 
markers. The seven regions showing evidence for linkage at nominal significance ≤0.01, 
corresponding to a lod score of 1.3,18,20 were further analysed in all 82 families. P-values 
corresponding to the obtained lod scores were approximated according to Holmans.20 
The threshold levels for linkage were according to the genome-wide significance levels as 
proposed by Lander and Kruglyak,18 with suggestive linkage at p = 7 x 10-4, significant 
linkage at p = 2 x 10-5 and highly significant linkage at p = 3 x 10-7 (corresponding lod 
scores are 2.6, 4.0 and 5.8, respectively).  
One could hypothesize that different genes are involved in childhood-onset and 
adult-onset coeliac disease. We tested this hypothesis in the two regions with evidence for 
linkage, 6q21-22 and 19p13.1. The families were divided into one group with 47 families 
with childhood-onset coeliac disease and another group with 33 families with adult-onset 
coeliac disease (see patients section). The linkage analysis was repeated in both age 
groups. The two families that did not fit into these categories were not included in this 
analysis. 
Markers from the genome-wide screen in regions with evidence for linkage were 
tested for association in a case-control study. Eight markers from the 6q21-22 region 
(D6S1563 to D6S1712, see Table 2) and five markers from the 19p13.1 region (D19S714 
to D19S215) were typed in 216 Marsh III coeliac disease patients and 216 age- and sex-
matched controls. Overall significance of the markers was obtained by means of an Nx2 
chi-square test (N = number of alleles at the marker locus with a frequency ≥ 0.05, plus 
one group of the remaining alleles). A Bonferroni correction was applied to correct for 
the thirteen markers that were tested. Association of marker D19S899 with coeliac 
disease was tested in the 82 families from the linkage analysis using the sib_tdt 
implementation of the ASPEX package. This program calculates empirical probabilities 
for association independent of linkage within families. 
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Results 
Initial genome-wide screen 
Sixty-seven families with 84 affected sibpairs were available for the initial genome-wide 
screen. Power calculations were performed to estimate the chance to detect susceptibility 
loci with different relative risks to a sibling of a coeliac disease patient (λs). It was 
estimated that with this set of families the chance to detect a locus with a λs of 1.5 was 
20%, a λs of 2.0 was 72%, a λs of 2.5 was 94% and λs of 3.0 was 99%. A whole genome 
screen with microsatellite markers was performed in these patients and their parents. The 
multipoint maximum lod scores (MMLS) on all chromosomes are depicted in Figure 1.  
Figure 1. Maximum lod scores from the multipoint linkage analysis present on each chromosome in the 
initial genome-wide screen in 67 families. The horizontal line indicates a nominal significance threshold of 
0.01. All regions reaching this threshold were further investigated in a follow-up study.  
 
Genome-wide significant linkage to the CELIAC1 locus in the HLA-region on 
chromosome 6 was detected (MMLS = 6.58). Six other regions, on chromosomes 1p, 5q, 
6q, 8q, 19 and 20p, were identified with nominal p-values ≤0.01 (MMLS > 1.3). The 
threshold for suggestive linkage was reached at chromosome 19 (MMLS = 2.98). The 
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region on chromosome 6q is approximately 70 cM downstream from the HLA-region 
and yielded an MMLS value of 1.92.  
 
Follow-up analysis of chromosomes 1, 5, 6, 8, 19 and 20 
The 15 additional families were typed for the markers from the seven regions with an 
MMLS >1.3. Furthermore, a total of 43 new markers were added to the interesting 
regions on chromosomes 1p, 6q, 8q, 19 and 20p to obtain a spacing of <5 cM, and these 
were typed in all 82 families. No extra markers were typed in CELIAC1 and CELIAC2 
regions (HLA and 5qter, respectively), as these regions were already densely covered with 
markers in the initial genome-wide screen. The results of linkage analysis of 
chromosomes 1, 5, 6, 9, 19 and 20 after fine-mapping are shown in Figure 2. For 
completeness, the linkage graphs of the other chromosomes after the initial genome-wide 
screen were also included in this figure. 
Suggestive linkage to chromosome 19 was detected in the initial genome-wide 
screen, between D19S714 on the p-arm and D19S587 on the q-arm. Twelve new markers 
were added to this region, leading to a map with a 1.0-4.3 cM spacing. This resulted in an 
increase of the MMLS value from 2.98 to 4.43 (nominal p = 6.2 x 10-6) at marker 
D19S899, reaching genome-wide significance. Genotyping all 82 families resulted in a 
comparable MMLS of 4.31 at the same position. This novel coeliac disease locus is 
located at 19p13.1.  
Genotyping twelve extra markers in the chromosome 6q region resulted in an 
increase of the MMLS value from 1.92 to 3.14 (nominal p = 1.3 x 10-4) in the initial 67 
families at region 6q21-22. Typing all 82 families for these markers resulted in a similar 
MMLS of 3.10. The MMLS at this locus peaked at marker D6S1608 at 122 cM and 
reached the threshold for suggestive linkage.  
Adding more markers to chromosomes 1p, 8q and 20p did not increase evidence 
for linkage in the initial 67 families. Genotyping these markers in all families did not 
change the results for chromosomes 1 and 20. However, the MMLS value on 
chromosome 8 dropped considerably from 1.96 to 0.75 after genotyping all families. 
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Figure 2. Distribution of MLS values in the initial 67 families (bold line) and in all 82 families (thin line). 
Graphs of chromosomes 1, 5, 6, 8, 19 and 20 are after fine-mapping of regions with a lod score >1.3; 
graphs of the other chromosomes represent the results of the initial genome-wide screen. The triangular 
symbols denote the positions of the markers on the chromosomes.  
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Typing the CELIAC1 region in all 82 families increased the MMLS value from 6.58 to 
8.14 (nominal p = 1.1 x 10-9), but the MMLS value in the CELIAC2 region on 
chromosome 5 dropped from 1.34 to 0.74. There was no evidence for linkage to the 
CELIAC3 region on chromosome 2 (MMLS = 0.0). 
The contributions of the19p13.1 and 6q21-22 loci to familial clustering of coeliac 
disease were determined as proposed by Risch21. The relative risk for a sibling due to a 
certain locus (λs, locus) equals the prior probability of affected siblings sharing 0 alleles 
(0.25) divided by the observed probability of no allele sharing. This resulted in a λs of 2.6 
for the 19p13.1 locus and a λs of 2.3 for the 6q21-22 locus, compared to a λs of 4.6 for 
the HLA region. 
 
HLA-DQ typing 
In 78 of the 82 families, all affected siblings were HLA-DQ2 positive. In three of the 
remaining families, at least one of the affected siblings carried HLA-DQ2, while the other 
patients were HLA-DQ8 positive. In the only DQ2-negative family, both affected 
siblings were HLA-DQ8 positive.  
 
Stratification for age of diagnosis 
The families were divided in two age groups depending on the age of diagnosis to 
determine whether the 6q21-22 and 19p13.1 are specifically involved in childhood- or 
adult-onset coeliac disease. Linkage analysis of the two regions was performed in both 
age groups separately. There was no difference in linkage to these regions between the 
families with childhood-onset coeliac disease and the families with adult onset coeliac 
disease, both age-groups contributed almost equally to the lod score (data not shown). 
 
Single point linkage analysis in the putative non-HLA regions 
A single point linkage analysis was also performed in the non-HLA the regions that 
showed moderate evidence for linkage (MMLS > 1.3, corresponding to a nominal p-value 
≤0.01) to determine the support for linkage to these regions (Table 2). Ten consecutive 
markers on chromosome 19 in a 22 cM interval yield lod scores >1 in the initial 67 
families, indicating the importance of this region. Interestingly, the lod score of marker  
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Table 2. Single point lod scores for markers in non-HLA regions with a maximum lod score 
>1.3 in the multipoint analysis of the initial genome-wide screen. 
    lod score 
Chromosome  Marker cMa Mbb Initial 67 
families 
All 82 
families 
1 D1S1728 109.04 82.17 0.22 0.30 
 D1S551 113.69 83.07 1.73 1.70 
 D1S2807 114.24 83.49 0.33 0.44 
      
5 D5S211 182.89 173.51 0.40 0.08 
 D5S498 184.66 174.07 1.14 0.41 
 D5S2111 187.81 - 1.14 0.45 
 D5S2008 190.18 177.72 0.37 0.25 
 D5S408 195.49 180.12 0.30 0.02 
 D5S2006 197.54 180.48 0.83 1.26 
      
6 D6S283 109.19 102.30 1.89 2.24 
 D6S1021 112.20 104.51 1.50 1.64 
 D6S1563 113.60 105.50 1.31 1.76 
 D6S278 116.26 108.16 2.74 1.78 
 D6S1594 117.29 108.34 1.21 1.31 
 D6S474 118.64 112.71 1.73 2.01 
 D6S261 120.31 133.99 1.23 1.43 
 D6S433 121.97 118.48 2.39 2.38 
 D6S1608 122.51 120.68 1.61 1.11 
 D6S1712 122.51 121.90 2.43 2.25 
      
8 GATA123H10 122.96 - 0.25 0.01 
 D8S592 125.27 117.44 2.28 1.44 
 D8S198 128.16 122.44 0.57 0.19 
      
19 D19S714 42.28 16.11 1.47 1.08 
 D19S899 45.48 17.73 3.92 3.81 
 D19S460 - 18.87 2.14 1.60 
 D19S407 48.14 20.56 4.83 3.95 
 D19S215 48.52 22.12 1.88 1.23 
 D19S433 51.88 31.03 2.17 1.78 
 D19S414 54.01 32.53 1.39 1.05 
 D19S868 56.69 - 1.07 0.67 
 D19S587 59.36 35.83 1.11 0.89 
 D19S400 64.70 42.17 1.38 0.90 
      
20 D20S194 18.26 6.13 0.22 0.15 
 D20S907 21.15 - 1.49 1.58 
 D20S917 24.70 9.28 0.21 0.47 
a cM positions are based on the genetic map of the Marshfield database.  
b Physical position according to the December 2002 release from the Ensembl database. 
Chapter 2 
44 
D19S407 at position 48.14 cM is 4.83, which is even higher than its result in the 
multipoint analysis. Seven markers with lod scores >1 were detected in all 82 families. In 
the chromosome 6q21-22 region, 10 consecutive markers, spanning 13 cM, also yielded 
lod scores >1. In the initial screen, two consecutive markers on chromosome 5qter with a 
lod score of 1.14 were detected, D5S498 and D5S2111. On analysing all 82 families, the 
lod scores for these markers dropped below 0.5, but the most telomeric marker 
(D5S2006) increased to 1.25. On chromosomes 1, 8 and 20, only one marker showed 
linkage at p ≤0.01, while the flanking markers gave no supporting evidence. The positive 
results on these chromosomes in the multipoint analyses were probably due to these 
markers solely. The physical locations of the markers were determined to check their 
order (Table 2). Unfortunately, four markers could not be mapped to the human genome 
sequence (December 2002 release of the Ensembl database). All the remaining 31 
markers could be mapped and were in the correct order. Marker D19S460 was not 
present on the Marshfield genetic map. 
 
Association analysis 
The allele frequencies of the markers in the 6q21-22 and 19p13.1 regions were 
determined in 216 independent Marsh III patients and 216 control individuals. A 
significant difference between the cases and controls was detected for marker D19S899, 
the marker at which the multipoint lod score peaked. For this marker 214 cases and 210 
controls could be genotyped, yielding an overall p-value of 0.0013. This result was still 
significant after correcting for the 13 markers that were tested (p = 0.016). The 
association of D19S899 was not due to one allele, but four out of the six tested alleles 
were increased in cases. Therefore, lack of power prohibited us to confirm this 
association in the 82 families used for the linkage analysis. None of the other markers 
showed significant association with coeliac disease in the case-control cohort. 
 
Discussion 
Sixty-seven families with affected sibpairs of Dutch ancestry were available for the initial 
genome-wide screen. A total of 84 affected sibpairs were present in these families. It was 
shown by power calculations that this data set had a very high chance of detecting a 
coeliac disease susceptibility locus with a locus-specific λs ≥ 2.5 (> 94%). Also, the chance 
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to detect a locus with a λs of 2.0 is still reasonably good (72%). However, this data set has 
limited power to detect loci with smaller effects, as is shown by the 20% chance to detect 
a locus with a λs of 1.5. Therefore, this data set has sufficient power to detect loci with 
moderate to high effects, but loci with very small effects may be missed. The total 
estimated λs for coeliac disease is 25, based on a 10% sibling recurrence risk and a 
population prevalence of 0.4%. Considering an estimated λs of 3-5 for the HLA-region,21-
23 the majority of the genetic susceptibility is due to unknown genes. This data set has a 
good chance to detect at least one of these loci. 
Multipoint linkage analysis revealed the presence of two non-HLA loci 
predisposing to coeliac disease in the Dutch population. A major non-HLA locus is 
located on chromosome 19. This region showed genome-wide significant linkage, with an 
MMLS value of 4.43 (nominal p = 6.2 x 10-6). This finding was supported by single point 
analysis, showing ten successive markers with lod scores >1 in this region. The results in 
all 82 families were in agreement with these findings. This high-risk coeliac disease locus 
accounts for a 2.6-fold increased risk to siblings, which is about half of the risk attributed 
by the HLA-region in our families (λs, HLA = 4.6). It is involved in development of coeliac 
disease in children as well as in adults. Moreover, marker D19S899 was associated with 
coeliac disease in an independent case-control cohort. The maximum lod score in the 
linkage analysis was obtained at the same marker, indicating that a coeliac disease 
susceptibility gene is located near this marker. Importantly, the case-control study 
revealed that four out of six tested D19S899 alleles were over-represented in the cases 
compared to the controls. These results imply either the presence of multiple 
independent disease-causing variants that, in turn, are present on different haplotypes, or 
a single disease-causing haplotype that shows association with different D19S899 alleles. 
The observed association with multiple alleles may also explain the lack of power to 
replicate these findings in the 82 families from the linkage analysis, since only a subset of 
the families will show association for each one of these four associated alleles. Altogether, 
the presence of association in the 19p13.1 region, which has been obtained in a different 
patient sample and by a different approach, provides independent evidence for the 
presence of a coeliac disease gene in this region.  
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The linkage graph on chromosome 19 peaked at 19p13.12, although the region 
that may contain the coeliac disease gene could be much larger. Ten markers with lod 
scores >1 were present in the initial 67 families, and seven in all 82 families, resulting in a 
candidate region of at least 11-22 cM (16-26 Mb) ranging from 19p13.12 to 19q13.2. For 
identification of this susceptibility gene, one may start testing genes in the support 
interval defined by the maximum lod score –1. This region spans from approximately 
43.5 and 47 cM (3Mb) and contains 92 known and predicted genes, according to the 
Ensembl database. It can however not be excluded that the gene is located outside this 
interval. 
Stratification of the families into two groups, HLA-DQ2 positive and HLA-DQ2 
negative, and re-analysing the data in these groups would in theory distinguish the non-
HLA loci that interact with HLA-DQ2 from those that act independently. Unfortunately, 
this is not possible in our data set, since HLA-DQ2 is present in all but one family.  
  So far, eight other genome-wide scans, all in Caucasian patients, have been 
undertaken to identify coeliac disease susceptibility loci. One of these studies included 
patients from a population isolate, whereas the others were undertaken in more outbred 
populations (Table 3). Three of these studies showed some evidence for linkage to 
chromosome 19, but at clearly different loci. Weak evidence for linkage was detected 
twice at 19p13.3 at ~10-16 cM, with an MMLS of 0.84 (nominal p = 0.0544)16 and a non-
parametric lod score (NPL) of ~2.1 (nominal p = 0.02)24 respectively. At chromosome 
region 19q13.4, an MMLS value of 1.84 (nominal p = 0.0544)16 was reported at 92 cM 
and a recessive heterogeneity lod score (HLOD) of 1.6 at the same position.25 Thus, the 
locus on 19p13.1 seems to be unique to the Dutch coeliac disease population. 
Interestingly, linkage of inflammatory bowel disease (IBD) to this region has been 
reported,26 perhaps representing a shared genetic background for intestinal inflammation. 
Suggestive linkage to chromosome 6q21-22 was detected in our genome-wide 
screen, with an MMLS value of 3.14 (nominal p = 1.3 x 10-4). The region of interest 
spans from approximately 113 to 125 cM, which is clearly distinct from the HLA-region 
at ~45 cM. Single point analysis revealed that the linkage in this region was contributed 
by ten consecutive markers, providing support for the presence of another coeliac disease 
gene on chromosome 6. The λs of this locus is with 2.3 comparable to that of the 
19p13.1 locus. This locus is also involved in both childhood- and adult-onset coeliac  
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Table 3. Overview of linkage to non-HLA regions in genome-wide screens conducted for 
coeliac disease. 
Population No. of 
families 
(1st/2nd/3rd)a 
Study design Suggestiveb 
linkage 
Significantb 
linkage 
Reference 
West Ireland 15/- Affected 
sibpairs 
6p23, 11p11 - 16 
Italy 39/57/87 Affected 
sibpairs 
5qter - 10,11 
UK 16/34 Extended 
families 
- -  25,33 
Sweden/ Norway 70/36 Affected 
sibpairs 
- - 13 
Finland 60/38 Affected 
sibpairs 
4p15 - 12 
Finland 9/1 Population 
Isolate 
- 15q12 7 
North Europe 24/- Extended 
families 
- - 24 
North America 62/- Extended 
families 
3p26, 5p14, 
18q23 
- 34 
Netherlands 67/15 Affected 
sibpairs 
6q21-22 19p13.1 this study 
a Number of families in initial genome-wide screen (1st) and subsequent follow-up studies (2nd and 3rd). 
b Suggestive linkage: p < 7.4 x 10-4; significant linkage: p < 2.2 x 10-5 (according to criteria proposed by 
Lander and Kruglyak18). The "-" symbol denotes that the indicated genome-wide significance threshold 
was not reached. 
 
disease. Evidence for linkage of coeliac disease to region 6p12 has been found previously. 
At 74 cM, a maximum lod score of 2.2 ( nominal p = 0.001) and an MMLS value of 1.42 
(nominal p = 0.0186) were identified.16,25 Since our linked region is 40-50 cM apart from 
the 6p12 locus, it probably represents a distinct locus on chromosome 6. Linkage of type 
1 diabetes mellitus to the 6q21 region has been reported several times.27 Furthermore, a 
locus around 100 cM (6p15-16.3) has been implicated in systemic lupus erythematosus28 
and in psoriasis.29 Taken together, these results indicate the possibility of a gene in the 
chromosome 6q15-22 region that is involved in the autoimmune process. 
Positive findings at a nominal p value ≤0.01 were present in four other regions in 
our initial genome-wide screen: 1p31.1, 5q35.2, 8q24.11 and 20p12.3. Single point 
analysis of the markers on chromosomes 1, 8 and 20 revealed that the positive results in 
the multipoint analysis were due to only one marker and there was no support from the 
flanking markers, suggesting that these loci are false-positive linkage results. This is in 
agreement with the number of false-positive findings that can be expected in a genome-
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wide screen. Simulation of a whole genome screen in 100 affected sibpairs, with no trait 
locus segregating in the families, showed 22 regions reaching nominal significance at p 
≤0.05, three of those reaching a significance level of ≤0.01 and one even reaching the 
threshold for suggestive linkage.18 Importantly, no significant linkage was present in this 
simulated genome-wide screen.  
It is difficult to interpret our findings in the CELIAC2 region on chromosome 
region 5qter. Some evidence for linkage to this region was detected in the initial 67 
families, but the addition of 15 more families resulted in a decrease of the MMLS value 
from 1.34 to 0.74. This might indicate heterogeneity in our families, but the possibility of 
a false-positive result cannot be excluded. Suggestive linkage to the CELIAC2 region was 
identified in Italian affected sibpairs,10,11 and support for linkage to this region was 
present in three other populations,12,13,16 indicating the presence of a minor coeliac 
disease susceptibility gene in this region. The CTLA4/CD28 region on chromosome 2 
(CELIAC3) and the chromosome 11p11 region have been implicated in coeliac disease 
in previous studies, but our results do not support linkage to these regions in the Dutch 
population.  
 In conclusion, two novel coeliac disease loci were identified in the Dutch 
population. Evidence for linkage to 19p13.1 reached the threshold for genome-wide 
significance. This locus is the major non-HLA coeliac disease locus in the Dutch 
population. Independent confirmation of involvement of the 19p13.1 locus in coeliac 
disease was provided by the presence of association within this region in a different data 
set. Furthermore, suggestive linkage to the 6q21-22 region was detected. The 19p13.1 and 
6q21-22 loci both confer a considerable risk for coeliac disease development, with a λs of 
2.6 and 2.3 respectively. None these loci are age-dependent. The next step is to identify 
these important coeliac disease genes. Recently, positional cloning of genes involved in 
complex diseases has proved to be successful. In 2000, the calpain-10 gene was identified 
as the type 2 diabetes mellitus susceptibility gene in the NIDDM1 region on 
chromosome 2.30 Furthermore, variants in the CARD15 (previously named NOD2) gene 
on chromosome 16 were found to be associated with Crohn's disease31 and the ADAM33 
gene on chromosome 20 was recently identified as an asthma susceptibility gene.32 The 
6q21-22 and 19p13.1 regions are still too large for candidate gene studies, and further 
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fine-mapping of the region is underway. Identification and characterization of these 
coeliac disease genes will lead to important new insights in the pathogenesis of coeliac 
disease and may open new opportunities for diagnosis. First of all, when the coeliac 
disease susceptibility alleles of these genes have been determined, more accurate risk 
estimations can be offered to relatives of Dutch coeliac disease patients, based on the 
genotype at HLA-DQA1 and DQB1, 19p13.1 and 6q21-22. This may also be helpful in 
diagnosing patients with a borderline pathology or patients who were already on a gluten-
free diet at the time of the first biopsy. Secondly, when the gene is known, functional 
studies can be performed to determine the role of this protein. Unravelling the biological 
pathway in which this protein acts will lead to understanding of the disease process and 
possibly to a target for therapeutic intervention.  
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Summary 
Objectives: Coeliac disease is caused by the interaction of multiple genes and environmental 
factors. Inheritance of the disease shows a complex pattern with a 10% sibling recurrence 
risk. The HLA-region is a major genetic risk locus in coeliac disease, but genes outside 
this region are expected to contribute to the disease risk as well. The aim of this study 
was to identify the loci causing coeliac disease in one large Dutch family with apparent 
dominant transmission of the disease. Methods: The family comprised 17 patients in four 
generations, with possible transmission of the disease by both grandparents. 
Microsatellite markers evenly spread over all chromosomes were genotyped and linkage 
analysis was performed using both dominant and recessive disease models and a model-
free analysis. Results: Disease susceptibility in the family was linked to the HLA-region 
(lod score of 2.33) and all patients were HLA-DQ2. A dominantly inherited non-HLA 
locus with a maximum lod score of 2.61 was detected at 9p21-13, which was shared by 16 
patients. Model-free analysis identified another possible non-HLA locus, at 6q25.3, which 
was shared by 14 patients (p = 0.01). Neither of these regions were detected in a genome-
wide screen in Dutch affected sibpairs, but the 9p21 locus has been implicated in 
Scandinavian families. Conclusions: Two potential non-HLA loci for coeliac disease were 
identified in this large Dutch family. Our results provide replication of the Scandinavian 
9p21 locus, and suggest that this locus plays a role in coeliac disease patients from 
different Caucasian populations.  
 
Introduction 
Coeliac disease is an autoimmune disorder with a multifactorial aetiology. Ingestion of 
gluten, present in wheat, barley and rye, leads to a range of aberrations in the small 
intestinal mucosa of these patients. The range of abnormalities can be classified according 
the modified Marsh classification. The Marsh type III lesion is the most severe lesion, 
with the presence of intra-epithelial lymphocytosis with damage of the mucosal epithelial 
cells, crypt hyperplasia and partial (IIIa), subtotal (IIIb) or total (IIIc) villous atrophy.1,2 A 
wide spectrum of clinical symptoms can be associated with this lesion, including 
diarrhoea, abdominal pain and bloating. Symptoms due to malabsorption of nutrients, 
like fatigue, weight loss, anaemia and osteopenia, are also frequently present. Most coeliac 
disease patients that adhere strictly to the gluten-free diet (GFD) show improvement or 
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complete disappearance of the clinical symptoms and recovery of the small intestinal 
mucosa.3 Recently, it has been recognized that less severe lesions, like lymphocytosis 
without or with crypt hyperplasia (Marsh types I and II, respectively), can also be 
associated with the same clinical spectrum.2-4 
 Coeliac disease is a strongly inheritable disorder, with a relative risk of 
approximately 10% for siblings of a patient.1 One important genetic factor is the HLA-
region, with the majority of patients expressing HLA-DQ2, and almost all of the 
remaining patients expressing HLA-DQ8.5 However, the genetic contribution of the 
HLA-region to coeliac disease has been estimated at only ~40%.6,7 Therefore, non-HLA 
genes must also contribute to the disease. 
Identification of susceptibility genes for multifactorial disorders is hampered by 
multigenic aetiology and genetic heterogeneity.8 It is expected that a causative variant in a 
susceptibility gene for these diseases will be common in the population, and most carriers 
of this variant will not develop the disease since they do not carry all the necessary 
disease susceptibility genes to pass the disease threshold. Furthermore, different genes 
can cause identical phenotypes in different families. To overcome these difficulties, large 
numbers of cases and controls are needed in association studies, and large numbers of 
families with multiple patients are needed for linkage analysis. Within a single family the 
disease is expected to be genetically homogeneous, as the same genes are likely to cause 
the disease in all patients from that family. Therefore, a large family with many patients in 
different generations may provide a unique opportunity to identify genes that cause these 
multifactorial diseases.  
We present here a family with 17 coeliac disease patients in four generations. Ten 
out of thirteen (76%) siblings from the second generation have coeliac disease, which is 
much more than would be expected from the average sibling relative risk. We therefore 
hypothesized that a single non-HLA gene, with high penetrance, causes coeliac disease in 
this family and a genome-wide screen was performed to localize this gene locus. 
 
Subjects and methods 
The study family 
This study was approved by the Medical Ethics Committee of the University Medical 
Centre Utrecht and written informed consent was obtained from all the participants. The 
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family is of Dutch origin and lives in the north of the Netherlands. At the time of 
ascertainment, only five patients were diagnosed with coeliac disease: individuals (IDs) 
05, 09, 14, 19 and 20 (Figure 1). Serological screening was offered to 36 additional family 
members and they were screened for antigliadin IgA (AGA), antigliadin IgG (AGG) and 
anti-endomysium (Ema) antibodies. Anti-tissue transglutaminase (tTG) antibodies could 
only recently be determined, and this test was performed in only three individuals. 
Twelve additional coeliac disease patients were diagnosed by a duodenal biopsy. All 
biopsy specimens, including those from the initial patients, were retrieved for re-
evaluation and Marsh classification by one experienced pathologist (JWRM). The 
histological lesions were classified according to Marsh.1 The Marsh III category was 
subdivided into three groups; i.e. partial (Marsh IIIa), subtotal (Marsh IIIb) and total 
(Marsh IIIc) villous atrophy.9 All patients were genotyped at the HLA-DQA1 and DQB1 
loci as described before.10 An overview of symptoms, serology, and Marsh classification 
before and on a GFD, together with the HLA-DQ type, is given in Table 1. Serology 
after GFD was not available. 
Linkage analysis was performed using an "affecteds-only" strategy, so only twenty-
three individuals were included in this study: the 17 coeliac disease patients, five spouses 
and the grandfather (Figure 1 and Table 1). Twelve of the patients had a Marsh III lesion 
and all of them responded well to the GFD. Three individuals, IDs 02, 19 and 24, 
showed a Marsh II lesion. The grandmother (ID 02) does not adhere to a GFD, but the 
presence of the coeliac disease-specific Ema antibodies, the Marsh II lesion and her 
clinical symptoms strongly suggest coeliac disease. Both IDs 19 and 24 showed 
significant clinical improvement after only two weeks on a GFD and they experience 
strong reactions to accidental gluten intake. The Marsh II lesion from ID 19 was 
normalized to Marsh 0 after two years on a GFD. Biopsy specimens from the proband 
(ID20) and ID14 reportedly showed villous atrophy, but could not be retrieved for re-
evaluation because the diagnoses were made in 1978 and 1980, respectively. ID 20 was 
hospitalised at the age of one for severe weight loss and diarrhoea, but recovered 
completely on a GFD; ID 14 also experienced serious complaints which all disappeared 
on a GFD. The grandfather (ID 01) was positive for AGA and AGG, but negative for 
the more coeliac disease specific Ema and tTG antibodies. He suffers from dermatitis 
herpetiformis and fatigue, but he refused a duodenal biopsy.  
Chapter 3 
58 
Genotyping of microsatellite markers 
A genome-wide screen was performed in all twenty-three individuals (Figure 1). A total 
of 321 microsatellite markers were genotyped, evenly spread over the genome with an 
average distance of 15 cM. A marker spacing <5 cM was obtained for regions that had 
been implicated in our genome-wide screen in Dutch affected sibpairs (6q21-22 and 
19p13.1)11 and regions showing linkage in other studies (CELIAC1 in the HLA-region, 
CELIAC2 at 5q31-33 and CELIAC3 in the CTLA4/CD28 region at 2q33-34). Regions 
with lod scores >1.0 were selected for fine-mapping, and 50 additional markers were 
Table 1. Patient characteristics. 
IDa Year 
of 
Birth 
Symptoms before GFDb Serologyc Marsh 
before 
GFDd
DQ 
type 
Symptoms 
after GFD 
Marsh 
after 
GFDd
01 1920 fatigue, DH, cannot eat 
bread 
AGA, 
AGG 
ND DQ2 no GFD  
02 1923 fatigue, anaemia AGA, Ema II DQ2 no GFD  
05 1947 fatigue, anaemia, weight 
loss, abdominal 
pain/bloating  
ND IIIb DQ2 disappeared IIIa 
07 1949 fatigue, diarrhoea, irritable AGA, Ema IIIc DQ2 disappeared ND 
08 1950 fatigue, abdominal pain AGA, Ema IIIa DQ2 disappeared ND 
09 1952 diarrhoea, abdominal pain ND IIIb DQ2 disappeared ND 
10 1953 fatigue Ema IIIa DQ2 improved ND 
11 1954 fatigue, diarrhoea AGA, 
AGG, Ema 
IIIb DQ2 improved ND 
12 1955 fatigue, abdominal 
pain/bloating 
AGA, Ema IIIa DQ2 disappeared II 
13 1957 fatigue, abdominal bloating, 
irritable 
AGA IIIa DQ2 disappeared ND 
14 1960 fatigue, diarrhoea, anaemia, 
weight loss, DH 
ND NA DQ2 disappeared ND 
16 1962 fatigue, diarrhoea Ema IIIa DQ2 improved II 
19 1971 fatigue, bleeding gums ND II DQ2 disappeared 0 
20 1976 fatigue, diarrhoea, weight 
loss, irritable, tooth enamel 
defects 
ND NA DQ2 disappeared 0 
24 1978 fatigue Ema II DQ2 disappeared ND 
32 1989 fatigue Ema IIIb DQ2 disappeared ND 
41 1998 fatigue, irritable AGA, Ema, 
tTG 
IIIb DQ2 disappeared ND 
55 1978 none Ema IIIb DQ2 no GFD  
a ID refers to the identification numbers used in Figure 1. 
b GFD = gluten-free diet; DH = Dermatitis Herpetiformis. 
c AGA = antigliadin IgA; AGG = antigliadin IgG; Ema = anti-endomysium IgA; ND = not done and  
  tTG = anti-tissue transglutaminase IgA. Note: tTG testing was only performed in ID 01 and 41. 
d NA = not available; ND = not done. 
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genotyped in these regions. Our marker set consisted mainly of screening set 6 from the 
Marshfield Centre for Medical Genetics, complemented with markers selected from the 
Marshfield and Ensembl genetic maps. DNA from the family members was amplified by 
PCR, together with three CEPH reference samples and a negative control. The reaction 
volume of 10 µl contained 25 ng of DNA, 0.2 mM dNTPs, 2.5 mM MgCl2, 50 ng 
fluorescence-labelled primer and 0.4 U AmpiTaq Gold (PE Applied Biosystems, Foster 
City, CA). The PCR products were pooled and separated on a 3700 DNA sequencer (PE 
Applied Biosystems) and analysed by Genescan 3.5 and Genotyper 2.0 software (PE 
Applied Biosystems). All genotypes were checked independently by two researchers. The 
identity of the markers was verified by comparing genotypes of the CEPH reference 
samples to the CEPH genotype database. A Mendelian inheritance check was performed 
and markers with Mendelian errors were excluded from the linkage analysis. 
 
Linkage analysis 
A parametric linkage analysis was performed with the MLINK program of the 
LINKAGE package12 using an “affecteds-only” approach. This approach is preferred in 
complex diseases, as it is possible that healthy individuals also carry some of the disease 
susceptibility loci. All 23 individuals who were genotyped were included in the linkage 
analysis and the disease status of the 17 patients, either with a Marsh II lesion, a Marsh 
III lesion or with unavailable biopsy specimens, was affected. The five spouses were not 
tested for coeliac disease and were labelled unknown. The disease status of the 
grandfather (ID 01) was also unknown, as coeliac disease was not histologically proven in 
this individual.  
A two-point linkage analysis was performed for all markers using a dominant 
inheritance model as well as a recessive model (parametric linkage analysis). A multipoint 
analysis was performed in regions with a lod score >1.0 using the FASTLINK program. 
For these analyses, the model that produced linkage in the two-point analysis was used. A 
maximum of three successive markers was included in the parametric multipoint analysis 
because of calculation time considerations. Power calculations were performed with the 
SLINK and MSIM programs. For all analyses, the penetrance for the normal genotype 
was equal to the population frequency of coeliac disease (0.005) and the penetrance of 
the disease genotype was 0.8. Disease allele frequency was 0.001, based on the hypothesis 
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that a rare variant of a single susceptibility gene is causing the exceptionally large number 
of patients in this family. Allele frequencies were set equal for all alleles, since all the 
parental genotypes were available and therefore the allele frequencies in the datafile were 
not used in the analysis. The order and location of the markers on the chromosomes was 
based on the Marshfield genetic map.  
Although the disease transmission in this family suggests autosomal dominant 
inheritance, other models cannot be excluded. To check for the possibility that linkage 
was missed because of applying a wrong model, a model-free (non-parametric) analysis 
was also performed using the Genehunter program.13 When calculating the non-
parametric lod score (NPL) statistic, a disease model is not used but the sharing of 
marker alleles by all possible pairs of affected individuals is determined and compared to 
the expected values based on the familial relationship. The study family is too large for 
the Genehunter program, and was therefore divided in two smaller families (family A: 
IDs 01, 02, 05, 07, 08, 09, 18, 19, 20, 21, 24, 40 and 41; family B: IDs 01, 02, 10, 11, 12, 
13, 14, 16, 31, 32, 54 and 55). For this purpose, the affection status of both grandparents 
(ID 01 and 02) was set as unknown. NPL values obtained for both family branches were 
totalled. 
 
Results 
To determine the power of the study family, simulation studies were performed using the 
same parameters as selected for the linkage analysis. The maximum attainable lod score 
was 4.17 assuming a dominant model of transmission and 3.65 assuming a recessive 
model. These simulation lod scores were obtained with 100% informativity of the marker 
and no recombination between the marker and the disease locus. The probability of 
obtaining lod scores of at least 1.0, 2.0 or 3.0 were 53%, 25% and 8% respectively. 
Because of the low probability of obtaining high lod scores, all regions with a lod score 
>1.0 were selected for fine-mapping. 
Two-point lod scores were calculated for all 321 microsatellite markers and seven 
regions with a lod score >1 were identified, on chromosomes 3, 6, 9, 10, 15, 16 and 19. 
Fifty additional markers were typed in these regions, and the highest lod scores obtained 
in each region are shown in Table 2, together with the p-value corresponding to the NPL 
statistic from the two-point model-free analysis.  
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Table 2. Regions with two-point lod scores >1.0. 
Location Positiona 
cM    Mb 
Markerb Lod scorec NPL  
p-valued 
Information 
content 
3q12.3 119.1  101.6 D3S2459 1.13 0.02 0.91 
6p21.3  – 31.3 MIB 2.33 0.01 0.95 
 45.0  31.7 D6S273 1.79 0.02 0.87 
9p21-13 55.3 31.1 D9S43 1.55 0.03 0.82 
 58.3  32.1 D9S1118 1.64 0.02 1.0 
 59.3 34.0 D9S1817 2.61 0.0005 1.0 
 –  35.3 D9S163 2.61 0.0003 0.66 
 59.9 36.1 D9S1804* 0.78 0.19 0.52 
 60.6 36.9 D9S50 2.61 0.0003 0.66 
 61.4 37.4 D9S1874* 0.80 0.16 0.52 
 –  38.2 D9S200 1.43 0.02 0.95 
10q26.2 156.2 – D10S1223 1.33 0.23 1.0 
 160.0 129.1 D10S1676 1.33 0.08 0.82 
15q22.3 62.4 59.7 D15S153* 1.36 0.12 0.61 
16q23.2 108.3 82.4 D16S3098 1.17 0.004 0.66 
 111.1  83.9 D16S422 1.17 0.23 0.66 
19p13.1 45.5 17.6 D19S899 1.17 0.42 1.0 
 47.3 18.3 D19S915 1.17 0.42 1.0 
a The genetic locations are based on the Marshfield genetic map and the physical locations are based on 
the Ensembl map (March 2003 release). Markers without a position were not present in that map. 
b Markers marked by an asterisk were not informative in ID 02. 
c Lod scores are based on the dominant transmission model, except for the markers at 10q26.2 which 
were obtained with the recessive model.  
d P-value corresponding to the NPL statistic of the non-parametric linkage analysis. 
 
The HLA region on chromosome 6 was linked to coeliac disease in this family, 
with a lod score of 2.33 at marker MIB. Multipoint linkage analysis resulted in the same 
lod score. The most promising non-HLA region is located on chromosome 9, which 
reached a maximum lod score of 2.61 at markers D9S50, D9S1817 and D9S163. 
D9S1817 was completely informative in all meioses, so the maximum multipoint lod 
score in this region was also 2.61. Model-free analysis also demonstrated increased allele 
sharing among the affected individuals, with an NPL score of 7.81 (p = 0.0005) at 
D9S1817. Haplotypes of eight markers from this region are depicted in Figure 1. Sixteen 
out of 17 patients share a five-marker haplotype ranging from D9S1817 to D9S1874. 
Only one patient, ID 11, inherited the other haplotype from the grandmother. The 
maximum size of this candidate region is 6.1 Mb and is defined by markers D9S1118 and 
D9S200. Multipoint linkage analysis of the 3q12.3, 10q26.2, 16q23.2 and 19p13.1 regions 
resulted in lod scores identical to the single point lod scores. A lower multipoint lod score 
was obtained for 15q22.3 (0.67). 
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Figure 1. Pedigree of the study family and chromosome 9p21-13 haplotypes.  
Only affected individuals are depicted. The disease status of individuals with open symbols and the 
grandfather (ID 01) was unknown, all others were considered to be affected. The region on chromosome 
9 that is shared by all affected individuals, except ID 11, is boxed. The arrow indicates the proband. 
 
Non-parametric linkage analysis identified three additional regions with nominal 
p-values <0.05 on chromosomes 6, 10 and 11. The NPL value at 6q25.3 was 4.58 (p = 
0.01) and peaked at marker D6S969. This locus was inherited from the grandfather (ID 
01) and is shared by 14 of 16 affected offspring. Only IDs 13 and 16 inherited the other 
haplotype. Marker D10S1227 at 10q21.1 produced an NPL value of 4.22 (p = 0.02), this 
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locus was inherited from the grandmother (ID 02) and was transmitted to 11 of 16 
offspring. On chromosome 11 at p15.4, an NPL value of 5.49 (p = 0.002) was obtained 
at markers D11S2362 and D11S1760. This locus is shared by 10 offspring and was 
inherited from the grandfather. It is present in all individuals in branch A of the family. 
However, only 2 individuals in branch B, IDs 11 and 13, also carry this haplotype. The 
high NPL value of this locus was contributed only by branch A, resulting in a biased total 
NPL value for the entire family.  
 
Discussion 
A Dutch family with 17 coeliac disease patients in four generations is presented in this 
paper. Although the family was already known with coeliac disease since 1978, only five 
patients were diagnosed by 2001. Intensive screening of the other family members 
resulted in the identification of 12 additional patients. Before diagnosis, most of these 12 
patients did not report complaints. But after only a few weeks of adhering to a GFD, 
most of them reported a dramatic decrease of fatigue and disappearance of mild 
abdominal pain and diarrhoea. All these individuals stated that their quality of life had 
increased significantly and they are willing to adhere to the GFD in the future. This 
emphasizes once again the importance of screening for coeliac disease in family members 
of patients, even when no obvious complaints are reported.  
The family presented here was originally collected for our affected sibpair study.11 
However, the family was excluded because of the exceptionally large number of affected 
individuals. This family alone would have provided 46 sibpairs, compared to 84 from the 
other 67 families and this would have seriously biased our results. One explanation for 
the high percentage of affected offspring in the second generation could be consanguinity 
between the grandparents, resulting in transmission of the same disease locus by both 
grandparents. The grandparents (IDs 01 and 02) originated from two small neighbouring 
villages in the north of the Netherlands, but genealogical investigation did not reveal 
consanguinity within the last six generations.  
The apparent dominant disease transmission through four generations suggested a 
Mendelian cause of the disease in this family. Surprisingly however, bilineal transmission 
of two possible non-HLA disease loci, at 9p21-13 and 6q25.3 respectively, was detected, 
and neither of these loci was shared by all patients. Sixteen affected individuals share a 
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haplotype of 2.1 cM at 9p21-13, which was transmitted by the affected grandmother (ID 
02). Only one patient, ID 11, inherited the other maternal haplotype. There are no 
reasons to doubt her diagnosis, so her disease is probably caused by other susceptibility 
genes. In addition, a locus at 6q25.3 was inherited from the grandfather (ID 01) and 
shared by 14 of 16 affected offspring. Transmission of a disease locus by the grandfather 
is not at all unlikely, as he presents with several characteristics compatible with coeliac 
disease. The 6q25.3 locus was missed in the parametric analysis, because of the model 
that was used. This locus is present in ID 11, possibly compensating for the absence of 
the 9p21-13 locus. Several other loci with parametric lod scores >1.0 and non-parametric 
p-values <0.05 were also present, and some of these may add to the disease risk in some 
patients. 
Recently we have completed a genome-wide screen in affected Dutch MIII 
sibpairs.11 We identified a major coeliac disease locus on chromosome region 19p13.1, 
and a second locus on chromosome region 6q21-22, distinct from HLA. No evidence for 
linkage to 9p21-13 or 6q25.3 was obtained in our affected sibpair study. So the major loci 
in this large family are not important loci in Dutch coeliac disease patients in general. On 
the other hand, the two major loci identified in the affected sibpair study have no 
significant effect in this family. However, further evidence for linkage of coeliac disease 
to 9p21 was provided by two previous studies in Swedish/Norwegian (p = 0.038)14 and 
Finnish affected sibpairs (lod = 1.11)15, indicating that this locus may be a true, but not a 
major, risk factor for coeliac disease in general. Linkage of coeliac disease to 6q25.3 was 
not present in other populations, but linkage to this region has been observed several 
times in type 1 diabetes mellitus.16 Type 1 diabetes mellitus is associated with coeliac 
disease,17 and this locus may harbour a shared susceptibility gene for these disorders. 
As expected, linkage to the HLA-region at 6p21.3 was also present, with a 
maximum lod score of 2.33 at marker MIB. Although all affected individuals in the study 
family are DQ2-positive and this marker is informative in all but one transmission, the 
maximum attainable lod score was not reached. Both grandparents are heterozygous 
DQ2 carriers, and ID 14 is homozygous DQ2. He has transmitted the grandfather’s 
DQ2 haplotype to his affected daughter (ID 32), thereby destroying the linkage. This 
situation illustrates the problems frequently encountered in linkage analysis in complex 
disorders. When risk alleles are common in the population, they can also be present in 
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healthy spouses. In this study family, DQ2 is also married-in by ID 18 (DQ2 
heterozygote) and ID 40 (DQ2/DQ8).  
 Even within this one family, the disease appears to be genetically heterogeneous 
and of multigenic origin. Surprisingly, the major loci identified in our affected sibpair 
study do not play a significant role in this family. Nevertheless, this large family may be 
important for understanding of the pathogenesis of coeliac disease. The loci involved in 
this family may not be of major importance for coeliac disease in general, but they may 
play a role in a small proportion of coeliac disease patients. These loci may be hard to 
detect by an affected sibpair approach because of the small relative risk of such loci. 
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Summary 
Coeliac disease is a common autoimmune disorder, which is strongly associated to the 
HLA region. However, the contribution of the HLA region has been estimated to be no 
more than 50%, so non-HLA genes must also be involved in the aetiology of coeliac 
disease. We have recently performed a genome-wide screen to localise these genes, and 
we identified significant linkage to 19p13.1. This region was subjected to systematic fine-
mapping in a case-control cohort, using a DNA pooling strategy, to identify the coeliac 
disease susceptibility gene. Firstly, the region was saturated with microsatellite markers 
and strongest association was detected at marker D19S899 (overall P-value = 0.0013), 
which is the marker at which the multipoint lod score peaked. The 450 kb region of 
interest around this marker was covered with single nucleotide polymorphisms (SNPs), 
which were typed in the patient and control pools. Eleven SNPs showed significant 
association, four of which were subsequent SNPs in the 3’ region of the gene encoding 
myosin IXB (MYO9B). Single typing of 15 SNPs in the MYO9B gene region showed 
association of six of them (P <0.01). Five SNPs in the MYO9B gene combine into a 
haplotype, which is present in 38.8% of patients and in 30.9% of controls (P = 0.02). 
However, the associated region may actually cover eight genes and further research 
should be directed towards the extent of the observed association before mutational 
analysis of positional candidate genes can be commenced. 
 
Introduction 
The development of coeliac disease is clearly influenced by genetic factors and the 
importance of HLA-DQ2 and DQ8 has been known for a long time. Furthermore, it has 
been well established that other, non-HLA genes must contribute to the disease as well. 
Ten genome-wide screens have been completed so far to localise these genes (see also 
Chapters 2 and 3). However, no non-HLA genes contributing to coeliac disease have 
been identified to date, although there is growing evidence for a role of the CTLA4 
gene.1 
We have recently completed a genome-wide screen in 101 Dutch sibpairs affected 
with coeliac disease and identified significant linkage to chromosome region 19p13.1 
(MMLS 4.31; P = 6.2 x 10-6, see also Chapter 2).2 This locus makes a considerable 
contribution to coeliac disease, with an estimated sibling relative risk of 2.6. The 
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identical-by-descent (IBD) allele sharing at the peak of the multipoint lod score was Z0 = 
0.095, Z1 = 0.5, Z2 = 0.405 (Z0,1,2 represents the proportion of affected sibpairs sharing 
0, 1 or 2 alleles IBD, respectively (data not shown)). This IBD distribution suggests that 
the 19p13.1 locus acts in a dominant mode with approximately 60% of the families linked 
to this locus, thus providing us with an excellent opportunity to identify this important 
susceptibility gene for coeliac disease. 
The 19p13.1 candidate region, defined by the maximum lod score –1 support 
interval, spans some 3 Mb (based on the linkage analysis in all 82 families). However, this 
region is very gene-rich and contains 92 genes and ESTs. To identify the coeliac disease 
susceptibility gene, we first performed fine-mapping of the region using a DNA-pooling 
strategy in order to narrow-down the number of candidate genes. SNPs within the 
associated region were subsequently tested for association with coeliac disease.   
 
Subjects and Methods 
Subjects 
DNA, isolated from whole blood or buccal cells, was available from 216 independent 
Dutch coeliac disease patients. The initial biopsy specimens of the patients were retrieved 
and all showed a Marsh III lesion upon re-evaluation by one experienced pathologist (Dr. 
Meijer, Rijnstate Hospital, Arnhem). The cohort consisted of children and adults, with 
65% females and a mean age of 39 years. There were also 216 Dutch controls available, 
matched for age and sex to the patients. In addition, 122 parent-case trios, with one child 
with a Marsh III lesion and both parents, were available for TDT. The study was 
approved by the Medical Ethics Committee of the University Medical Centre Utrecht and 
written informed consent was obtained from the coeliac disease patients and the control 
individuals. 
 
Preparation of DNA pools 
DNA pools were constructed by pooling equal amounts of genomic DNA isolated from 
peripheral blood lymphocytes from patients and controls. DNA isolated from buccal 
cells was excluded because of its lower quality. Therefore, 199 coeliac disease patients 
were included and divided into two patient pools. Two control pools were created, 
comprising 199 matched control individuals. The DNA pools were constructed 
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according to standard protocols.3 In short, the DNA concentration of the individual 
samples was measured with PicoGreen and 200 ng of DNA of each individual was added 
to the appropriate pool. Pools were purified by phenol extraction and dissolved in water 
to a final concentration of 15 ng/µl.  
 
Genotyping of microsatellite markers 
All known microsatellite markers within the candidate region (based on the Ensembl map 
of November 2002) were genotyped in the patient and control pools, giving an average 
distance of 250 kb (Table 1). Several markers adjacent to this region were also typed to 
ensure that the entire region that could harbour the gene was covered, as the 3 Mb region 
is merely a support interval, based on the results in all 82 families (which is smaller than 
the support interval estimated from the results in the initial 67 families). Five of the 23 
markers included in this study were also used for the linkage analysis in affected sibpairs.2 
The markers were genotyped as described in Chapter 2, but using 27 cycles instead of 33 
to reduce PCR artefacts. The positions of the microsatellite markers were checked in the 
Ensembl (July 2003) and Celera databases (July 2003). 
 
Genotyping of single nucleotide polymorphisms (SNPs) 
Fine-mapping of the candidate region by microsatellite markers resulted in a region of 
interest of ~450 kb between 16.80 to 17.25 Mb (based on the Ensembl map of July 
2003). Fifty-two SNPs covering this region were selected from the Ensembl database. 
SNPs were positioned with an average spacing of 10 kb and those with a minor allele 
frequency >10% were preferred. These SNPs were genotyped on the patient and control 
pools by SNaPshot technology (AppliedBiosystems). Fifteen SNPs were subjected to 
individual genotyping using Assays-on-Demand or Assays-by-Design on the TaqMan 
7900HT system (AppliedBiosystems). These SNPs were selected from the Celera map 
and five of them had also been genotyped on the pools. The positions of all SNPs were 
checked in the Ensembl (July 2003) and Celera databases (July 2003). 
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Table 1. Microsatellite markers for association analysis in DNA pools. 
 Markera Position 
(Mb)c 
1 D19S714* 15.57 
2 D19S411 15.75 
3 D19S711 15.94 
4 D19S885 16.05 
5 D19S917 16.21 
6 D19S1171 16.74 
7 D19S930 16.81 
8 D19S899* 17.08 
9 D19S593 17.15 
10 D19S410 17.24 
11 D19S429 17.48 
12 D19S915 17.76 
13 D4S2293b 17.92 
14 D19S460* 18.22 
15 D19S898 18.32 
16 D19S48 18.99 
17 D19S566 19.01 
18 D19S603 19.21 
19 D19S407* 19.91 
20 D19S911 20.69 
21 D19S925 21.14 
22 D19S215* 21.45 
23 D19S560 23.69 
a Markers in italics are located within the maxLOD-1 support interval. Markers marked by an asterisk were 
also included in the linkage analysis (Chapter 2). 
b Marker D4S2293 is now mapped to chromosome 19. 
c The positions of the markers are based on the Ensembl Human Genome Map, July 2003. They were 
verified in the Celera Human Genome Map, July 2003, in which all positions were 0.06 Mb further. 
 
Statistical analysis 
Allele frequency estimation in DNA pools 
Allele frequencies of the microsatellite markers were estimated in the patient and control 
pools after correction for PCR-induced stutter artefacts (Schnack et al., manuscript 
submitted). In short, a marker specific stutter model was derived from genotype patterns 
of eleven individual samples, and pool patterns were corrected for stutter using this 
model. Allele frequencies were then estimated from the stutter-corrected pool patterns by 
adding the heights of all peaks and determining the percentage that each allele contributes 
to the total height. SNP allele frequencies were estimated directly from the peak heights 
of both alleles from the DNA pool patterns. 
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Association analysis 
The distribution of microsatellite marker alleles was compared between the patient and 
the control pools by χ2-analysis. Overall P-values were calculated by testing alleles with a 
frequency >5% and the remaining alleles pooled into one group, resulting in a χ2-test 
with n-1 degrees of freedom (df, n = number of tested alleles). Also, a P-value for the 
most significantly increased allele in cases was determined by testing one allele against the 
rest (χ2-test with 1 df). Allele frequencies of the SNPs were also compared between the 
patient and control pools by a χ2-test with 1 df. Markers and SNPs that were individually 
genotyped were tested by the same procedure. Haplotypes were estimated using the 
SNPHAP program from the individually generated genotypes (D. Clayton; available from 
http://www-gene.cimr.cam.ac.uk/clayton/software/).  
 Nine markers were also typed in the parent-case trios and analysed by the 
transmission/disequilibrium test (TDT). All alleles with a frequency >5% were tested for 
non-random transmission by χ2-analysis with 1 df. 
  
Results 
Fine-mapping with microsatellite markers  
Allele frequencies of the 23 microsatellite markers were estimated in the patient and the 
control pools (Table 1). Association analysis was performed for each marker by 
calculating overall P-values (Figure 1a) and a P-value for the most significantly increased 
allele in the cases (Figure 1b). Overall P-values of eleven markers were significant (P < 
0.05, -log10(P) > 1.3). It should be noted that the highly significant results of markers 
D19S714 and D19S930 (markers 1 and 7 from Table 1 and Figure 1) were mainly due to 
an increase in controls of alleles with a frequency <5% that were pooled into the rest 
group. When looking at the most significantly increased allele in cases, ten markers 
showed significant association. On comparing these results, there were two consistent 
regions with multiple associated markers. The first block of ~450 kb ranges from 
D19S930 to D19S410 (markers 7-10) and includes D19S899, the marker at which the 
multipoint lod score peaked (see also Chapter 2).2 The second block lies just outside the 
support interval and ranges from D19S566 to D19S407 (markers 17-19). The observed 
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association in this block is mainly due to one specific allele with a higher frequency in 
cases and there is little support from overall P-values. 
 
Figure 1. Association analysis of the microsatellite markers in cases and controls by DNA pooling (a + 
b) and by individual genotyping (c + d). P-values are presented as –log10(P) values. A P-value <0.05 was 
considered significant, corresponding to –log10(P) >1.3, and this threshold is indicated by the horizontal 
line. Positions are according to the Ensembl Human Genome Map, July 2003. The diamond symbols 
represent the markers, an overview of the markers is listed in Table 1. a + c. Overall P-value of the 
marker. The small horizontal lines indicate the markers that were subjected to individual genotyping with 
the numbers corresponding to those in Table 1. b + d. P-value of the most significantly increased allele in 
cases. 
 
To confirm the results obtained from the DNA pools, nine markers were 
subjected to individual genotyping: the four markers in the first block (markers 7-10), the 
three markers in the second block (markers 17-19), D19S48 (marker 16) because it is very 
close to D19S566, and D19S898 (marker 15) because of its significant result in the pools. 
Association of D19S899 (marker 8) could be confirmed with an overall P-value of 0.0013 
and an allele specific P-value of 0.0009 (Figures 1c and 1d). The overall P-value of 
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D19S410 (marker 10, P = 0.036) and the allele specific P-value of D19S407 (marker 19, P 
= 0.02) were also significant. Association of the other markers could not be confirmed.  
 The same nine markers were also genotyped in the parent-case trios, and only 
markers D19S48 (marker 16, P = 0.008) and D19S566 (marker 17, P = 0.006) showed 
preferential transmission of one specific allele. These alleles also form a haplotype, which 
was significantly more often transmitted (P = 0.009). 
 Even though the observed association of D19S899 could not be confirmed in the 
parent-case trios, this remains the prime region of interest. This marker is most 
significantly associated with coeliac disease in the case-control cohort and is located 
exactly at the position of the maximum lod score in the multipoint analysis. We therefore 
continued our search for the 19p13.1 coeliac disease gene in the region surrounding 
D19S899. However, the D19S48-D19S566 region is also of considerate interest and 
should also be subjected to further research.  
 
Table 2. Genes in the region of interest at 19p13.12. 
Noa Name Function Start 
positionb 
End 
positionb 
Ensembl ID 
1 SIN3B Unknown 16785441 16836373 ENSG00000127511     
2 F2RL3  Coagulation factor 
II (thrombin) 
receptor-like 3 
16845208 16847015 ENSG00000127533 
3 NM_015692  Alpha-2 
macroglobulin 
family protein VIP 
16849128 16982661 ENSG00000160111 
4 Q9BT25  Unknown 17005746 17031439 ENSG00000131351 
5 MYO9B  Myosin IXB 17057737 17169313 ENSG00000099331 
6 NM_018467  Uncharacterised 
hemato-poietic 
stem/progenitor 
cells protein 
MSD032 
17171408 17175847 ENSG00000053501 
7 NM_024578  Unknown 17182222 17185233 ENSG00000099330 
8 NR2F6  Orphan nuclear 
receptor EAR-2 
17187901 17201364 ENSG00000160113 
9 NM_031941 AIE-75 binding 
protein  
17206243 17220317 ENSG00000130307 
10 NM_014173 Unknown 17223442 17235355 ENSG00000105393 
11 NM_152363 Unknown 17239538 17243456 ENSG00000160117 
12 NM_024527 Unknown 17248150 17259443 ENSG00000127220 
a These numbers refer to the numbering of genes in Figure 2. 
b Positions were based on the Ensembl Human Genome Map, July 2003. 
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SNP genotyping in region of interest 
The region subjected to further study ranged from 16.80 to 17.25 Mb and contained 12 
genes (Figure 2 and Table 2). None of these genes were obvious functional candidates, so 
they were all investigated further. Fifty-two SNPs in this region of interest, evenly 
distributed with an average spacing of 10 kb, were genotyped in the patient and control 
pools. However, seven of these SNPs turned out not to be polymorphic and eleven SNPs 
could not be genotyped due to PCR problems. Eleven of the remaining 34 SNPs that 
could be successfully analysed showed association with coeliac disease (P <0.05, Figure 
2). Four of them were subsequent SNPs in a 27 kb region of the same gene, the gene 
encoding myosin IXB (MYO9B). The associated microsatellite marker D19S899 is also 
located in this gene. The myosin IXB gene region therefore received the highest priority 
and fifteen SNPs in this region were subjected to individual genotyping (Figure 2). Six of 
them showed significant association, five of which are located in the 3’ half of MYO9B 
(P-values varying from 0.02 to 0.003). The haplotype formed by the increased alleles of 
these five SNPs in cases is also significantly increased on comparing cases (38.8%) and 
controls (30.9%) (P = 0.02). 
 
Discussion 
Linkage analysis in Dutch affected sibpairs resulted in localisation of a susceptibility gene 
for coeliac disease to chromosome region 19p13.1. The candidate region spanned 3 Mb 
and contained 92 genes. Since fine-mapping of a region of this size would require a 
considerable amount of individual genotyping, we attempted to reduce the 19p13.1 
candidate region by screening for microsatellite marker association in pooled DNA. 
Allele frequencies were compared using two strategies, as previously suggested.4 
Comparison of overall allele distributions is expected to be a sensitive measure when 
multiple alleles of one marker are associated with the disease. Single associated alleles are 
more likely to be detected by testing each allele against the combined rest. Our aim was 
to reduce the candidate region to a size that could be followed up by individual 
genotyping. Therefore, no correction was applied for the number of tested markers and 
alleles in order to minimize the chance of false-negative results, thereby accepting an 
increased false-positive rate.  
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Figure 2. Overview of genes, SNPs and microsatellite markers in the region of interest on 19p13.12. 
Positions of genes, SNPs and markers are based on the Ensembl Human Genome Map, July 2003. The 
position on the X-axis is given in kb, position 0.0 corresponds to 16785441. The horizontal bars depict 
the genes in this region with the arrowheads indicating the transcription direction. The numbers above 
and below the genes correspond to the numbering in Table 2. The diamond symbols denote the 34 SNPs 
that were analysed in the DNA pools. The arrows indicate SNPs with significant different allele 
frequencies between the patient and control pools (P <0.05). The triangular symbols denote the 15 SNPs 
that were subjected to individual genotyping and the arrows indicate the significantly associated SNPs (P 
<0.05). The cross symbols denote the microsatellite markers that were also subjected to individual 
genotyping with the arrows indicating significantly associated markers (Poverall <0.05, see Figure 1). 
 
When looking at overall P-values obtained from the DNA pools, as many as half 
the markers showed significant association with coeliac disease. For some of these 
markers, most contribution came from the rare alleles that were pooled into one group, 
and that were increased in the controls. Testing for the most significantly increased allele 
in cases did not decrease the number of associated markers. However, significance levels 
were lower and only one region clearly showed the strongest association: the region 
around marker D19S899 (see Figures 1a and b). Association of two markers in this 
region, D19S899 and D19S410, could be confirmed by individual genotyping. D19S593, 
located between these two markers, did not show association, but this marker was not 
very informative, with a cumulative frequency of 80% for only two alleles. When 
combining all the results, the region of interest was narrowed-down to ~450 kb at 
19p13.12. This region contains only 12 genes, a reduction of 80 possible candidate genes.  
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 Genotyping of SNPs from the 450 kb region of interest in the DNA pools 
showed eight significantly associated SNPs in the 3’ 150 kb part of this region. Individual 
genotyping revealed the presence of six significantly associated SNPs in a region of 70 kb. 
However, no SNPs have yet been subjected to individual genotyping in the final 3’ 75 kb 
part of the region, and the disease-associated region may therefore span the entire 3’ 150 
kb part of the region. This region contains eight genes, four of which are of unknown 
function and four with functions that are not obviously compatible with coeliac disease. 
At this moment, the most interesting candidate gene is MYO9B since five of the six 
significantly associated SNPs are located in the 3’ part of this gene, which also form a 
significantly increased haplotype in cases. The MYO9B gene encodes an unconventional 
myosin which exhibits a GTPase activating protein (GAP) domain for Rho family small 
G-proteins in its tail.5 Myosin IXB regulates Rho activity by converting active Rho-GTP 
into the inactive Rho-GDP state. Rho activation results in formation of actin filament 
bundles (stress fibres) and focal adhesion complexes.6 Overexpression of the rat 
orthologue of myosin IXB (myr5) resulted in loss of actin filaments and cell contacts by 
inactivation of Rho.7 Furthermore, myosin IXB was shown to be an active motor, 
capable of binding to actin filaments independent of ATP presence.8 Human myosin IXB 
is most highly expressed in blood leukocytes, but is also expressed at lower levels in 
several other tissues, including small intestine.5 At first sight myosin IXB is not an 
obvious candidate for causing coeliac disease. However, it is possible that the presence of 
an intact cytoskeleton and/or focal adhesion complexes in the gut is necessary to deal 
with the gluten-derived peptides. The signal transduction capacity of myosin IXB may 
regulate this process.  
Although most evidence points towards the MYO9B gene region harbouring the 
gene predisposing to coeliac disease, other genes cannot be excluded yet. Markers 
D19S48 and D19S566, located approximately 2 Mb downstream of the MYO9B region, 
showed significant increased transmission to coeliac disease patients in the parent-case 
trios. These results could not be confirmed in the case-control cohort. The associated 
allele of D19S48 has a frequency of 66% in the controls, and this high frequency may 
have prohibited detection of association. However, the associated allele of D19S566 has a 
frequency of only 17% in controls. The case-control cohort does not have sufficient 
power to detect allele frequency differences ≤5%, which may explain the discrepancy. On 
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the other hand, about 30% parents will be heterozygous for the associated allele and, 
therefore, enough informative transmissions to affected children in the parent-case trios 
can be included to obtain statistical significance. D19S48 and D19S566 are both located 
within a gene with unknown function (NM_033415). Four SNPs in this gene were 
genotyped in the DNA pools, but there was no evidence for association (data not 
shown). However, it cannot be excluded that this gene, or another gene residing in this 
region, is also predisposing to coeliac disease.  
In conclusion, systematic fine-mapping of the 19p13.1 candidate region reduced 
the number of possible candidate genes from 92 to only eight. Additional SNPs in this 
region have to be tested by individual genotyping in the case-control cohort to determine 
the extent of the associated region. SNPs that show significant association should be 
confirmed in the parent-case trios and also typed in the 82 families from the linkage study 
to determine whether these SNPs explain the linkage. Genes within this region will have 
to be subjected to functional assays to determine which one is actually involved in coeliac 
disease. 
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Summary 
Objectives: The aim of this study was to determine whether the tissue transglutaminase 
gene (TGM2) is a causal factor in the pathogenesis of coeliac disease. Methods: A total of 
147 Dutch families with at least one biopsy-proven coeliac disease patient were available 
for this study. All the patients were diagnosed according to the revised European Society 
for Paediatric Gastroenterology and Nutrition (ESPGAN) criteria. A microsatellite 
marker in a non-coding region of the TGM2 gene was investigated for both linkage and 
association. Linkage was tested by determining the amount of allele sharing between 
affected brothers and sisters (affected sibpair analysis). Association was determined by 
comparing transmission of certain TGM2 alleles from parents to coeliac disease patients 
to the non-transmitted alleles by the transmission/disequilibrium test (TDT). Results: 
Linkage analysis did not show co-segregation of the TGM2 gene with coeliac disease in 
our families, neither was there any association between certain TGM2 alleles and coeliac 
disease. Furthermore, the TGM2 gene could be excluded as a coeliac disease susceptibility 
gene. Conclusions: Our results indicate that the TGM2 gene can be excluded as a major 
primary genetic factor in coeliac disease pathogenesis. 
 
Introduction 
Coeliac disease is a common food-intolerance in humans affecting 1/150 to 1/300 
individuals in the Netherlands.1,2 The disease is caused by dietary gluten, which are 
present in wheat, barley and rye. Ingestion of gluten leads to villous atrophy, crypt cell 
hyperplasia and infiltration of intestinal epithelium by lymphocytes in coeliac disease 
patients.3 Coeliac disease is strongly associated with human leukocyte antigen (HLA) 
DQ2: 90-95% of Caucasian patients express this molecule. The HLA-DQ2 negative 
patients are HLA-DQ8.4 HLA-DQ2 occurs frequently in the Dutch population, with a 
prevalence of ~25%.5 It is therefore anticipated that other genes will also be involved in 
coeliac disease aetiology. 
Gluten-derived peptides have been shown to bind to HLA-DQ2 and HLA-DQ8. 
These complexes are recognized by small intestinal T cell clones from coeliac disease 
patients. However, treatment with tissue transglutaminase (tTG) results in deamidation of 
specific glutamine residues in gliadin peptides. It has been shown that these modified 
peptides bind much better to HLA-DQ2 or HLA-DQ8 and the activity of the T cell 
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clones was greatly enhanced.6,7 Interestingly, autoantibodies to tTG are present in the 
serum of coeliac disease patients and these are very specific markers of coeliac disease.8 
Besides deamidation of glutamine residues to glutamic acid, tTG is an enzyme that 
catalyses the cross-linking of proteins.9 It is expressed in many tissues, including the small 
intestinal wall.10 In coeliac disease, tTG activity in small intestinal biopsy specimens from 
treated and untreated patients is higher than in control samples.11 It is unclear, however, 
whether this increased tTG activity is involved in the pathogenesis of coeliac disease, or 
whether this is a secondary effect due to the presence of the coeliac lesion.  
One could hypothesize that coeliac disease patients express a certain isoform of 
the gene encoding tTG (TGM2), resulting in an inadequate response to gluten ingestion. 
A recent study revealed no differences in the coding sequence of the TGM2 gene 
between eight patients and four controls.12 However, a pathogenic role for the TGM2 
gene in coeliac disease should not yet be excluded. Polymorphisms in regulatory, non-
coding sequences can lead to differences in the expression of the gene, and therefore in 
activity of the tTG protein. We studied the involvement of the TGM2 gene in coeliac 
disease by using a dinucleotide repeat polymorphism in the promoter region of the gene 
as a marker. This marker in TGM2 was tested for both linkage and association in a cohort 
of 147 Dutch families with at least one patient with coeliac disease, assuming that if a 
polymorphism in the TGM2 gene causing coeliac disease exists, it will be in linkage 
disequilibrium (LD) with the marker. 
 
Materials and Methods 
Subjects 
A total of 147 Dutch coeliac disease families were ascertained for this study. For the 
linkage analysis, 72 Dutch families with at least 2 children with coeliac disease were 
ascertained. DNA was collected from the patients and their first-degree relatives. These 
families contained a total of 81 affected sibpairs, which were used for affected sibpair 
analysis. In addition, association was studied using the transmission/disequilibrium test 
(TDT), which scores transmission of certain alleles to affected children. For this test, 
families with at least one child with coeliac disease and both parents willing to participate 
were collected. Forty-four of the families that participated in the linkage study were 
included in the association study. Another 75 Dutch families were ascertained for this 
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study, so that in total 119 families were available to perform the TDT test. All patients 
were diagnosed according to the revised European Society for Paediatric 
Gastroenterology and Nutrition (ESPGAN) criteria.13 The patients in this study included 
both children and adults. A total of 89 healthy Dutch Caucasian controls were available 
to determine allele frequencies of the TGM2 repeat polymorphism. 
 
Analysis of the tissue transglutaminase gene 
A GT repeat in the promoter region of the human TGM2 gene on chromosome 20, 
500bp upstream of the translation start site14 (GenBank accession number U13920), was 
amplified by PCR using the following primers: TGM2for, 5'-ATC CAT GTC ACT GTG 
TCT GC-3'; TGM2rev, 5'-ATA CAG ATA CAC GCA GCA CC-3'. The size of the 
products was determined as described elsewhere.15 The allele frequencies of this 
polymorphism were determined in 89 healthy Dutch controls. The CEPH reference 
samples 1331-01, 1331-02 and 1347-02 were included in all runs as control samples to 
allow adjustment of the sizes of the patient and control alleles between different 
experiments. 
 
Statistical analysis 
A linkage analysis was performed to determine whether the TGM2 alleles segregated with 
coeliac disease in families. This was done by calculating maximum likelihood scores 
(MLS) using the Mapmaker/sibs program,16 which calculates the allele sharing between 
affected siblings, and determines whether this is significantly different from the average 
sharing of 50% between brothers and sisters. Exclusion analysis was performed to 
determine whether the TGM2 gene could be excluded as an inherited gene for coeliac 
disease with different relative risks. The threshold for exclusion is at a lod score ≤ -2. 
To determine whether the one of the TGM2 alleles was associated with coeliac 
disease in our patients, an association analysis was performed by TDT,17 using the asstdt 
routine from the GAS package version 2.0 (A. Young, available from: 
ftp://ftp.ox.ac.uk/pub/users/ayoung). This test scores the transmission of alleles from 
heterozygous parents to affected children by comparing the transmitted alleles to the 
non-transmitted alleles. If an allele is not associated with the disease, a random 
transmission of 50% would be expected. Families with both parents available that were 
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used for the linkage analysis were also included in the association analysis. This can be 
justified, as it is possible that different TGM2 alleles segregate with coeliac disease in 
different families. In this situation, the polymorphism studied is probably not the causal 
variant, but in LD with the true functional variant causing the disease. Therefore, a 
certain polymorphism can be linked to a disease, but not be associated with that disease. 
In families with more than one affected child, transmissions to all affected children were 
included, which is allowed when linkage, as demonstrated by affected sibpair analysis, is 
absent. Association analyses was only performed with alleles with a frequency of 5% or 
more in the population to minimize multiple testing. 
 
Results 
The GT repeat in the promoter region of the human TGM2 gene was first tested in 178 
chromosomes from subjects without coeliac disease. Six different alleles were detected, 
ranging in size from 298 bp to 308 bp (Table 1). The observed heterozygosity of this 
microsatellite marker in the Dutch population was 67.6%. Alleles 2 and 4 were frequent 
in our population, but alleles 1, 3 and 5 occurred much less frequently. Allele 6 was 
present in only one person. The polymorphic repeat was investigated in the coeliac 
disease families. All alleles, except allele 6, were present in this group. However, a new 
allele of 296 bp was present on one chromosome in one person.  
 
Table 1. Frequency of the TGM2 promoter polymorphism alleles in the Dutch population. 
Allele Size (bp)a Allele frequencies 
1 298 0.13 
2 300 0.44 
3 302 0.06 
4 304 0.33 
5 306 0.03 
6 308 0.01 
a Allele sizes of the CEPH reference samples: 1331-01, 300/300 bp; 1331-02, 300/300 bp and 1347-02, 
300/304 bp. 
 
Linkage analysis in 81 affected sibpairs demonstrated a random distribution of 
TGM2 alleles, with 25% of the affected sibpairs sharing 0 alleles, 50% sharing 1 allele and 
25% sharing 2 alleles. This allele distribution resulted in a maximum likelihood score 
(MLS) of 0.0, as expected. The results of the exclusion analysis showed that the TGM2 
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gene could be excluded as a coeliac disease locus with a relative risk of 2 or higher (Table 
2). Therefore, the TGM2 gene could be excluded as a major coeliac disease locus. 
 
Table 2. Results of exclusion analysis. 
Relative risk Lod score 
1.25 -0.48 
1.5 -1.08 
1.75 -1.68 
2 -2.24 
2.5 -3.23 
3 -4.08 
3.5 -4.80 
4 -5.44 
 
Association analysis of the four alleles with a frequency of 5% or more (i.e. alleles 
1, 2, 3 and 4) was performed in 119 families. If the TGM2 gene is involved in coeliac 
disease, the TGM2 allele that confers risk to coeliac disease should be transmitted 
significantly more often to affected children than not transmitted. The presence of a 
TGM2 risk allele was tested by performing a TDT test (Table 3). Our results clearly show 
that none of these alleles were preferentially transmitted to coeliac disease patients. 
 
Table 3. Transmission of the major TGM2 alleles to coeliac disease patients. 
Allele Transmitted Not transmitted P-value 
1 41 47 NSa 
2 85 80 NS 
3 17 22 NS 
4 70 62 NS 
a NS: not significant. 
 
 
Discussion 
The major genetic contribution to coeliac disease known to date comes from the DQA1 
and DQB1 genes in the HLA-region, encoding the HLA-DQ heterodimer. Ninety-five 
percent of coeliac disease patients express the HLA-DQ2 protein. However, since 25% 
of the general population also express HLA-DQ2, it is likely that other genes are also 
involved in coeliac disease. This can also be concluded from the results of studies that 
tried to determine the contribution of the HLA-region.18,19 Both studies concluded that 
the relative risk for a sibling of a coeliac disease patient (λs) contributed by the HLA-
locus could not be more than 4. In view of the total predicted λs for coeliac disease of 
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approximately 25, which is based on a population prevalence of 1 in 250 and a 10% risk 
for a sibling, non-HLA loci must play a considerable role in coeliac disease.  
However, none of the two whole genome screens that have been performed so 
far20,21 have identified loci with a lod score higher than the HLA-region, except for one 
locus in the Irish population on the short arm of chromosome 6, telomeric to HLA.20 
However, this result was not replicated by other groups.21-23 So, it seems that there may 
be many additional loci, which each contribute only a little to the total genetic risk.  
An alternative to the whole genome approach is the study of candidate genes 
based on knowledge of the disease process. The gene encoding tissue transglutaminase 
can be considered as an attractive functional candidate gene for coeliac disease. First, tTG 
is involved in the repair of damaged tissue.9 In the small intestinal mucosa of coeliac 
disease patients, constant inflammation and tissue damage is present. Second, it is capable 
of deamidating gluten peptides, thereby creating a strong epitope for HLA-DQ2 and 
HLA-DQ8 proteins.6,7 Third, its activity is increased in the gut of both untreated coeliac 
disease patients and patients on a gluten-free diet.11 In particular, the increased activity in 
treated patients points to the possible effect of a functional polymorphism in the TGM2 
gene itself. It is unknown however whether expression of tTG in the gut of coeliac 
disease patients is also increased. And fourth, the tTG enzyme was identified as the target 
of the endomysial antibodies,8 although the exact role of these antibodies in the disease 
process remains unclear.24 
To implicate tTG as a causal factor in the pathogenesis of coeliac disease, a 
functional polymorphism in the TGM2 gene should be involved in the pathogenesis of 
the disease. The repeat in the promoter region of the TGM2 gene turned out to be highly 
polymorphic and proved to be a good marker for studying the involvement of this gene 
in coeliac disease. It is not necessary however that this repeat polymorphism itself will 
affect the activity or expression of the protein. If a functional variant, either coding or 
non-coding, causing coeliac disease is present in the TGM2 gene, it is assumed that the 
alleles of the repeat polymorphism will be in LD with this functional variant in coeliac 
disease families. Therefore, the alleles of the repeat polymorphism will segregate with the 
disease in coeliac disease families and, as a consequence, increased sharing of the alleles 
will be present in affected siblings, which can be detected by linkage analysis. 
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Furthermore, if the functional variant is in LD with the same repeat allele in unrelated 
patients, than this specific repeat allele would also be associated with coeliac disease. 
The polymorphic repeat in the TGM2 gene was used for linkage and association 
studies. Affected sibpair analysis showed that the alleles of this marker did not co-
segregate with the coeliac disease in our families. Furthermore, the TGM2 gene could be 
excluded as a susceptibility locus for coeliac disease with a relative risk (λs) of 2 or higher. 
These results were confirmed by association analysis by TDT, which demonstrated that 
none of the TGM2 alleles were associated with coeliac disease.  
This is the first report of a genetic approach in a large number of families to study 
whether variants in the TGM2 gene are inherited factors in coeliac disease. Our findings 
clearly show that it is very unlikely that polymorphisms in the TGM2 gene are causally 
related to coeliac disease. These results complement those of Aldersley et al.,12 who 
found no differences in the coding region of the TGM2 gene between a small number of 
coeliac disease patients and controls. The increased tTG activity that is measured in small 
intestinal biopsy samples of coeliac disease patients could be a secondary effect of the 
disease process, even in patients on a gluten-free diet. However, it can also be caused by 
polymorphisms in genes coding for proteins that regulate transcription of the TGM2 
gene. To find such other genes, genome-wide scans in multiply affected families have to 
be performed. Further understanding of the role of tTG in coeliac disease pathogenesis 
will have to be elucidated by future studies.  
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Summary 
Coeliac disease is an autoimmune disorder, characterised by villous atrophy of the small 
intestine, which results from a T-cell mediated response to gluten-derived peptides. The 
cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) is involved in regulation of T-cell 
activation and the CTLA4 +49 A/G polymorphism has been implicated in several 
autoimmune disorders. Association of this polymorphism with coeliac disease has been 
demonstrated in some populations, but not in others. The role of the +49 A/G variant in 
coeliac disease patients of Dutch origin was determined by typing the polymorphism in 
210 coeliac disease patients and 208 controls. Neither allele nor genotype frequencies 
were significantly different distributed between cases and controls. However, a small 
effect of the GG-genotype was observed, which was present in 18% of cases and in 11% 
of controls (OR 1.78, 95% CI 0.99-3.31, p = 0.038). Although these findings suggest that 
the CTLA4 gene is not a major determinant of coeliac disease susceptibility in the Dutch 
population, the GG-genotype may confer an increased risk for developing the disease. 
Recently it was shown that the haplotype carrying the G-allele is associated with lower 
mRNA levels of the soluble CTLA-4 isoform, providing a possible mechanism for the T-
cell mediated destruction of the small intestine. 
 
Introduction 
Coeliac disease is an autoimmune disorder and is strongly associated with the HLA 
region. The majority of the patients express the HLA-DQ2 protein and almost all 
remaining patients express HLA-DQ8. Coeliac disease is characterised by an 
inappropriate T-cell response to gluten in the small intestine. Gluten proteins are present 
in wheat, barley and rye, and gluten-derived peptides can bind to HLA-DQ2 and DQ8 
on the surface of antigen-presenting cells. These complexes are recognised by gluten-
specific T-cells in the gut of coeliac disease patients, resulting in inflammation, crypt 
hyperplasia and villous atrophy.1,2 The HLA association only partly explains the genetic 
contribution, so non-HLA genes must also be involved in coeliac disease.  
The cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and the cell 
designation 28 antigen (CD28) are involved in regulation of T-cell activation. CD28 
induces the T-cell response, whereas CTLA-4 has an inhibitory effect.3 Because of their 
functions they are interesting candidate genes for autoimmune disorders. The genes 
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encoding these proteins are both located within a 150 kb region on chromosome 2q33-
34. The A/G polymorphism at position +49 in exon 1 of the CTLA4 gene has been 
extensively studied in autoimmune disorders and association with type 1 diabetes 
mellitus,4 Graves' disease,5,6 Hashimoto’s thyroiditis7 and multiple sclerosis8 has been 
demonstrated (for a review, see9). It is likely that coeliac disease shares a common genetic 
background with other autoimmune diseases, so the CTLA4 gene may be involved in 
coeliac disease as well. We investigated the contribution of the CTLA4 gene to coeliac 
disease risk by typing the +49A/G polymorphism in a Dutch case-control cohort.  
 
Subjects and Methods 
Subjects 
A total of 216 independent, biopsy-proven coeliac disease patients of Dutch origin were 
available for this study. Their mean age was 39 years and 65% were female. The control 
group consisted of 216 sex- and age-matched independent Dutch individuals. The study 
was approved by the Medical Ethics Committee of the University Medical Centre Utrecht 
and written informed consent was obtained from all the participants. 
 
Genotyping 
Genotypes of the A/G polymorphism at position +49 of the CTLA4 gene were 
determined by PCR-restriction fragment enzyme analysis (PCR-RFLP) with the Fnu4HI 
enzyme. The fragment containing the polymorphism was amplified with primers 5'-TTG 
CCT TGG ATT TCA GTG GC-3' and 5'-CTG CTG AAA CAA ATG AAA CCC-3', 
resulting in a fragment of 175 bp. Digestion with Fnu4H1 of the product containing the 
G-allele resulted in fragments of 42 bp and 133 bp. The genotyping procedure was 
verified by sequencing of three samples with predicted genotypes AA, AG and GG, 
respectively. These three samples were included as positive controls in each of the five 
sample plates. 
 
Statistical analysis 
Allele and genotype frequencies of the CTLA4 +49 A/G polymorphism were 
determined in cases and controls. Significance of allele and genotype distributions was 
tested by means of a χ2 test with 1 and 2 degrees of freedom (df), respectively. 
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Association of the GG-genotype was tested versus the other genotypes by χ2 analysis 
with 1 df. The genotype frequencies were tested for Hardy-Weinberg equilibrium by χ2 
analysis, with a value of p<0.05 considered as not in equilibrium. Odds ratios for G- 
allele and the GG-genotype versus AA and AG genotypes were calculated using the 
Woolf-Haldane correction. 
 
Results 
The +49 A/G polymorphism in the CTLA4 gene could be genotyped in 210 cases and 
208 controls (Table 1). The genotypes in the controls were in Hardy-Weinberg 
equilibrium (χ2 = 0.48, p = 0.49). The frequency of the G-allele was slightly increased in 
the coeliac disease patients, but this difference was not significant. The distribution of the 
three genotypes was not significantly different between cases and controls. However, the 
GG-genotype was more prevalent in the coeliac disease patients, with a frequency of 18% 
in cases compared to a frequency of 11% in controls (OR 1.78, 95% CI 0.99-3.31, p = 
0.038). 
 
Table 1. Allele and genotype frequencies of the CTLA4 +49A/G polymorphism. 
 Coeliac disease  
(n = 210) 
Controls  
(n = 208) 
P-value (χ2) OR (95% CI) 
Allele     
A 0.61 0.66   
G 0.39 0.34 0.14 (2.17) 1.23 (0.92-1.65) 
     
Genotypea     
AA 0.39 0.42   
AG 0.43 0.47   
GG 0.18 0.11 0.038 (4.27) 1.78 (0.99-3.31) 
a P-value for the global genotype distribution: P = 0.12 (χ2 = 4.29, 2 df). 
 
 
Discussion 
The CTLA4 gene has been implicated as a general susceptibility gene for autoimmune 
diseases9. The +49 A/G polymorphism is the most extensively studied, as this is the only 
polymorphism in the CTLA4 gene that alters an amino acid.10 The G-allele encodes an 
alanine residue at codon 17 of the protein, whereas the A-allele encodes a threonine 
residue. Type 1 diabetes mellitus, Graves' disease, Hashimoto’s thyroiditis and multiple 
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sclerosis have all been associated with the G-allele. So the codon 17 alanine residue may 
be common denominator for autoimmunity. 
In our sample, the frequency of the G-allele was also found to be increased in the 
cases, although not significantly. Even though the genotype distributions were not 
significantly different between cases and controls, there was a small effect of the GG-
genotype. These results indicate that the GG-genotype may be associated with a slightly 
increased risk for coeliac disease in the Dutch population.  
Several other groups have investigated the involvement of the CTLA4 gene in 
coeliac disease, but the results have been conflicting. Association of the +49 A/G 
polymorphism has been reported in French and Swedish/Norwegian populations,11-13 
but was absent in Italian, Tunisian and Finnish populations and in a combined sample of 
families from Northern Europe.14-16 Recently, a meta-analysis of these studies was 
performed.16 Combining data from the seven studies that were analysed by the 
transmission/disequilibrium test (TDT) resulted in a non-significant p-value of 0.20. One 
may conclude that this polymorphism does not contribute to coeliac disease risk, but lack 
of power of the TDT approach may also have influenced these results. The TDT design 
may not be an appropriate test for association since parents have a 55% probability of 
being homozygous at this locus, based on the allele frequencies in Dutch controls. This 
dramatically reduces the power and a case-control design may be preferred. Inclusion of 
the only case-control study11 in the meta-analysis reduced the p-value to 0.019. However, 
the results from this case-control study should be regarded with circumspection as the 
genotypes of the controls were not in Hardy-Weinberg equilibrium, which may have 
resulted from genotyping errors. 
Remarkably, the positive association of the +49 A/G polymorphism with coeliac 
disease in French and Swedish/Norwegian populations was with the A-allele.11-13 This 
argues in favour of the possibility that not the +49 A/G polymorphism itself, but a 
variant in linkage disequilibrium with this polymorphism is contributing to the disease 
risk. Indeed, a recent publication10 showed that the causal variant involved in Graves’ 
disease, autoimmune hypothyroidism and type 1 diabetes mellitus is most probably 
located in the 6.1 kb region 3’ of the CTLA4 gene, and the +49 A/G polymorphism 
could be rejected as a causal polymorphism. Two very common CTLA4 haplotypes were 
present: one protective haplotype with the A-allele at position +49 and one disease-
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susceptible haplotype with the G-allele at position +49. More importantly, the disease-
susceptible haplotype encodes an alternatively spliced CTLA-4 mRNA, resulting in lower 
mRNA levels of the soluble CTLA-4 isoform compared to the protective haplotype.  
Taken together, the CTLA4 gene seems to confer an increased risk to coeliac 
disease, at least in some populations. The risk is probably mediated by the disease-
susceptible haplotype, associated with lower mRNA levels and possibly with lower 
protein levels of the soluble CTLA-4 isoform. This may result in a disruption in the 
regulation of the T-cell response by CTLA-4 and CD28, leading to a T-cell mediated 
destruction of the gut. Determination of the mRNA levels of the soluble CTLA-4 
isoform in small intestinal tissue from coeliac disease patients may provide more insight 
into the role of the CTLA4 gene in coeliac disease pathogenesis. 
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Summary  
Background: Coeliac disease is a complex inflammatory disorder of the small intestine. It is 
characterized by an inappropriate T cell response to dietary gluten in genetically 
susceptible individuals. One of the most important cytokines in this process is interferon-
γ (IFN-γ), which becomes highly expressed in the gut of patients when stimulated with 
gluten. Notably, expression of IFN-γ is also increased in treated patients with complete 
clinical recovery, suggesting that a genetic factor influencing the expression of the IFNG 
gene may predispose to coeliac disease. We therefore aimed to investigate whether the 
IFNG gene is a causal factor in coeliac disease pathogenesis by testing for association 
with a microsatellite marker in the first intron, of which a certain allele is associated with 
high expression of IFN-γ. Methods: The CA repeat in IFNG was genotyped in 207 coeliac 
disease patients and 210 normal controls. The marker was also genotyped in 122 parent-
case trios. Overall association of the polymorphism was determined, as well as a specific 
effect of the allele associated with high expression of IFN-γ. Results: The allele 
frequencies were not significantly different distributed between cases and controls. 
Furthermore, there was no evidence for a specific effect of the highly expressed allele. 
Likewise, all alleles were randomly transmitted to affected children in the parent-case 
trios. Discussion: The IFNG gene is not a predisposing factor in coeliac disease, even 
though IFN-γ is a very important cytokine in the pathogenesis of this disease. 
 
Introduction 
Coeliac disease is a gluten-sensitive enteropathy of the small intestine, characterised by 
increased numbers of lymphocytes in the gut epithelium and lamina propria, crypt 
hyperplasia and villous atrophy. Clinical symptoms include gastrointestinal complaints 
such as diarrhoea and abdominal distension but also fatigue, weight loss, growth 
retardation, anaemia, osteopenia and failure to thrive.1 The disease is caused by ingestion 
of wheat gluten and similar proteins in barley and rye. Gluten peptides are not completely 
digested by the enzymes in the stomach and small intestine.2 The partially digested gluten 
peptides cross the gut epithelium by an unknown mechanism. These peptides are bound 
by HLA-DQ2 and -DQ8 proteins on the cell surface of antigen presenting cells and 
recognized by the T cells in the lamina propria.3 This explains the well-known genetic 
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association between coeliac disease and HLA-DQ, with over 90% of patients expressing 
DQ2 and almost all DQ2-negative patients expressing DQ8. Withdrawal of gluten from 
the diet usually results in normalisation of the small intestinal lesion and complete 
disappearance of the clinical symptoms.  
 Interferon-γ (IFN-γ) plays an important role in coeliac disease pathogenesis. The 
expression of IFN-γ mRNA is highly increased in small intestinal biopsies from untreated 
patients compared to histologically normal controls. 4-7 The proportion of IFN-γ 
producing T cells was also increased in untreated patients.4,5,7 Moreover, in vitro gliadin 
challenge of biopsies from treated patients (patients on a gluten-free diet with normal 
histology) showed IFN-γ mRNA levels that were increased to the levels detected in 
untreated patients.5 In addition, cultured duodenal biopsy specimens from normal 
individuals showed damage to enterocytes when stimulated with IFN-γ or supernatants 
from gluten-sensitive T cells.8 The toxic effects of the supernatants from gluten-sensitive 
T cells could be blocked by administration of anti-IFN-γ antibodies, indicating that IFN-
γ is involved in the destruction of the enterocytes.  
Notably, expression of IFN-γ by intra-epithelial lymphocytes was still increased in 
treated, symptom-free patients with normal histology.4 One explanation could be a 
predisposition of coeliac disease patients to high IFN-γ expression. Polymorphisms in 
genes involved in the expression of IFN-γ may be associated with a high expression level 
of IFN-γ and, therefore, with coeliac disease. However, a polymorphism in the IL12B 
gene, encoding the p40 subunit of interleukin (IL)-12 which is a strong inducer of IFN-γ 
secretion, was not associated with increased risk to coeliac disease.9,10 Likewise, no 
evidence has been found for association of coeliac disease with the gene encoding 
interferon regulatory factor (IRF)-1, a transcription factor potentially involved in 
expression of IL-12.10 Therefore, the IFN-γ gene (IFNG) itself may be considered as a 
candidate gene. 
The gene encoding IFN-γ (IFNG) is located on chromosome region 12q15 and it 
does not contain any polymorphisms in coding regions.11 One of the intronic 
polymorphisms is a CA-repeat in the first intron of the gene, which was shown to be in 
complete linkage disequilibrium with an A/T single nucleotide polymorphism (SNP) at 
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position +874. This SNP showed an absolute correlation between the presence of a T-
allele at +874 and the presence of 12 CA repeats.12 It has been suggested that these alleles 
are associated with increased levels of IFN-γ production,13-15 although others were unable 
to confirm this finding.16,17 The CA-repeat polymorphism has been shown to be 
associated with several auto-immune disorders like type 1 diabetes mellitus,18,19 
rheumatoid arthritis,20 and multiple sclerosis.21,22 The aim of this study was to evaluate 
the role of the IFNG gene in coeliac disease by association analysis of the CA-repeat in 
two cohorts of Dutch coeliac disease patients.  
 
Subjects and Methods 
Subjects 
The first cohort consisted of 207 independent Dutch biopsy-proven coeliac disease 
patients and 210 independent Dutch individuals as controls. The cases and controls both 
consisted of Caucasians with a mean age of 39 years and a male-to-female ratio of 35% vs 
65%. The second cohort comprised 122 Caucasian, Dutch parents-case trios for analysis 
by the transmission/disequilibrium test (TDT), consisting of one child with biopsy-
proven coeliac disease and both parents. The patients in this cohort had a mean age of 17 
years and also 65% were females.  
 
IFNG CA-repeat typing 
PCR fragments containing the IFNG CA-repeat polymorphism were obtained in a 
reaction volume of 10 µl containing 25 ng of DNA, 0.2 mM dNTPs, 2.5 mM MgCl2, 50 
ng of forward primer 5’-TTA TTC TTA CAA CAC AAA ATC AAA TC-3’, 50 ng of 
reverse, fluorescence-labelled primer 5’-ATA CAA AAA CAA AAA ACA GCA AAG C-
3’ and 0.4 U AmpiTaq Gold. The PCR products of 190-200 bp were separated on a 3700 
DNA sequencer and analysed by Genescan 3.5 and Genotyper 2.0 software. The 
nomenclature of the alleles is adapted from the report by 14, in which five alleles of this 
polymorphism are described (alleles 1-5 correspond to 11-15 CA-repeats, respectively). In 
our sample, allele 1 was not present, and alleles 6 and 7 (16 and 17 CA-repeats, 
respectively) had frequencies below 0.5% and were not included in the analysis. 
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Statistical analysis 
Allele and genotype frequencies were compared between cases and controls and P-values 
were obtained by χ2 analysis. Alleles transmitted and non-transmitted to affected 
offspring in the parent-case trios were compared by a χ2 test with 1 df. 
 
Results and Discussion 
The overall distribution of IFNG CA-repeat alleles was not significantly different 
between cases and controls (Table 1). The influence of allele 2 (12 CA-repeats) was 
specifically investigated, as this allele was shown to be associated with high in vitro 
expression of IFN-γ. Homozygosity or heterozygosity for this allele did not significantly 
contribute to disease risk (Table 1). Likewise, no significant distortion of random 
transmission of CA-repeat alleles to affected offspring was present in the parent-case 
trios (Table 2). In conclusion, there was no evidence for association of any of the IFNG 
CA-repeat alleles with coeliac disease in the two cohorts. IFNG is therefore unlikely to be 
a predisposing gene in coeliac disease. 
 
Table 1. Allele and genotype frequencies of the IFNG CA-repeat polymorphism in cases and 
controls. 
 Coeliac disease  
(N = 207) 
Controls  
(N = 210) 
Allelea   
2 0.46 0.49 
3 0.44 0.41 
4 0.06 0.06 
5 0.04 0.04 
   
Genotypea   
2,2 0.23 0.22 
2,3 0.37 0.41 
2,4 0.04 0.08 
2,5 0.04 0.04 
2,7 0.004 0.0 
X,Xb 0.32 0.25 
a No significant differences in either allele or genotype frequencies were present between cases and 
controls. 
b Allele X is not allele 2. 
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Table 2. Transmission of IFNG CA-repeat alleles to coeliac disease patients. 
Allele Transmitteda Not transmitted 
2  51 51 
3  47 51 
4  14 12 
5   7   6 
a None of the alleles were significantly over-transmitted to affected offspring. 
 
 
The results obtained in this study complement those from our linkage analysis in 
Dutch affected sibpairs, in which we found no evidence for linkage of coeliac disease to 
12q15.23 It is unlikely that IFNG will make a strong contribution to coeliac disease in 
other populations, since no evidence for linkage to this region was found in eight other 
genome-wide screens.24-31 Nevertheless, it cannot be excluded that the up-regulation of 
IFN-γ mRNA expression by intraepithelial lymphocytes of treated coeliac disease patients 
could still be due to a genetic predisposition by a polymorphism in a gene regulating the 
expression of IFNG. Alternatively, the gluten-free diet may contain trace amounts of 
gluten, which are not sufficient to induce histological changes, but may activate T cells in 
the small intestinal tissue. On the other hand, persisting T cell activation may just be a 
consequence of the lesions in the small intestine that were present during the active 
disease period. 
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Summary 
The major genetic susceptibility to coeliac disease is contributed by the HLA region. The 
primary association is with the HLA-DQ2 molecule, encoded by the DQA1*05 and 
DQB1*02 alleles, which is expressed in over 90% of patients. The aim of our study was 
to perform an extensive scan of the entire HLA region to determine whether there is any 
evidence for the presence of additional HLA susceptibility genes, acting independently of 
DQ2. Sixteen microsatellite markers and the DQA1 and DQB1 genes were genotyped in 
120 DQ2-positive simplex coeliac disease families and in 86 DQ2-positive simplex 
control families. Allele frequencies of markers on phase-known DQ2-positive haplotypes 
transmitted to patients were compared to a combined group of DQ2-positive non-
transmitted and control haplotypes, thereby controlling for the DQ2 contribution. No 
significant differences at any of the marker loci were detected, suggesting that DQ2 is the 
major HLA susceptibility locus for coeliac disease on DQ2-haplotypes. Individuals 
homozygous for DQ2 or heterozygous for DQA1*05-DQB1*02/DQA1*0201-
DQB1*02 were found to be at five-fold increased risk for development of coeliac disease 
(P <10-8). This risk was conferred by the presence of a second DQB1*02 allele next to 
one DQA1*05-DQB1*02 haplotype, independently of the second DQA1 allele.  
 
Introduction 
Coeliac disease is a common food intolerance in humans, with a prevalence estimated to 
be as high as 0.5%-0.3% in the Netherlands.1,2 The disease is characterized by lesions of 
the small intestine with partial to total villous atrophy, crypt hyperplasia and invasion of 
lymphocytes into the gut epithelium and lamina propria.3,4 The main clinical symptoms 
include chronic diarrhoea and growth retardation, but abdominal pain, anaemia, 
osteopenia,  and chronic fatigue may also occur.5 However, most patients show only 
some of these symptoms, while others are monosymptomatic or have no symptoms at 
all. Coeliac disease is caused by dietary intake of gluten peptides from wheat and related 
proteins from barley and rye. A gluten-free diet usually results in recovery of the small 
intestinal lesions and disappearance of the clinical symptoms. 
 Coeliac disease is strongly associated to the human leukocyte antigen (HLA) 
region. It has been well established that the primary association is with HLA-DQ2, with 
over 90% of patients expressing this molecule.6 There is substantial evidence for 
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involvement of DQ2 in coeliac disease pathogenesis. Gluten-derived peptides are 
modified by the enzyme tissue transglutaminase, which improves binding to DQ2 on the 
surface of antigen presenting cells. These complexes are recognized by gluten-specific T 
cells isolated from small intestinal tissue of coeliac disease patients.7,8 Most of the DQ2-
negative patients express the HLA-DQ8 molecule, which is also capable of binding 
gluten-derived peptides with subsequent activation of gluten-specific T cells.7 
The heterodimeric DQ2 protein is encoded by the HLA-DQA1*05 and HLA-
DQB1*02 alleles, in either the cis or the trans configuration. In North European 
populations, the DQA1*0501 and DQB1*02 alleles are frequently present on the 
extended HLA-B8-DR3-DQ2 haplotype.6,9 This haplotype has also been shown to be 
associated with other autoimmune disorders, including type 1 diabetes mellitus, systemic 
lupus erythematosus, Graves’ disease, Hashimoto’s disease, and myasthenia gravis, 
suggesting that the genes on this haplotype are involved in autoimmunity in general (for a 
review, see10). In coeliac disease it was shown that different DQ2 genotypes account for 
different disease risks. In particular, the homozygous DQA1*05-DQB1*02/DQA1*05-
DQB1*02 (DR3/3) and the heterozygous DQA1*05-DQB1*02/DQA1*0201-DQB1*02 
(DR3/7) genotypes were shown to be associated with increased risk.11-14 
The extended HLA-DR3-DQ2 haplotype includes many other genes that play a 
role in the immune response and it cannot be excluded that another HLA gene also 
confers increased risk to coeliac disease. The HLA region is known to display extensive 
linkage disequilibrium (LD). Therefore, one may expect that specific alleles at various loci 
in this region will show an increased frequency in coeliac disease patients, not because 
those alleles enhance or complement the DQ2 risk, but simply because they are in LD 
with DQ2. However, it has been suggested that non-class II loci also predispose to 
coeliac disease, independently of DQ2.  
The aim of this study was to test whether there was evidence for the presence of 
additional HLA susceptibility loci for coeliac disease in DQ2-positive patients of Dutch 
origin. Sixteen markers, covering the entire HLA region and flanking regions, were 
genotyped in simplex coeliac disease and in control families. In this way, phase-known 
DQ2-positive haplotypes from cases and controls could be generated and tested for 
association. In addition, the effect of different DQ2 genotypes to coeliac disease risk was 
evaluated. 
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Subjects and methods 
Subjects 
The case families consisted of 120 unrelated DQ2-positive coeliac disease patients with 
both parents available. The patients had a mean age of 17 years and 65% were female. 
The diagnosis of all patients was confirmed by histological re-evaluation of the initial 
small-intestinal biopsy specimens (JWRM). All patients presented with partial to total 
villous atrophy in the presence of intraepithelial lymphocytosis and crypt hyperplasia. 
Control DQ2 haplotypes were derived from 86 control families without a history of 
coeliac disease. The control families were selected for the presence of at least one parent 
carrying DQ2 in cis and also consisted of one child and both parents. The DQ2-positive 
controls had a mean age of 48 years and 50% were female. Individuals from the case and 
control families were all Caucasians of Dutch origin. The study was approved by the 
Medical Ethics Committee of the University Medical Centre Utrecht and written 
informed consent was obtained from all the participants. 
 
Table 1. Position, order and primers of the marker loci. 
Marker Position 
(Mb)a 
Forward primer (5’-3’) Reverse primer (5’-3’) 
D6S291 36.26 CTCAGAGGATGCCATGTCTAAAATA GGGGATGACGAATTATTCACTAACT
D6S2414 32.85 AACTGGGCTGAGATGTACCA AAGGAGAGGAATGTGTGTGC 
TAP1 32.82 GCTTTGATCTCCCCCCTC GGACAATATTTTGCTCCTGAGG 
STR2 32.71 GATTCATGAGCCAAGAACCC ATAATGCCATTCAATGTAAGC 
DQB1 32.63 ATGTGCTACTTCACCAACGG CTGGTAGTTGTGTCTGCACAC 
DQA1 32.61 ATGGTGTAAACTTGTACCAGT TTGGTAGCAGCGGTAGAGTTG 
D6S273 31.74 GCAACTTTTCTGTCAATCCA ACCAAACTTCAAATTTTCGG 
TNFa 31.59 CCTCTAGATTTCATCCAGCCACAG CCTCCCCCTCTCTCCCCTGC 
MICB 31.53 AGTGTTTTCCATTGCAGGCG ATGGGCAAGACTTCAATGGC 
MICA 31.43 CCTTTTTTTCAGGGAAAGTGC CTTACCATCTCCAGAAACTGC 
MIB 31.4 ACCACAGTCTCTATCAGTCC TCTACCATGACCCCCTTCC 
STR1 31.31 AGCATATCTGCCATTTGGCC GAAACTTGGGCAATGAGTCC 
D6S2700 30.84 AAAAGGAGGAAGAGCCACGGAG CTGTGAGTAGTAAGAACCCCC 
D6S2704 30.23 GAGCACAATATCTGGTCTGCTGC TTTTGCCACTCTGGAGGATGG 
D6S2707 29.77 CAGTTTCGCAACCTGTTTGCC TCTGATAAGAGATTAATATCCAG 
D6S105 27.83 GCCCTATAAAATCCTAATTAAC GAAGGAGAATTGTAATTCCG 
D6S2223 27.72 AATGTTAAGTAACAAACTAGAGTAC ACTCCAGCCTGGGCAATAGAGC 
D6S1281 25.35 GATGCCACGTTTTAAAATGC AGAAGCAGCTGTGCTTTGTT 
a The position of the markers was obtained by blasting the primer sequences against the Ensembl 
database, June 2003 release. 
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Genotyping the HLA loci 
A total of 18 loci were genotyped in the case and control families (Table 1 and Figure 1). 
The DQA1 and DQB1 genes were typed as described before, and primer sequences are 
listed in Table 1.15 Fourteen microsatellite markers, spanning the entire HLA region, and 
two flanking markers (D6S291 and D6S1281) were amplified in multiplex PCR reactions 
(Table 1). The reaction volume of 10 µl contained 25 ng of DNA, 0.2 mM dNTPs, 2.5 
mM MgCl2, 50 ng fluorescence-labelled primer and 0.4 U AmpiTaq Gold (PE Applied 
Biosystems, Foster City). The PCR products were pooled and separated on a 3700 DNA 
sequencer and analysed by Genescan 3.5 and Genotyper 2.0 software (all from PE 
Applied Biosystems). All genotypes were checked independently by two researchers 
(MJvB and AFJB). Primers sequences were obtained from the Genome Database 
(www.gdb.org), except for markers STR1, STR2, MICB, MIB, TNFa and TAP1, which 
were designed in our lab. Primer sequences for all loci were blasted against the Ensembl 
database (June 2003 release) to determine the correct order of the loci. 
 
 
Figure 1. Overview of major genes in the HLA region and marker loci from this study. Vertical bars 
indicate genes, with names and locations depicted in the lower half of the figure. The location of the 
genes was based on the June 2003 release of the Ensembl human genome map. Marker loci are depicted 
in italics in the upper half of the figure. 
 
Statistical analysis 
Phase-known haplotypes from the case and control families were constructed with the 
SHOWHAPLO program (F. Dudbridge). Four patients turned out to be DQ2-positive, 
but in the trans configuration and they were therefore excluded from the analysis. Six of 
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the 116 cis DQ2-positive patients were not informative at either the DQA1 or DQB1 
locus, resulting in 110 informative case families that were eventually included in the 
analysis. These 110 cases carried in total 150 DQ2-positive haplotypes (T haplotypes), 
while 36 DQ2-positive haplotypes were not transmitted to the cases (NT haplotypes). 
The control families contained 93 cis DQ2-positive parents who carried together 103 
DQ2-positive haplotypes (control haplotypes). 
 Allele frequencies at the 16 microsatellite marker loci were determined on the T, 
NT and control haplotypes. The overall allele distribution on T haplotypes was compared 
to the combined group of NT and control haplotypes. In addition, alleles with a 
frequency ≥10% were tested separately for association. Statistical significance was 
determined by χ2 analysis. TDT analysis, conditioned on the presence of DQ2 was 
performed in the case families by the CETDT program.16  
 The effect of DQ2 genotype to coeliac disease risk was determined in cases and 
controls. Association of the different DQ2 genotypes was tested for significance by χ2 
analysis with 1 df, by testing each DQ2 genotype against all other DQ2 genotypes. Odds 
ratios were calculated using Woolf’s method with Haldane’s correction relative to 
DQA1*05-DQB1*02/DQA1*X-DQB1*X (DR3/X) as reference genotype. 
 
Results 
Comparison of microsatellite marker loci on cis DQ2-positive haplotypes 
Allele frequencies of all 16 microsatellite markers were determined on the T, NT and 
control haplotypes. The overall allele distribution was not significantly different between 
T and the combined group of NT and control haplotypes at any of the marker loci (data 
not shown). The most frequent allele on the T haplotypes was determined and the 
frequency of this allele was also compared to the combined group of NT and control 
haplotypes. These alleles are markers of the B8-DR3-DQ2 haplotype, characterized by 
alleles TNFa*2, MICB*10, MICA*3 and MIB*11 (Table 2).17,18 This haplotype is the 
major DQ2 haplotype in patients and controls, with a frequency >75%. No evidence for 
significant association of these B8-DR3-DQ2 specific alleles was found. Other alleles 
with a frequency of 10% or more were also tested for association with coeliac disease 
(Table 3). These less frequent alleles could be compared for eight markers, but no 
significant evidence for association with coeliac disease was found. Only one marginally 
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significant result was obtained for allele 4 of marker D6S2707, but the significance was 
lost after correction for multiple testing. 
 
 
 
Table 2. Comparison of the most frequent allele of each microsatellite marker on DQ2-positive 
haplotypes transmitted (T) and non-transmitted (NT) to patients and on control haplotypes. 
Locus Allele 
(bp) 
T 
(N = 150) 
NT 
(N = 36) 
Controls 
(N = 103) 
NT + 
Controls  
(N = 139) 
P-value 
T vs NT + 
Controls 
D6S291 2   (201) 57 13 44 57 0.60 
D6S2414 2   (170) 93 24 53 77 0.19 
TAP1 3   (192) 106 26 66 92 0.27 
STR2 6   (108) 127 28 81 109 0.19 
D6S273 7   (140) 110 22 82 104 0.62 
TNFa 2   (104) 121 24 86 110 0.67 
MICB 10 (292) 114 24 77 101 0.68 
MICA 3   (187) 117 26 79 105 0.83 
MIB 11 (354) 106 26 78 104 0.64 
STR1 6   (127) 110 26 76 102 0.73 
D6S2700 3   (227) 109 30 72 102 0.36 
D6S2704 7   (165) 75 17 56 73 0.73 
D6S2707 9   (312) 83 20 56 76 0.78 
D6S105 5   (119) 65 13 44 57 0.70 
D6S2223 3   (170) 110 25 75 100 0.75 
D6S1281 4   (194) 39 7 27 34 0.67 
Table 3. Comparison of other alleles with frequencies ≥10% on DQ2-positive haplotypes in 
cases (T) and a combined group of non-transmitted and control haplotypes (NT + controls). 
Locus Allele 
 (bp) 
T 
(N = 150) 
NT + Controls  
(N = 139) 
P-value 
T vs NT + Controls 
D6S291 1 (199) 38 34 0.86 
 6 (209) 15 16 0.68 
D6S2414 3 (174) 34 39 0.30 
TAP1 2 (190) 28 34 0.15 
MICB 1 (272) 15 11 0.57 
D6S2704 8 (167) 23 17 0.42 
D6S2707 4 (302) 18 6 0.023a 
D6S105 6 (121) 15 8 0.18 
 7 (123) 21 28 0.16 
 8 (125) 18 10 0.17 
D6S1281 5 (198) 37 27 0.23 
 6 (202) 30 35 0.33 
a This P-value is not corrected for multiple testing.
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Conditional extended TDT (CETDT) 
CETDT analysis in the case families, conditioned on DQ2, did not detect any alleles at 
the marker loci that showed significant distortion of random transmission. 
 
Effect of different DQ2 genotypes 
The DQ2 genotypes carried by the 110 DQ2-positive cases and 93 DQ2-positive 
controls are shown in Table 4. The homozygous DQA1*05-DQB1*02/DQA1*05-
DQB1*02 (DR3/3) and heterozygous DQA1*05-DQB1*02/DQA1*0201-DQB1*02 
(DR3/7) genotypes both conferred a five-fold increased risk for coeliac disease. 
Homozygosity for DQB1*02 was strongly associated with coeliac disease (P <10-8). 
 
 
Discussion 
We investigated whether there was support for the presence of additional risk factors for 
coeliac disease in the HLA region, independent of DQ2. As the HLA region exhibits 
strong LD, several approaches have been suggested to correct for this. The homozygous 
Table 4. DQ2 genotype frequencies in cis DQ2-positive coeliac disease patients and controls.  
DQ2 genotypea DR typeb Cases 
(N = 110) 
Controls  
(N = 93) 
P-valuec  OR (95% CI)d 
DQA1*05-DQB1*02/ 
DQA1*05-DQB1*02 
DR3/3  40 (36%) 10 (11%) 0.00002 5.54 (2.5-12.1) 
      
DQA1*05-DQB1*02/ 
DQA1*0201-DQB1*02 
DR3/7 24 (22%) 6 (6%) 0.002 5.31 (2.1-13.5) 
      
DQA1*05-DQB1*02/ 
DQA1*0301- DQB1*0302 
DR3/4 7 (6%) 13 (14%)   
      
DQA1*05-DQB1*02/ 
DQA1*05-DQB1*0301 
DR3/5 3 (3%) 10 (11%)   
      
DQA1*05-DQB1*02/ 
DQA1*X-DQB1*X 
DR3/X 36 (33%) 54 (58%)   
a Haplotypes are phase-known as parents or children were also genotyped. DQA1*X-DQB1*X refers to 
anything except those haplotypes listed in Table 4. 
b DR genotype was not acquired, but derived from alleles at the DQA1 and DQB1 locus. X refers to 
anything except DR3, 4, 5 or 7. 
c P-values for association with coeliac disease were calculated by testing each DQ2 genotype against all 
other DQ2 genotypes. P-value for the presence of two DQB1*02 alleles <10-8. 
d Odds ratios were calculated relative to the DR3/X type as reference. OR for the presence of two 
DQB1*02 alleles = 5.68 (95% CI 2.9-11.2).
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parent TDT was first applied to search for HLA genes in type 1 diabetes mellitus.19 Only 
transmissions from parents homozygous for DQ2 and DR3 and heterozygous at the test 
loci were included in the analysis. This approach was later extended to a case-control 
design, in which only DR3 homozygous cases and controls were included.20 Although 
both methods control elegantly for the existing LD, they have very little power. Only 
individuals homozygous for DQ2 or DR3 are informative, which leads to exclusion of 
the majority of the data set. Recently, a TDT approach using affected family-based 
controls (AFBAC) was applied to two large data sets of coeliac disease families.21,22 This 
approach allows for construction of phase-known haplotypes, in which transmitted 
DQ2-positive haplotypes are compared to non-transmitted DQ2-positive haplotypes. A 
major advantage is that all DQ2-positive haplotypes are included in the analysis. 
However, less then 20% of DQ2-positive haplotypes were non-transmitted, so it requires 
a rather large data set to provide sufficient power.21,22 
In view of this all, we chose to use a combined case-control and AFBAC 
approach, as well as CETDT, to maximize the power of our data set, which is of 
moderate size. By also genotyping the parents of cases and children of controls, we were 
able to obtain phase-known haplotypes in both groups. Hence, all the DQ2-positive 
haplotypes could be used in the case-control analysis. The AFBAC DQ2-positive 
haplotypes were combined with the DQ2-positive control haplotypes into one control 
group since both should represent population control haplotypes. This case-control 
design greatly increased the power of our study, as an AFBAC case-control approach 
would have resulted in only 36 DQ2-positive control haplotypes, compared to 139 when 
using the combined group of AFBAC and control haplotypes. 
We performed an extensive scan of the HLA region using microsatellite markers, 
but no evidence for independent association between any of the loci and coeliac disease 
was found. Likewise, no significant differences were present when comparing T and NT 
haplotypes, or T and control haplotypes separately (data not shown). Three other 
extensive screens of the HLA region in search for additional risk loci have been 
performed in coeliac disease. Two of them did not find significant association, 
independently of DQ2, at any of the microsatellite loci either.21,23 The presence of an 
additional risk locus in the MIC gene region was suggested by the third study.22 
Association of the MICA gene in a DQ2-positive population has been reported twice, 
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but the control DQ2 groups were small in both studies.24,25 In addition, independent 
association of a single nucleotide polymorphism (SNP) in the TNF gene region has been 
reported by several groups.21,26-28 These results indicate the possibility of additional HLA 
risk loci in these regions, but large collections of phase-known DQ2-positive patients and 
controls are necessary to provide unambiguous evidence. Furthermore, there is a 
possibility that a SNP conferring increased disease risk may not be detected by 
association of nearby microsatellite markers because of their high mutation rate. 
Therefore, SNPs may be the preferred type of polymorphism for studying the presence 
of additional HLA susceptibility loci. 
The presence of an independent, additional risk locus for coeliac disease, located 
telomeric to the HLA class I region, has been suggested in a case-control study using 
DR3 homozygous patients and controls.20 Allele 3 of marker D6S2223 was significantly 
less frequent in cases. However, we were unable to confirm these findings in our data set. 
Furthermore, we found no evidence for association of allele 3 in an unstratified analysis 
of both case-control (76% vs 74%, P = NS) and TDT (43 T vs 39 NT, P = NS) data 
(data not shown). Three other studies, all using large data sets, were also unable to 
confirm association of D6S2223 with coeliac disease.21-23 These results indicate that it is 
unlikely that a gene near D6S2223 predisposes to coeliac disease. The previously reported 
association may have occurred by chance due to the rather small sample size of 46 
patients.  
The majority of the DQ2-positive haplotypes in cases and controls consisted of 
B8-DR3-DQ2 haplotypes (see also Table 2).17,18 We were therefore unable to determine 
whether there was a locus specifically associated with coeliac disease on other 
backgrounds. For example, the B18-DR3-DQ2 extended haplotype, characterized by 
alleles TNFa*1, MICB*1, MICA*1 and MIB*1, was rare in our cohorts with 9 T, 1 NT 
and 5 control haplotypes (data not shown).17,18 This haplotype is carried by 84% of DQ2-
positive Sardinian coeliac disease patients, and this population is therefore more suitable 
for studying the presence of additional HLA risk loci on B18-DR3-DQ2 haplotyes.29 
In addition to our search for the presence of additional non-class II HLA loci, our 
data set also enabled us to establish the risk of different DQ2 genotypes to coeliac disease 
in the Dutch population. Homozygous DQA1*05-DQB1*02/DQA1*05-DQB1*02 and 
heterozygous DQA1*05-DQB1*02/DQA1*0201-DQB1*02 individuals were at five-fold 
Chapter 8 
130 
increased risk. This risk is attributed by the presence of a second DQB1*02 allele and 
seems independent of the second DQA1 allele, since the odds ratio for homozygosity of 
DQB1*02 is almost equal to those for both risk genotypes. Similar risks were observed in 
other populations, although these studies were conducted in an ordinary case-control 
setting, in which haplotypes had to be estimated.12-14 Recently, a family study using a 
TDT approach with phase-known haplotypes also demonstrated increased risk for these 
two genotypes.11 A possible explanation for the increased risk may reside in number of 
DQ molecules capable of gluten presentation that arise from each genotype. The 
homozygous DQA1*05-DQB1*02 genotype produces 100% DQ2 molecules. The 
heterozygous DQA1*05 DQB1*02/DQA1*0201-DQB1*02 genotype produces only 
50% DQ2 molecules and the other 50% is comprised by the α1*0201-β1*02 
heterodimer. However, the α1*0201-β1*02 molecule was shown to be able to present 
certain gluten epitopes to T cells as well, thereby implicating this molecule in the 
pathogenesis of coeliac disease (Vader et al., manuscript submitted). The DQA1*05 
DQB1*02/DQA1*X-DQB1*X genotype results in just 25% DQ2 molecules, which may 
account for the lower disease risk of this genotype.  
In conclusion, in this study in coeliac disease using phase-known DQ2-positive 
case and control haplotypes, we were not able to find support for the presence of an 
additional HLA susceptibility gene, acting independently of DQ2. We were able to 
confirm the increased risk conferred by homozygosity for the DQB1*02 allele, which is 
most likely due to a combination of the number of DQ2 molecules expressed and the 
gluten presenting capacity of the heterodimer encoded by DQA1*0201 and DQB1*02. 
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Coeliac disease: a common but underrecognized genetic disorder 
The prevalence of coeliac disease in the Netherlands has been estimated by two large 
population screens at about 1 in 250 (0.4%).1,2 Consequently, we would expect 
approximately 64,000 coeliac disease patients in the Netherlands, based on 16,000,000 
inhabitants. However, at the beginning of 2003, the Dutch Coeliac Disease Foundation 
had only 6000 members.3 Most patients join the foundation for support and dietary 
advice, so their membership is a good indication of the total number of patients 
diagnosed with coeliac disease. The large discrepancy indicates that the vast majority of 
patients (90%) remain undiagnosed. The undiagnosed group includes patients that are 
asymptomatic and, hence, will not be tested for coeliac disease unless perhaps when other 
family members have been diagnosed with the disease. However, many patients suffering 
from non-specific complaints like chronic fatigue, anaemia or abdominal pain remain 
unrecognised. Clinicians, not only specialists but also general practitioners, should always 
be aware of the possibility of coeliac disease in patients with vague complaints that could 
be associated with the disease (see also Chapter 1).  
Coeliac disease is a disorder with a strong genetic aetiology. The sibling recurrence 
risk is about 10%,4-12 which leads to a sibling relative risk (λs) of 25 for the Dutch 
population.13,14 This λs value is relatively high and therefore provides a good opportunity 
for the identification at least some of the coeliac disease susceptibility genes in a data set 
of average size. The identification of these genes will be of great importance for 
understanding the pathogenesis of the disease. It will provide new insights into the 
pathways that are impaired in the disease, which may assist diagnosis of the disease and 
even lead to new therapeutic targets. The aim of this PhD project was to investigate the 
genetic factors that underlie coeliac disease in the Dutch population. For this purpose, 
three different cohorts of coeliac disease patients were created: a cohort of affected 
sibpairs to localise the disease genes (Chapter 2), and a case-control cohort and a cohort 
of parent-case trios to perform association analysis of candidate regions (Chapter 4), and 
candidate genes (Chapters 5-7) and to further establish the contribution of the HLA 
region (Chapter 8). Great effort was put into ensuring homogeneity of the diagnoses of 
the patients included in all three cohorts. The initial biopsy specimens of all patients were 
re-evaluated by Dr. J.W.R. Meijer (an experienced pathologist of the Rijnstate hospital, 
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Arnhem). All three cohorts consisted of patients with a Marsh III lesion; patients with 
less severe lesions or whose biopsy specimens were unavailable were not included in 
these cohorts. 
The initial goal was to collect 100 affected sibpairs of Dutch origin and perform 
the first genome-wide screen in Dutch coeliac disease patients. At the beginning of the 
project in 1998, about 3000 patients were diagnosed with coeliac disease. Based on a 
sibling recurrence risk of 10%, there were expected to be approximately 300 families with 
two affected children in the Netherlands. But after five years of extensive, nationwide 
searching, only 82 families with 101 affected sibpairs have been collected while at the 
same time the total number of diagnosed patients has doubled. Since the patients and 
their families were very cooperative, the apparent shortage of families was probably due 
to an overestimation of their occurrence. Recurrence risks for first-degree relatives were 
based on family screening studies.4,6-12 The actual numbers of diagnosed siblings is lower 
since the disease also remains unrecognised in family members. Furthermore, several 
families had to be excluded because some patients presented with the less severe Marsh I 
and II lesions, some patients had been diagnosed many years ago and their biopsy 
specimens were no longer available, and some patients had not been diagnosed by a small 
intestinal biopsy. Taking all these considerations into account, our affected sibpair cohort 
probably contains the majority of families with multiple affected Marsh III siblings 
present in the Netherlands. The case-control cohort (216 patients and matched controls) 
and parent-case trios (122 families) were fairly easy to obtain via the Paediatric 
Gastroenterology department of our own hospital (Dr. R.H.J. Houwen, UMC Utrecht) 
and via the Gastroenterology department of the Rijnstate hospital in Arnhem (Prof. dr. 
C.J.J. Mulder, currently at the VUMC, Amsterdam). Both cohorts are of moderate size as 
highest priority was given to collecting affected sibpairs, but they should be large enough 
to detect association of genes conferring moderate to large risks (relative risk (RR) ≥2). 
However, it should be relatively easy to extend these cohorts for future experiments so 
that genes with small relative risks can be detected as well. 
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Coeliac disease and the HLA region 
Coeliac disease is strongly associated with the HLA region 
In the early 1970’s it was already noticed that coeliac disease was associated with the 
human leukocyte antigen (HLA) region. First reported associations were with the B8 
antigen from the class I region, but later a stronger association with the class II DR3 
antigen was found (Figure 1).13 Now it is well established that the primary association is 
with the class II antigen DQ2. Over 90% of patients express this heterodimeric molecule, 
encoded by the DQA1*05 and DQB1*02 alleles. Most patients of northern European 
origin carry these alleles on the extended HLA-B8-DR3-DQ2 haplotype, which explains 
the early reported associations with HLA-B8 and HLA-DR3.13,15 The occurrence of the 
extended B8-DR3-DQ2 haplotype in the majority of patients has initiated a search for 
additional susceptibility genes in the HLA region that increase the disease risk 
independently of DQ2. This haplotype has certain functional characteristics due to the 
presence of specific alleles at regulatory loci, including high expression of tumour 
necrosis factor (TNF) α and the production of a truncated MICA protein.16,17 Four 
extensive scans of the HLA region with microsatellite markers were performed to localize 
these possible additional risk loci. Three of them, including our study in a case-control 
cohort using phase-known DQ2 positive haplotypes, did not find association of any 
marker independently of DQ2.18,19 The presence of an additional risk locus in the MIC 
gene region was suggested in one study.20 In addition, independent association of a single 
nucleotide polymorphism (SNP) in the TNF gene region has been reported by several 
groups.19,21-23 There is a possibility that a SNP conferring increased disease risk may not 
be detected by association with nearby microsatellite markers because of their high 
mutation rate. Therefore, SNPs may have been a better choice for studying the presence 
of additional, non-class II HLA susceptibility loci. However, SNPs only contain two 
alleles and single SNPs therefore provide low information. Furthermore, genotyping only 
one SNP will be insufficient to localize the putative additional risk locus, as this SNP may 
be in linkage disequilibrium (LD) with another variant that is actually causing the disease. 
Therefore, studies should include several polymorphisms in multiple genes and 
construction of phase-known haplotypes to identify the regions containing additional 
susceptibility genes. Nevertheless, detection of additional susceptibility loci may be nearly 
impossible due to extensive LD displayed by the HLA region. 
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Figure 1. Overview of major genes in the HLA region. Vertical bars indicate genes, with names and 
locations depicted in the lower half of the figure. The location of the genes was based on the June 2003 
release of the Ensembl human genome map.  
 
In patients from certain southern European populations, the DQ2 risk alleles are 
frequently carried on the extended B18-DR3-DQ2 haplotype.24 This haplotype shares the 
DQA1*05, DQB1*02 and DRB1*03 alleles with the B8-DR3-DQ2 haplotype, but differs 
at most other loci, indicating that the DQ-DR region is essential for development of 
coeliac disease.17,25 A third haplotype, the B21-DR3-DQ2 haplotype, was shown to be 
associated with coeliac disease in Indian patients.26 The presence of different disease 
associated DR3-DQ2 haplotypes implies that these haplotypes may harbour unique 
additional risk loci. To find such loci, association analysis should be focused on different 
DQ2 subgroups, stratified on the presence of either B8, B18 or B21. Not all populations 
will be suitable for this type of study, as the distribution of these haplotypes varies in 
Europe.13 North European populations can be used for studying the contribution of the 
B8-DR3 haplotype, while for example the Sardinian population provides a unique 
possibility to determine the contribution of the B18-DR3 haplotype, as 84% of DQ2-
positive patients were shown to carry this haplotype.24  
 The majority of DQ2-negative patients are DQ8-positive and carry the 
DQA1*0301 and DQB1*0302 alleles on the DR4 haplotype. It would be interesting to 
determine whether evidence exists for the presence of additional risk loci on this 
haplotype. However, since DQ2-negative, DQ8-positive patients comprise only a small 
part of all coeliac disease patients, very large patient groups are required to obtain enough 
power to reach statistical significance. For example, only two out of 122 (1.6%) patients 
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in our parent-case trios carried the DQ8 alleles in the absence of DQ2. So, this question 
can only be addressed by large-scale collaboration between research groups. However, 
even the large collection of coeliac disease patients by a European consortium contained 
only 60 DQ2-negative, DQ8-positive patients on a total of 1008 (6%) independent 
patients. Unfortunately, a scan of the HLA region to search for additional HLA 
susceptibility loci that act independently of DQ8 has not yet been performed.  
 
The DQB1*02 gene dosage effect 
Several studies reported that individuals homozygous for DR3/3 and heterozygous for 
DR3/7 were at higher risk for development of coeliac disease compared to heterozygous 
DR3/X individuals (where X is not 3 or 7).27-29 The increased risk was due to the 
presence of a second DQB1*02 allele, either on a DR3 or DR7 haplotype, next to one 
DR3 haplotype. This gene dosage effect was confirmed in our cohort, with a five-fold 
increased risk for both DQA1*05-DQB1*02/DQA1*05-DQB1*02 (DR3/3) 
homozygous and DQA1*05-DQB1*02/DQA1*0201-DQB1*02 (DR3/7) heterozygous 
individuals (see Chapter 8). 
The increased risk conferred by these two genotypes may reside in the percentage 
of DQ2 molecules they encode, which is higher than for the DR3/X genotype (Table 1). 
The similar risks conferred by DR3/3 and DR3/7 are most likely due to functional 
characteristics of the α1*0201-β1*02 heterodimer, which was recently implicated in 
gluten presentation to T cells (Vader et al., manuscript submitted). Other genotypes also 
produce 50% or more DQ2 and DQ8 molecules and may therefore be expected to be 
associated with an increased disease risk as well (Table 1). No significant evidence in 
favour of this has been generated, but this may be due to the fact that these genotypes are 
rare among coeliac disease patients. Furthermore, no data is available on the functional 
characteristics of the DQ heterodimers they encode. Notably, most of the 60 DQ8 
patients studied by the European consortium were either homozygous DQA1*0301-
DQB1*0302 (48%) or heterozygous DQA1*0301-DQB1*0302/DQA1*0201-DQB1*02 
(18%), but no data on a control DQ8 population was available.30  
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Table 1. Potential DQ alpha-beta chain combinations in coeliac disease associated haplotypes 
and their gluten presenting capacity. 
DQ2 and DQ8 genotypesa DR 
type 
Possible DQ 
moleculesb 
DQ 
typec 
Gluten-
presenting 
capacity 
% of gluten-
presenting 
DQ molecules
DQA1*05-DQB1*02 3/3 α1*05/β1*02 DQ2 + 100 
DQA1*05-DQB1*02      
      
DQA1*05-DQB1*02/ 3/7 α1*05/β1*02 DQ2 + ≥50 
DQA1*0201-DQB1*02  α1*0201/β1*02 − ±d  
      
DQA1*05-DQB1*02 3/X α1*05/β1*02 DQ2 + 25 
DQA1*X-DQB1*X  α1*05/β1*X − −  
  α1*X/β1*02 − −  
  α1*X/β1*X − −  
      
DQA1*05-DQB1*02 3/5 α1*05/β1*02 DQ2 + 50 
DQA1*05-DQB1*0301  α1*05/β1*0301 − ?  
      
DQA1*05-DQB1*02 3/4 α1*05/β1*02 DQ2 + 50 
DQA1*0301-DQB1*0302  α1*05/β1*0302 − ?  
  α1*0301/β1*02 − ?  
  α1*0301/β1*0302 DQ8 +  
      
DQA1*0301-DQB1*0302 4/4 α1*0301/β1*02 DQ8 + 100 
DQA1*0301-DQB1*0302      
      
DQA1*0301-DQB1*0302 4/7 α1*0301/β1*0302 DQ8 + ≥25 
DQA1*0201-DQB1*02  α1*0301/β1*02 − ?  
  α1*0201/β1*0302 − −  
  α1*0201/β1*02 − ±d  
      
DQA1*05-DQB1*0301 5/7 α1*05/β1*0301 − ? ≥25 
DQA1*0201-DQB1*02  α1*05/β1*02 DQ2 +  
  α1*0201/β1*0301 − −  
  α1*0201/β1*02 − ±d  
a DQA1*X is not 05 or 0201 and DQB1*X is not 02. 
b α1*X is not 05 or 0201 and β1*X is not 02. 
c “−” refers to not DQ2 or DQ8. 
d This molecule was able to present certain gluten-peptides to T cells, but not all (Vader et al., manuscript 
submitted). 
 
Are DQ2 and DQ8 essential? 
The presence of either DQ2 or DQ8 appears to be necessary for development of coeliac 
disease. Almost all patients carry these alleles and functional involvement of both DQ 
molecules in presentation of gluten to the immune system has been demonstrated 
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unambiguously. Nevertheless, patients sensitive to gluten but negative for DQ2 and DQ8 
have been described.30-32 Of the 1008 coeliac disease patients studied by the European 
consortium, 61 (6%) were found to be DQ2 and DQ8 negative.30 However, 57 (93%) of 
them carried half of the DQ2 heterodimer: 41 (72%) were positive for DQA1*0201-
DQB1*02 and 16 (28%) were positive for DQA1*05-DQB1*0301. As mentioned earlier, 
the molecule encoded by the DQA1*0201 and DQB1*02 alleles has been implicated in 
gluten presentation to T cells. However, no data has been generated yet on the T cell 
stimulation capacity of the α1*05-β1*0301 heterodimer. The current data are of great 
importance for the clinical practice of diagnosing coeliac disease. Negativity for DQ2 and 
DQ8 should not be used to reject a possible diagnosis of coeliac disease and a small 
intestinal biopsy should be performed in all individuals who carry at least half of the DQ2 
heterodimer and suffer from any complaint compatible with coeliac disease.  
Of course, one has to bear in mind that some of the reported DQ2 and DQ8 
negative patients may have been incorrectly diagnosed with coeliac disease. After a biopsy 
specimen is taken, it should be handled with care and oriented properly to avoid artificial 
damage and misdiagnosis.33,34 Patients diagnosed with coeliac disease but negative for 
DQ8, DQA1*05 and DQB1*02 should be subjected to a more extensive diagnostic 
procedure to confirm the diagnosis. The original criteria, formulated by the European 
Society of Paediatric Gastroenterology and Nutrition (ESPGAN) during the Interlaken 
meeting in 1969, may provide a good protocol for these cases.35 This protocol involves 
small intestinal biopsies at three different stages. The diagnosis is confirmed upon the 
presence of villous atrophy on a gluten-containing diet in the first biopsy, recovery of the 
villous structure on a gluten-free diet, and reoccurrence of villous atrophy after a gluten 
challenge.  
 The three different Dutch patient cohorts described in this thesis did not contain 
any DQ2 and DQ8 negative patients. Based on the 6% occurrence of DQ2/8 negative 
patients reported by the European consortium, at least 10 such patients would be 
expected in our data set. Our inclusion criteria were not based on the presence of either 
DQ2 or DQ8, but only on the presence of a Marsh III lesion upon re-evaluation of the 
initial biopsy specimens. Patients presenting with less severe lesions (Marsh I or II) are 
frequently negative for both DQ2 and DQ8, indicating that DQ2 and DQ8 may be 
associated with more severe damage of the small intestine (Crusius et al., manuscript 
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submitted).31 This would explain the non-occurrence of DQ2/8 negative patients in our 
cohorts, since only Marsh III patients were included and genotyped at the DQA1 and 
DQB1 loci. The DQ2/8 negative patients studied by the European consortium were not 
subjected to histological re-evaluation, and it is possible that some of the patients 
exhibited less severe Marsh I or II lesions. 
 
Implications for population screening 
Coeliac disease fulfils all five WHO criteria for population screening:36 1. It is a common 
disease, 2. Most patients are not recognized by clinical symptoms, 3. Highly sensitive and 
specific antibody screening tests are available, 4. An effective treatment is available, 5. 
Severe complications could occur in untreated patients. Certainly, several aspects of the 
disease plead in favour of population screening: the vast majority of patients remain 
unrecognised, untreated disease may lead to irreversible complications such as 
osteoporosis, autoimmune disorders and intestinal malignancies,37-40 and increased 
mortality in untreated patients was observed.40,41 One important aspect to consider is that 
the sensitivity of anti-Ema and anti-tTG antibodies is high in patients with (sub)total 
villous atrophy but much lower in patients with only partial villous atrophy.42,43 A large 
proportion of patients may therefore be missed by antibody screening since patients 
presenting with partial villous atrophy are frequent. Another aspect to take into account 
is that although the gluten-free diet may be a very effective treatment for coeliac disease, 
it is not an easy diet. As asymptomatic patients do not experience clinical benefits, their 
motivation to adhere to the diet might be low. Indeed, it has been shown that dietary 
compliance of screening-detected patients was lower than compliance of symptomatic 
patients.44 Furthermore, there is currently no evidence that treatment of asymptomatic 
patients would reduce morbidity and mortality.45 These last two aspects would severely 
impact the clinical and cost benefits of population screening at this time. Pilot studies 
should be performed first to indicate whether population screening is likely to result in 
decreased morbidity and mortality in coeliac disease patients. Recently, a study 
investigating the costs and health benefits of population screening for coeliac disease in 
the Netherlands concluded that a screening programme was unlikely to be cost saving 
based on the direct medical costs of the complications, but that important health gains 
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could be achieved by prevention of these complications.46 It was therefore recommended 
to start a large research project to further investigate the value of population screening. 
If population screening would prove to be a cost-effective disease prevention 
strategy, who should be screened and how should this be done? Coeliac disease is rare in 
DQ2 and DQ8 negative individuals, so instead of screening the entire population a two-
step strategy may be preferred. HLA typing for the presence of DQ2 and DQ8 genotypes 
will identify the approximately 30% of the general population that are potentially at risk 
for coeliac disease.47,48 Only these individuals need to be subjected to serological 
screening for coeliac disease. But what should be done with individuals that carry only 
half of the DQ2 heterodimer? Since these individuals seem to have an increased risk of 
developing of the disease too, it may be justified to include them in the serological 
screening. However, this would increase the costs as more individuals have to be 
considered for serological testing. The strategy which may provide the best cost/benefit 
ratio is to screen for coeliac disease only in individuals that are homozygous DQA1*05-
DQB1*02 (DR3/3) or heterozygous DQA1*05-DQB1*02/DQA1*0201-DQB1*02 
(DR3/7). These genotypes were shown to be associated with the highest disease risk and 
together account for only 4% of the general population but for almost 60% of coeliac 
disease patients (see Chapter 8).  
HLA genotyping could be included in the screening program for phenylketonuria 
(PKU) in which blood is collected from all newborns. One other advantage of population 
HLA typing for DQ2 and DQ8 is that these genotypes are also associated with an 
increased risk for other autoimmune disorders like type 1 diabetes mellitus, autoimmune 
thyroid disease and systemic lupus erythematosus.16,49 Individuals that carry these risk 
genotypes could also be monitored for the development of other autoimmune disorders, 
thereby increasing the probability of early detection and prevention of disease associated 
complications. However, because of the conservative approach of population screening 
in the Netherlands, combined screening programmes for multiple disorders are unlikely 
to be approved.  
The serological screening for coeliac disease should preferably be performed in 
early childhood, since the prevalence of other autoimmune disorders in coeliac disease 
patients was shown to be correlated with the duration of gluten intake.37 Furthermore, 
compliance to the gluten-free diet is better in children diagnosed at a young age.50 
General Discussion 
145 
However, patients may develop coeliac disease later in life, which means that the 
serological screenings may have to be repeated after a certain time. 
 
Coeliac disease as a model for HLA-associated disorders 
Coeliac disease is the only HLA-associated disorder for which both a major gene (HLA-
DQ) and a major antigen (gluten peptides) are known. Association with the HLA region 
has been well established for many autoimmune diseases, but except for coeliac disease, 
the disease-causing gene is not known in any of these diseases. Genetic studies are limited 
in their resolving power to distinguish between genes, largely because of the extensive 
LD displayed by the HLA region. Therefore, functional studies are necessary to 
determine which of the genes are involved in the disease process. However, the affected 
tissue in most disorders is not easily accessible, which makes it almost impossible to 
perform these experiments. In contrast, small intestinal biopsies are routinely taken for 
diagnosis of coeliac disease and additional samples for research purposes can be obtained 
without significant additional risk or burden to the patient. This makes coeliac disease a 
unique model for studying the interaction between HLA molecules and their antigens, 
and the subsequent response by the immune system. These studies may lead to new 
insights into autoimmune destruction of tissues, which is of great importance for the 
understanding of autoimmune processes in general.   
 
Contribution of non-HLA genes to coeliac disease 
Non-HLA genes confer at least 50% of the genetic contribution 
Although the HLA region seems essential for development of coeliac disease, it is not the 
sole genetic factor underlying this disease. The large difference in disease concordance 
rates between monozygous twins (86%) and HLA-identical siblings (30%) strongly 
suggests a contribution of non-HLA genes.13,51 This is supported by the observation that 
<2% of HLA-DQ2 or DQ8 positive individuals eventually develop coeliac disease. 
Estimations of the relative contribution of the HLA region to the overall genetic risk vary 
from 21% to 44%, based on a multiplicative model.14,52 The estimated contribution by 
the HLA region in the Dutch population is approximately 47%, based on the observed 
λs, HLA of 4.6 and a λs of 25 for coeliac disease. (Chapter 2).53 These results indicate that 
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the HLA contribution comprises at most half of the total genetic risk, and that non-HLA 
genes will contribute at least 50%.  
 The chance to find these non-HLA genes depends on the specific contribution of 
each of them. At the moment, ten whole genome screens have been performed in coeliac 
disease, including the two described in this thesis (Chapters 2 and 3).53-61 While linkage to 
the HLA region was present in all of them, linkage to other regions reached much lower 
significance levels. These results indicate that the non-HLA contribution is very unlikely 
to be attributable to a single gene and, therefore, the contribution of each non-HLA 
locus is expected to be much smaller than that of the HLA region. Hence, the probability 
of detecting these non-HLA loci is lower and larger numbers of patients will be required 
to detect them. The total number of non-HLA susceptibility loci involved in coeliac 
disease will have to be elucidated by association and linkage studies involving large 
collections of independent cases and controls and families with multiple affected 
individuals. 
 
Candidate gene studies 
The search for susceptibility genes underlying complex diseases has in the past mainly 
been focussed on functional candidate genes, since information about localisation of the 
disease genes was not available. A logical approach is typing polymorphisms with a 
functional effect on the protein.62 Association should be replicated in another data set 
from the same population, or in another population, before involvement of this gene can 
be accepted. However, this approach has not been very successful in complex 
diseases.63,64 Failure to replicate association in a different data set may have several 
reasons, which are all due to typical features of complex diseases. Firstly, the second data 
set is a different sample, in which a different allele of the same gene may be associated 
with the disease (allelic heterogeneity, see also Chapter 1). Secondly, a locus associated 
with the disease in the first data set may only have a small effect in the second sample, 
especially when this sample is from a different population (locus heterogeneity). Thirdly, 
complex disease phenotypes can vary greatly between different patients. Defining the 
appropriate phenotype can be difficult, and the different data sets may contain different 
phenotypes, which may be associated with different genotypes.64 Fourthly, associations 
may just occur by chance. To avoid these false-positive associations, higher significance 
General Discussion 
147 
thresholds in the order of P <10-6-10-8 have been proposed.65 This would certainly 
dramatically reduce the false-positive rate, but it would also increase the false-negative 
rate. To reach such low P-values, cohorts of at least 1000 cases and controls are required, 
which can be difficult to collect.65 As a compromise, association at a significance 
threshold of P <0.05, with independent confirmation in at least one different data set 
could be considered a more realistic proof of association of a given polymorphism with 
the disease. 
 Candidate gene studies in coeliac disease have mainly focussed on the gene 
encoding the cytotoxic T-lymphocyte-associated protein 4 (CTLA4 at 2q33), because this 
gene has been implicated as a general susceptibility gene for autoimmunity (see also 
Chapter 6).66 This gene contains only one non-silent missense SNP, the A/G 
polymorphism at position +49, and this polymorphism has therefore received most 
attention. Association was first reported in a case-control study in French patients and 
later confirmed by two studies in different Scandinavian populations.67-69 The GG 
genotype conferred a slightly increased risk to coeliac disease in the Dutch population 
(Chapter 6). A microsatellite marker in the 3’ untranslated region of the gene has also 
been tested, but association was not found.70-72 Again, lack of association between a 
microsatellite marker and a disease might be attributed to the high mutation rate of the 
marker, resulting in the presence of several disease-associated alleles. Therefore, when 
testing a candidate gene, functional polymorphisms are the preferred type of 
polymorphism, although typing just one polymorphism is often not sufficient. LD can 
extend over long regions and the association pattern in the region surrounding a 
candidate gene must be determined before the causal variant can be identified. In a study 
that investigated the role of the CTLA4 gene region in Graves’ disease, type 1 diabetes 
mellitus and autoimmune hypothyroidism, LD was shown to extend over a region of 
100kb, including the entire CTLA4 gene and part of its neighbouring gene.73 This LD 
block contained 78 SNPs, including the +49A/G polymorphism, of which no less than 
55 were significantly associated with Graves’ disease. Moreover, regression analysis 
indicated that the +49A/G polymorphism could not be the causal variant, which was 
mapped to a 6.1 kb region containing four other SNPs. The disease-susceptible haplotype 
of these SNPs was tested for mRNA expression and this haplotype was associated with 
lower levels of soluble CTLA4 mRNA. Each SNP should be tested separately to 
Chapter 9 
148 
determine which of the four SNPs is actually responsible for the lowered expression. 
This study showed how a systematic approach of typing many SNPs in the entire 
candidate region resulted in mapping of the causal variant to a very small region and 
provide a functional explanation for the observed association with the risk haplotype.  
 Not many other candidate gene studies have been performed in coeliac disease. 
Two intragenic microsatellite markers in the genes encoding the functional candidates 
tissue transglutaminase (TGM2 at 20q11.23) and interferon-γ (IFNG at 12q15) were 
tested in Dutch patients, but association could not be detected (Chapters 5 and 7, 
respectively).74 Also, sequencing of the coding region of TGM2 did not reveal differences 
between cases and controls.75 Several studies investigated the contribution of the T cell 
receptor alpha (TRA at 14q11.2), beta (TRB at 7q34), gamma (TRG at 7p14.1) and delta 
(TRD at 14q11.2) genes, but no association was found with any of them.76-78 Marginal 
associations with the mannose binding lectin gene (MBL2 at 10q21.1) and the genes 
encoding the GM immunoglobulin allotypes (at 14q32.33) have been reported, but these 
results have to date not been confirmed in independent data sets.79,80  
In conclusion, candidate gene analysis has not resulted in unambiguous 
identification of any non-HLA susceptibility gene for coeliac disease, except for a 
putative role of the CTLA4 gene region. However, the contribution of the CTLA4 
region should be investigated by typing multiple SNPs in this region, in addition to the 
+49A/G polymorphism. Future studies should also include SNPs from the 6.1 kb region 
shown to harbour the causal variation for Graves’ disease, type 1 diabetes mellitus and 
autoimmune hypothyroidism. 
 
Localising non-HLA susceptibility genes 
Candidate gene analysis can be a powerful tool for implicating genes in disease processes, 
but it has some serious limitations. A good understanding of the disease pathogenesis is 
essential to prioritise the list of possible genes. Furthermore, only genes with known 
functions can be considered. The completion of the Human Genome Project will 
eventually lead to identification and characterisation of all genes in the human genome. 
However, by July 2003, 40% of the 23,299 predicted protein coding genes in the 
Ensembl database were still of unknown function. 
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No genes conferring susceptibility to coeliac disease were known outside the HLA 
region at the beginning of this project. This meant that the only realistic approach was to 
map the position of susceptibility loci in the human genome by linkage analysis in 
families with multiple affected individuals. No large coeliac disease families were available 
and, therefore, a non-parametric linkage analysis approach using affected sibpairs was 
chosen. Affected sibpairs were preferred because these are more easily collected and 
genotyped compared to other relative pairs. However, it has been argued that mapping 
genes in more distant affected relative pairs might be more powerful.81 A very important 
part of a linkage study is the phenotyping of the patients. Inclusion of patients with 
uncertain or different phenotypes can produce noise or even completely conceal a linkage 
signal.82 Therefore, only sibpairs presenting with a proven Marsh III lesion were included 
in the study. Patients with less severe lesions were excluded, because it is currently 
unknown whether these lesions are caused by the same disease mechanisms. 
To date, ten whole genome screens in search for coeliac disease loci have been 
completed: five were conducted in affected sibpairs,53-57 three in extended families,58,60,61 
one in a population isolate59 and one in a four-generation family (Chapter 3). Significant 
evidence for linkage was present in just two studies: in the population isolate59 and in the 
Dutch affected sibpairs.53 It is tempting to speculate that the significant linkage detected 
in our study was attributable to careful phenotyping of the patients. None of the other 
studies re-evaluated the biopsy specimens of the patients, although most of them 
thoroughly investigated the histological and clinical reports. However, this may be 
insufficient, since until just a few years ago coeliac disease was still quite rare in most 
countries, and pathologists may not have been experienced enough to make the correct 
diagnosis in damaged or poorly oriented biopsies. We were also lucky with the presence 
of a major non-HLA locus in the Dutch population. The data set used in the initial 
genome-wide screen had little power to detect loci with a λs ≤1.5 and identification of 
such loci would have been difficult, even in a carefully phenotyped data set. 
 What have we gained from these ten linkage studies? As many as 50 non-HLA 
loci with nominal P-values ≤0.05 were found, thirteen of which were replicated in at least 
one other data set (Table 2). However, this has not yet lead to the identification of 
susceptibility genes in these regions. It is also apparent that none of the functional 
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candidate genes previously tested for association with coeliac disease are located in 
regions showing linkage to the disease (see previous section). A few candidate genes 
within the linked regions have been tested: the IL12B gene at 5qter, the natural killer cell 
immunoglobulin-like receptor (KIR) and leukocyte immunoglobulin-like receptor (LILR) 
gene clusters at 19q13.4, and the matrix metalloproteinase (MMP) 1 and 3 genes at 
11qter.83-85 However, no evidence for association between coeliac disease and any of 
them was found. Linkage to most regions only reached low significance, so they probably 
harbour genes with small effects, which would be difficult to identify by association 
analysis. Combining different data sets may result in data sets with sufficient power to 
identify these loci. The 5qter region seems the best candidate for this approach, as it is 
most consistent region between the populations. Also 4p15, 9p21 and 11qter are 
promising loci with replications in at least two studies.  
 
Table 2. Overview of non-HLA loci reported in at least two linkage studies in coeliac disease 
with nominal P <0.05. 
 
 
 
 
Locus 
 
Finland 
(sibpairs) 
(56) 
 
Finland 
(isolate) 
(59) 
 
Ireland 
 
(54) 
 
Italy 
 
(55) 
Populationa 
Netherlands 
(sibpairs) 
(Chapter 2) 
 
Netherlands 
(family) 
(Chapter 3) 
 
Northern 
Europe 
(58) 
 
Sweden/ 
Norway 
(57) 
 
UK 
 
(60)
 
USA 
 
(61) 
1p36 +        +  
3p24        +  + 
4p15 + +     +  +  
5qter + + + + +   +   
9p21 +     +  +   
11p11   +      +  
11qter    +    + +  
16q23      +   +  
17q21        + +  
18q23         + + 
19p13.3   +    +    
19p13.1     + +     
19q13.4   +      +  
a References are listed between brackets. 
 
When no obvious candidate genes are present in a candidate region obtained by 
linkage analysis, systematic fine-mapping using linkage disequilibrium has to be 
performed to narrow-down the number of possible candidates. The remaining positional 
candidate genes all become equally interesting, independent of their putative functions. 
Only genes with expression patterns inconsistent with the disease may be excluded as 
possible disease susceptibility genes, for example those not expressed in small intestine in 
case of coeliac disease. None of the regions showing linkage to coeliac disease have been 
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subjected to fine-mapping yet, except the 19p13.1 locus in our study (Chapter 4 and next 
section).  
 
Positional cloning of disease susceptibility genes 
Linkage analysis is very suitable for roughly localising complex disease susceptibility 
genes in the genome. However, candidate regions obtained by linkage analysis tend to be 
quite large and generally contain many genes. This is due to the fact that affected relatives 
share large parts of their genomes, in case of sibpairs even 50%. Therefore, shared 
regions around the disease gene are also large, as they have not yet been subjected to 
recombination, resulting in large candidate regions obtained by linkage analysis. When no 
obvious candidate genes are present in the candidate region, fine-mapping has to be 
performed to narrow-down the region and thereby the number of possible candidate 
genes. For this purpose, an LD mapping strategy is applied, which involves the search for 
shared segments around the causal variant. It is based on the hypothesis that a mutation 
event occurred on a certain genetic background. Numerous recombinations have reduced 
the region around this variant, but small regions are still shared between carriers of the 
variant. Therefore, not only the causal variant will show association with the disease, but 
also surrounding polymorphisms. Consequently, covering the candidate region with 
densely spaced polymorphisms in unrelated patients, either in a case-control or TDT 
design, and testing for association of each polymorphism with the disease will pinpoint 
the location that contains the causal variant.  
 LD mapping will be most successful for detecting common disease-causing 
variants. Common variants have relatively high frequencies in the population and they are 
shared by a large proportion of patients, which allows for association analysis to detect 
them. Furthermore, these variants are also likely to be present in different populations, 
resulting in identical disease associated alleles in different populations.86 On the other 
hand, multiple disease-causing mutations may have occurred in the same gene on 
different genetic backgrounds. This scenario results in the presence of multiple rare 
disease-causing variants, which are much harder to detect by association analysis.87 
Moreover, rare variants are more likely to be population-specific, with different disease-
causing alleles in different populations. Isolated populations are most suitable for 
detecting rare variants as they are likely to display less allelic diversity.88 Recently, LD 
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mapping following a linkage study proved to be successful for positional cloning of 
susceptibility genes in complex disorders. Common alleles of the CAPN10 and 
ADAM33 genes were shown to be associated with type 2 diabetes mellitus89 and 
asthma90, respectively. Different rare alleles of SNPs in the CARD15/NOD2 gene were 
identified as susceptibility alleles for Crohn’s disease.91 However, the rare alleles of the 
associated SNPs were mostly present on a shared, common background, which facilitated 
their detection by LD mapping.91,92 All three susceptibility genes were identified using a 
sequence-based map, in which mainly SNPs within genes were typed. 
 A slightly different strategy was used for fine-mapping of the candidate region for 
coeliac disease at 19p13.1. Our strategy was to use map-based polymorphisms (selected 
based on their relative positions) instead of sequence-based (selected based on their 
predicted effect on protein function).93 This strategy was based on the observation that 
LD seems to have a block-like structure.94 Therefore, one polymorphism in a haplotype 
block containing the causal variant would be sufficient to detect association. Recently, the 
haplotype block structure of chromosome 19 was published, showing that our candidate 
region resides in a region with low LD.95 The advantage of low LD is that the shared 
region around the causal variant will be rather small and this will facilitate the 
identification of the actual disease associated gene. On the other hand, a higher density of 
polymorphisms may be necessary to detect the association. However, this information 
was not yet available when the fine-mapping study was initiated and, therefore, we started 
by typing all available microsatellite markers followed by equally spaced SNPs. The 
haplotype block information can be used for selecting additional SNPs in genes in the 
region 3’ of MYO9B, by covering all haplotype blocks with at least one SNP and selecting 
more SNPs for regions with low LD. However, the haplotype block structure can differ 
substantially between populations so only information from closely related populations 
should be used.82 The results obtained so far indicate that the causal variant is located 
within the MYO9B gene region. The alleles of the five SNPs in the MYO9B gene that 
were significantly increased in patients formed a haplotype that was also significantly 
increased in patients. Next, the disease associated SNPs have to be typed in the affected 
sibpair cohort to indicate whether the disease associated haplotype in the case-control 
cohort explains the linkage in this region, provided that the affected sibpair cohort has 
sufficient power for this purpose. Likewise, excess transmission of the disease associated 
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haplotype in the parent-case trios may confirm the association. Overall, the 19p13.1 
region is the first to show systematic association in a coeliac disease candidate region 
identified by linkage analysis, and it provides the best chance so far for identification of a 
major non-HLA susceptibility gene for coeliac disease. 
Our LD mapping strategy also involved a DNA pooling approach as a quick 
initial screening tool. This seemed applicable as 30% of the chromosomes were estimated 
to carry a disease associated allele (based on the assumption that 60% of patients carry a 
dominant risk allele at the 19p13.1 locus (see also Chapter 4)). Detection of association 
should be easily made in DNA pools, assuming that all patients carry the same disease-
causing variant. However, association involving different rare variants may be missed. 
Indeed, the DNA pooling approach performed well, although some differences in 
significance levels were present between estimated and actual allele frequencies. One 
drawback of the DNA pooling approach is that only allele frequencies can be estimated. 
However, typing of single SNPs may not be sufficient to detect the association and 
haplotypes involving multiple SNPs will have to be constructed for which individual 
genotypes must be available. Therefore, DNA pooling can be applied as a quick tool for 
reducing the size of a candidate region, but single typing has to be performed within this 
smaller region to determine the disease-causing haplotype.  
When different variants in the disease-causing haplotype are in complete LD, 
genetic studies cannot provide any more information about the identity of the actual 
disease variant. From that point onwards, RNA and protein studies have to be performed 
with the candidate genes within the region. For the coeliac disease locus on 19p13.1, 
mRNA expression of the remaining candidate genes could be investigated in small 
intestinal tissue of patients and normal controls. Differences in mRNA levels or length of 
the transcripts may lead to recognition of the gene involved and to elucidation of the 
disease-causing mechanism. Furthermore, antibodies against the candidate proteins may 
exist and they can be used for determining the localisation and expression level of the 
protein in the small intestine of patients and controls. Once differences at the mRNA or 
protein level have been detected, it is necessary to identify which variant is responsible 
for this and whether this variant is also part of the disease associated haplotype. 
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Future prospects 
This project has provided important insights into the localisation of the major genes 
underlying coeliac disease in the Dutch population. Obviously, the next step is to identify 
and characterize the susceptibility gene in the 19p13.1 region. LD mapping has reduced 
the candidate region to approximately 150 kb containing only eight genes. Association 
analysis of additional SNPs in the genes 3’ of MYO9B may reduce the region even 
further. The gene density in the 150 kb candidate region is very high, so the disease 
associated haplotype is likely to contain multiple genes. In that case, mRNA studies may 
provide more information about the identity of the disease-causing gene. When the 
disease-causing gene is identified, its function will have to be determined and also its role 
in the disease pathogenesis. This will provide important new information about the 
pathways involved in coeliac disease. 
 In addition, it is important to test whether the MYO9B region is also associated 
with coeliac disease in other populations. The Dutch population is not an isolated 
population so the disease-causing variant may also be carried by patients from other 
European or North American populations, although it may confer a lower risk. 
Combining the results of such studies would facilitate the estimation of the 19p13.1 locus 
contribution to coeliac disease in general. 
The same LD mapping approach can be used for the candidate region at 6q21-22. 
However, the maximum lod score in this region was considerately lower than that of the 
19p13.1 region. Therefore, it may be harder to detect association in the current case-
control cohort. Increasing this cohort may be necessary to detect this locus. Another 
possibility is to include patients with type 1 diabetes mellitus as both diseases are likely to 
share part of their genetic background. The prevalence of coeliac disease is increased in 
patients with type 1 diabetes mellitus and linkage of this disease to 6q21 has been 
demonstrated in several data sets.49,96 The presence of association between a 
polymorphism and both diseases would support involvement of that region in 
autoimmune processes, even if significance levels are low. 
The genetic contribution to coeliac disease in Dutch patients cannot be explained 
completely by the action of the HLA-DQ, 19p13.1 and 6q21-22 loci. Several other genes 
with smaller genetic contributions are therefore expected to be involved as well. 
Promising loci are, for example, the CTLA4 gene and the 5qter region. However, the 
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current case-control and parent-case cohorts are unlikely to have sufficient power to 
detect loci with such small effects. International collaboration with other groups or with 
the European coeliac disease consortium may therefore be required to obtain a complete 
understanding of the genetic contribution eventually. 
 And finally, the question remains whether the coeliac disease patients will derive 
any benefit from the results obtained by this project? A genome-wide screen is just the 
beginning of the search for non-HLA susceptibility genes, and identification of these 
genes was therefore not to be expected. However, the 19p13.1 candidate region provides 
a very good opportunity for identification of a major gene and the identity of this gene is 
likely to be known in the near future. This may not only point to a new pathway involved 
in coeliac disease, but it may also provide new targets for possible therapeutic 
intervention. Furthermore, genotyping of the 19p13.1 disease-causing variant may assist 
in diagnosis of the disease, for example in patients presenting with minor lesions or those 
who are already on a gluten-free diet. In addition, it is important to know whether this 
gene confers different risks in DR3/3, 3/7 and 3/X individuals. This information could 
then be applied to design family and population screening strategies for the identification 
of individuals at high risk of developing coeliac disease. Such individuals could be 
subjected to regular clinical investigations in order to diagnose the disease at an early 
stage.  
 
References 
1. Csizmadia CG, Mearin ML, von Blomberg BM, Brand R, Verloove-Vanhorick SP. An 
iceberg of childhood coeliac disease in the Netherlands. Lancet 1999; 353: 813-4. 
2. Rostami K, Mulder CJ, Werre JM, et al. High prevalence of celiac disease in apparently 
healthy blood donors suggests a high prevalence of undiagnosed celiac disease in the 
Dutch population. Scand J Gastroenterol 1999; 34: 276-9. 
3. Nederlandse Coeliakie Vereniging (www.coeliakievereniging.nl). 
4. Maki M, Holm K, Lipsanen V, et al. Serological markers and HLA genes among healthy 
first-degree relatives of patients with coeliac disease. Lancet 1991; 338: 1350-3. 
5. Marsh MN. Gluten, major histocompatibility complex, and the small intestine. A 
molecular and immunobiologic approach to the spectrum of gluten sensitivity ('celiac 
sprue'). Gastroenterology 1992; 102: 330-54. 
6. Stenhammar L, Brandt A, Wagermark J. A family study of coeliac disease. Acta Paediatr 
Scand 1982; 71: 625-8. 
7. Rolles CJ, Myint TO, Sin WK, Anderson M. Proceedings: Family study of coeliac 
disease. Gut 1974; 15: 827. 
8. Stevens FM, Lloyd R, Egan-Mitchell B, et al. Reticulin antibodies in patients with coeliac 
disease and their relatives. Gut 1975; 16: 598-602. 
Chapter 9 
156 
9. Stokes PL, Ferguson R, Holmes GK, Cooke WT. Familial aspects of coeliac disease. Q J 
Med 1976; 45: 567-82. 
10. Vogelsang H, Wyatt J, Penner E, Lochs H. Screening for celiac disease in first-degree 
relatives of patients with celiac disease by lactulose/mannitol test. Am J Gastroenterol 1995; 
90: 1838-42. 
11. Mylotte M, Egan-Mitchell B, Fottrell PF, McNicholl B, McCarthy CF. Family studies in 
coeliac disease. Q J Med 1974; 43: 359-69. 
12. David TJ, Ajdukiewicz AB. A family study of coeliac disease. J Med Genet 1975; 12: 79-82. 
13. Sollid LM, Thorsby E. HLA susceptibility genes in celiac disease: genetic mapping and 
role in pathogenesis. Gastroenterology 1993; 105: 910-22. 
14. Petronzelli F, Bonamico M, Ferrante P, et al. Genetic contribution of the HLA region to 
the familial clustering of coeliac disease. Ann Hum Genet 1997; 61: 307-17. 
15. Alper CA, Fleischnick E, Awdeh Z, Katz AJ, Yunis EJ. Extended major 
histocompatibility complex haplotypes in patients with gluten-sensitive enteropathy. J 
Clin Invest 1987; 79: 251-6. 
16. Candore G, Lio D, Colonna Romano G, Caruso C. Pathogenesis of autoimmune 
diseases associated with 8.1 ancestral haplotype: effect of multiple gene interactions. 
Autoimmun Rev 2002; 1: 29-35. 
17. Bolognesi E, Dalfonso S, Rolando V, Fasano ME, Pratico L, Momigliano-Richiardi P. 
MICA and MICB microsatellite alleles in HLA extended haplotypes. Eur J Immunogenet 
2001; 28: 523-30. 
18. Louka AS, Moodie SJ, Karell K, et al. A collaborative European search for non-
DQA1*05-DQB1*02 celiac disease loci on HLA-DR3 haplotypes: analysis of 
transmission from homozygous parents. Hum Immunol 2003; 64: 350-8. 
19. Louka AS, Lie BA, Talseth B, et al. Coeliac disease patients carry conserved HLA-DR3-
DQ2 haplotypes revealed by association of TNF alleles. Immunogenetics 2003; 55: 339-43. 
20. Bolognesi E, Karell K, Percopo S, et al. Additional factor in some HLA DR3/DQ2 
haplotypes confers a fourfold increased genetic risk of celiac disease. Tissue Antigens 2003; 
61: 308-16. 
21. McManus R, Wilson AG, Mansfield J, Weir DG, Duff GW, Kelleher D. TNF2, a 
polymorphism of the tumour necrosis-alpha gene promoter, is a component of the celiac 
disease major histocompatibility complex haplotype. Eur J Immunol 1996; 26: 2113-8. 
22. de la Concha EG, Fernandez-Arquero M, Vigil P, et al. Celiac disease and TNF promoter 
polymorphisms. Hum Immunol 2000; 61: 513-7. 
23. Garrote JA, Arranz E, Telleria JJ, Castro J, Calvo C, Blanco-Quiros A. TNF alpha and 
LT alpha gene polymorphisms as additional markers of celiac disease susceptibility in a 
DQ2-positive population. Immunogenetics 2002; 54: 551-5. 
24. Congia M, Frau F, Lampis R, et al. A high frequency of the A30, B18, DR3, DRw52, 
DQw2 extended haplotype in Sardinian celiac disease patients: further evidence that 
disease susceptibility is conferred by DQ A1*0501, B1*0201. Tissue Antigens 1992; 39: 78-
83. 
25. Grimaldi MC, Clayton J, Pontarotti P, Cambon-Thomsen A, Crouau-Roy B. New highly 
polymorphic microsatellite marker in linkage disequilibrium with HLA-B. Hum Immunol 
1996; 51: 89-94. 
26. Kaur G, Sarkar N, Bhatnagar S, et al. Pediatric celiac disease in India is associated with 
multiple DR3-DQ2 haplotypes. Hum Immunol 2002; 63: 677-82. 
27. Mearin ML, Bouquet J, Mourad N, et al. HLA-DR antigens and phenotypes in Dutch 
coeliac children and their families. Clin Genet 1985; 27: 45-50. 
28. Ploski R, Ek J, Thorsby E, Sollid LM. On the HLA-DQ(alpha 1*0501, beta 1*0201)-
associated susceptibility in celiac disease: a possible gene dosage effect of DQB1*0201. 
Tissue Antigens 1993; 41: 173-7. 
General Discussion 
157 
29. Louka AS, Nilsson S, Olsson M, et al. HLA in coeliac disease families: a novel test of risk 
modification by the 'other' haplotype when at least one DQA1*05-DQB1*02 haplotype 
is carried. Tissue Antigens 2002; 60: 147-54. 
30. Karell K, Louka AS, Moodie SJ, et al. Hla types in celiac disease patients not carrying the 
DQA1*05-DQB1*02 (DQ2) heterodimer: results from the european genetics cluster on 
celiac disease. Hum Immunol 2003; 64: 469-77. 
31. Wahab PJ, Crusius JB, Meijer JW, Mulder CJ. Gluten challenge in borderline gluten-
sensitive enteropathy. Am J Gastroenterol 2001; 96: 1464-9. 
32. Tursi A, Brandimarte G. The symptomatic and histologic response to a gluten-free diet 
in patients with borderline enteropathy. J Clin Gastroenterol 2003; 36: 13-7. 
33. Farrell RJ, Kelly CP. Diagnosis of celiac sprue. Am J Gastroenterol 2001; 96: 3237-46. 
34. Mulder CJ. When is a coeliac a coeliac? Report of a working group of the United 
European Gastroenterology Week in Amsterdam, 2001. Eur J Gastroenterol Hepatol 2001; 
13: 1123-8. 
35. Walker-Smith JA. Revised criteria for diagnosis of coeliac disease. Report of Working 
Group of European Society of Paediatric Gastroenterology and Nutrition. Arch Dis Child 
1990; 65: 909-11. 
36. Fasano A. European and North American populations should be screened for coeliac 
disease. GUT 2003; 52: 168-9. 
37. Ventura A, Magazzu G, Greco L. Duration of exposure to gluten and risk for 
autoimmune disorders in patients with celiac disease. Gastroenterology 1999; 117: 297-303. 
38. Cellier C, Flobert C, Cormier C, Roux C, Schmitz J. Severe osteopenia in symptom-free 
adults with a childhood diagnosis of coeliac disease. Lancet 2000; 355: 806. 
39. Holmes GK, Prior P, Lane MR, Pope D, Allan RN. Malignancy in coeliac disease--effect 
of a gluten free diet. Gut 1989; 30: 333-8. 
40. Corrao G, Corazza GR, Bagnardi V, et al. Mortality in patients with coeliac disease and 
their relatives: a cohort study. Lancet 2001; 358: 356-61. 
41. Logan RF, Rifkind EA, Turner ID, Ferguson A. Mortality in celiac disease. 
Gastroenterology 1989; 97: 265-71. 
42. Rostami K, Kerckhaert J, Tiemessen R, von Blomberg BM, Meijer JW, Mulder CJ. 
Sensitivity of antiendomysium and antigliadin antibodies in untreated celiac disease: 
disappointing in clinical practice. Am J Gastroenterol 1999; 94: 888-94. 
43. Tursi A, Brandimarte G, Giorgetti GM. Prevalence of antitissue transglutaminase 
antibodies in different degrees of intestinal damage in celiac disease. Clin Gastroenterol 
2003; 36: 219-21. 
44. Fabiani E, Taccari LM, Ratsch IM, Di Giuseppe S, Coppa GV, Catassi C. Compliance 
with gluten-free diet in adolescents with screening-detected celiac disease: a 5-year 
follow-up study. J Pediatr 2000; 136: 841-3. 
45. Kumar P. European and North American populations should be screened for coeliac 
disease. GUT 2003; 52: 170-1. 
46. Sneeuw KCA, Brodin H, Broker M, et al. Screening for celiac disease in the Netherlands: 
estimation of costs and benefits. TNO report 2001. 
47. Moghaddam PH, de Knijff P, Schipper RF, et al. Selective co-evolution of the D6STNFa 
microsatellite region with HLA class I and II loci. Tissue Antigens 1998; 52: 213-9. 
48. Schipper RF, Schreuder GM, D'Amaro J, Oudshoorn M. HLA gene and haplotype 
frequencies in Dutch blood donors. Tissue Antigens 1996; 48: 562-74. 
49. Pociot F, McDermott MF. Genetics of type 1 diabetes mellitus. Genes Immun 2002; 3: 
235-49. 
50. Hogberg L, Grodzinsky E, Stenhammar L. Better dietary compliance in patients with 
coeliac disease diagnosed in early childhood. Scand J Gastroenterol 2003; 38: 751-4. 
Chapter 9 
158 
51. Greco L, Romino R, Coto I, et al. The first large population based twin study of coeliac 
disease. Gut 2002; 50: 624-8. 
52. Bevan S, Popat S, Braegger CP, et al. Contribution of the MHC region to the familial risk 
of coeliac disease. J Med Genet 1999; 36: 687-90. 
53. van Belzen MJ, Meijer JW, Sandkuijl LA, et al. A major non-HLA locus in celiac disease 
maps to chromosome 19. Gastroenterology 2003; 125: 1032-41. 
54. Zhong F, McCombs CC, Olson JM, et al. An autosomal screen for genes that predispose 
to celiac disease in the western counties of Ireland. Nat Genet 1996; 14: 329-33. 
55. Greco L, Corazza G, Babron MC, et al. Genome search in celiac disease. Am J Hum Genet 
1998; 62: 669-75. 
56. Liu J, Juo SH, Holopainen P, et al. Genomewide linkage analysis of celiac disease in 
Finnish families. Am J Hum Genet 2002; 70: 51-9. 
57. Naluai AT, Nilsson S, Gudjonsdottir AH, et al. Genome-wide linkage analysis of 
Scandinavian affected sib-pairs supports presence of susceptibility loci for celiac disease 
on chromosomes 5 and 11. Eur J Hum Genet 2001; 9: 938-44. 
58. Popat S, Bevan S, Braegger CP, et al. Genome screening of coeliac disease. J Med Genet 
2002; 39: 328-31. 
59. Woolley N, Holopainen P, Ollikainen V, et al. A new locus for coeliac disease mapped to 
chromosome 15 in a population isolate. Hum Genet 2002; 111: 40-5. 
60. King AL, Yiannakou JY, Brett PM, et al. A genome-wide family-based linkage study of 
coeliac disease. Ann Hum Genet 2000; 64: 479-90. 
61. Neuhausen SL, Feolo M, Camp NJ, Farnham J, Book L, Zone JJ. Genome-wide linkage 
analysis for celiac disease in North American families. Am J Med Genet 2002; 111: 1-9. 
62. Lander ES, Schork NJ. Genetic dissection of complex traits. Science 1994; 265: 2037-48. 
63. Glazier AM, Nadeau JH, Aitman TJ. Finding genes that underlie complex traits. Science 
2002; 298: 2345-9. 
64. Tabor HK, Risch NJ, Myers RM. Opinion: Candidate-gene approaches for studying 
complex genetic traits: practical considerations. Nat Rev Genet 2002; 3: 391-7. 
65. Todd JA. Interpretation of results from genetic studies of multifactorial diseases. Lancet 
1999; 354 Suppl 1: SI15-6. 
66. Kristiansen OP, Larsen ZM, Pociot F. CTLA-4 in autoimmune diseases--a general 
susceptibility gene to autoimmunity? Genes Immun 2000; 1: 170-84. 
67. Djilali-Saiah I, Schmitz J, Harfouch-Hammoud E, Mougenot JF, Bach JF, Caillat-
Zucman S. CTLA-4 gene polymorphism is associated with predisposition to coeliac 
disease. Gut 1998; 43: 187-9. 
68. Naluai AT, Nilsson S, Samuelsson L, et al. The CTLA4/CD28 gene region on 
chromosome 2q33 confers susceptibility to celiac disease in a way possibly distinct from 
that of type 1 diabetes and other chronic inflammatory disorders. Tissue Antigens 2000; 56: 
350-5. 
69. Popat S, Hearle N, Wixey J, et al. Analysis of the CTLA4 gene in Swedish coeliac disease 
patients. Scand J Gastroenterol 2002; 37: 28-31. 
70. King AL, Moodie SJ, Fraser JS, et al. CTLA-4/CD28 gene region is associated with 
genetic susceptibility to coeliac disease in UK families. J Med Genet 2002; 39: 51-4. 
71. Holopainen P, Arvas M, Sistonen P, et al. CD28/CTLA4 gene region on chromosome 
2q33 confers genetic susceptibility to celiac disease. A linkage and family-based 
association study. Tissue Antigens 1999; 53: 470-5. 
72. Popat S, Hearle N, Hogberg L, et al. Variation in the CTLA4/CD28 gene region confers 
an increased risk of coeliac disease. Ann Hum Genet 2002; 66: 125-37. 
73. Ueda H, Howson JM, Esposito L, et al. Association of the T-cell regulatory gene CTLA4 
with susceptibility to autoimmune disease. Nature 2003; 30: 30. 
General Discussion 
159 
74. van Belzen MJ, Mulder CJ, Pearson PL, Houwen RH, Wijmenga C. The tissue 
transglutaminase gene is not a primary factor predisposing to celiac disease. Am J 
Gastroenterol 2001; 96: 3337-40. 
75. Aldersley MA, Hamlin PJ, Jones PF, Markham AF, Robinson PA, Howdle PD. No 
polymorphism in the tissue transglutaminase gene detected in coeliac disease patients. 
Scand J Gastroenterol 2000; 35: 61-3. 
76. Roschmann E, Wienker TF, Gerok W, Volk BA. T-cell receptor variable genes and 
genetic susceptibility to celiac disease: an association and linkage study. Gastroenterology 
1993; 105: 1790-6. 
77. Roschmann E, Wienker TF, Volk BA. Role of T cell receptor delta gene in susceptibility 
to celiac disease. J Mol Med 1996; 74: 93-8. 
78. Yiannakou JY, Brett PM, Morris MA, et al. Family linkage study of the T-cell receptor 
genes in coeliac disease. Ital J Gastroenterol Hepatol 1999; 31: 198-201. 
79. Bouguerra F, Dugoujon JM, Babron MC, et al. Susceptibility to coeliac disease in 
Tunisian children and GM immunoglobulin allotypes. Eur J Immunogenet 1999; 26: 293-7. 
80. Boniotto M, Braida L, Spano A, et al. Variant mannose-binding lectin alleles are 
associated with celiac disease. Immunogenetics 2002; 54: 596-8. 
81. Risch N. Linkage strategies for genetically complex traits. II. The power of affected 
relative pairs. Am J Hum Genet 1990; 46: 229-41. 
82. Botstein D, Risch N. Discovering genotypes underlying human phenotypes: past 
successes for mendelian disease, future approaches for complex disease. Nat Genet 2003; 
33 Suppl: 228-37. 
83. Louka AS, Torinsson Naluai A, D'Alfonso S, et al. The IL12B gene does not confer 
susceptibility to coeliac disease. Tissue Antigens 2002; 59: 70-2. 
84. Louka AS, Stensby EK, Ek J, Gudjonsdottir AH, Ascher H, Sollid LM. Coeliac disease 
candidate genes: no association with functional polymorphisms in matrix 
metalloproteinase 1 and 3 gene promoters. Scand J Gastroenterol 2002; 37: 931-5. 
85. Moodie SJ, Norman PJ, King AL, et al. Analysis of candidate genes on chromosome 19 
in coeliac disease: an association study of the KIR and LILR gene clusters. Eur J 
Immunogenet 2002; 29: 287-91. 
86. Risch NJ. Searching for genetic determinants in the new millennium. Nature 2000; 405: 
847-56. 
87. Pritchard JK. Are rare variants responsible for susceptibility to complex diseases? Am J 
Hum Genet 2001; 69: 124-37. 
88. Wright AF, Carothers AD, Pirastu M. Population choice in mapping genes for complex 
diseases. Nat Genet 1999; 23: 397-404. 
89. Horikawa Y, Oda N, Cox NJ, et al. Genetic variation in the gene encoding calpain-10 is 
associated with type 2 diabetes mellitus. Nat Genet 2000; 26: 163-75. 
90. Van Eerdewegh P, Little RD, Dupuis J, et al. Association of the ADAM33 gene with 
asthma and bronchial hyperresponsiveness. Nature 2002; 418: 426-30. 
91. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat 
variants with susceptibility to Crohn's disease. Nature 2001; 411: 599-603. 
92. Vermeire S, Wild G, Kocher K, et al. CARD15 genetic variation in a Quebec population: 
prevalence, genotype-phenotype relationship, and haplotype structure. Am J Hum Genet 
2002; 71: 74-83. 
93. Peltonen L, McKusick VA. Genomics and medicine. Dissecting human disease in the 
postgenomic era. Science 2001; 291: 1224-9. 
94. Daly MJ, Rioux JD, Schaffner SF, Hudson TJ, Lander ES. High-resolution haplotype 
structure in the human genome. Nat Genet 2001; 29: 229-32. 
95. Phillips MS, Lawrence R, Sachidanandam R, et al. Chromosome-wide distribution of 
haplotype blocks and the role of recombination hot spots. Nat Genet 2003; 33: 382-7. 
Chapter 9 
160 
96. Holmes GK. Screening for coeliac disease in type 1 diabetes. Arch Dis Child 2002; 87: 
495-8. 
 
 
 
 
 
 
 
 
  
  
  
 
Summary 
 
 
 
 
Summary 
164 
Coeliac disease is a common food intolerance with a complex genetic aetiology. It is 
caused by ingestion of gluten peptides from wheat and related proteins from barley and 
rye in genetically susceptible individuals. The disease affects the small intestine and leads 
to abnormalities ranging from the infiltration of the villous epithelium by lymphocytes to 
total villous atrophy. Clinical symptoms include gastrointestinal complaints such as 
diarrhoea and abdominal pain but also fatigue, weight loss, anaemia, osteopenia, growth 
retardation and failure to thrive. Coeliac disease is treated by a life-long gluten-free diet; 
there is no drug therapy available. Complete understanding of the genetic factors 
underlying the disease will provide insight into the pathways involved in the disease and 
this will hopefully identify possible targets for development of a therapy. 
One important genetic factor contributing to coeliac disease is the human 
leukocyte antigen (HLA) DQ locus. The majority of patients are positive for DQ2, and 
almost all of the remaining patients are positive for DQ8. However, the contribution of 
the HLA region comprises at most half of the total genetic risk. Therefore, non-HLA 
genes must also play an important role in coeliac disease pathogenesis, but little is known 
about the location and identity of these genes. The results described in this thesis provide 
important new insights into the genetic background of coeliac disease in general and into 
the specific genetic factors underlying the disease in the Dutch population. 
 Chapter 2 describes the first localisation of susceptibility loci for coeliac disease in 
the Dutch population. A genome-wide screen was performed in a well-characterized set 
of affected sibpairs. Linkage analysis revealed the presence of two important non-HLA 
loci conferring a considerable risk to coeliac disease. The major locus was found to be 
located at chromosome region 19p13.1, which was the first to reach genome-wide 
significance in coeliac disease in an outbred population. The other susceptibility locus is 
located at chromosome region 6q21-22 and reached the threshold for genome-wide 
suggestive linkage. This region is also implicated in other autoimmune disorders and it 
may therefore harbour a general susceptibility gene for autoimmunity. Both the 19p13.1 
and 6q21-22 loci present novel susceptibility loci for coeliac disease. A second genome-
wide screen was performed in a four-generation family with 17 coeliac disease patients. 
The results, described in Chapter 3, showed that neither the chromosome 19p13.1 locus 
nor the chromosome 6q21-22 locus contributed significantly to the disease. Surprisingly, 
a third locus, located at chromosome region 9p21-13, was identified as the major locus in 
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this family. This locus had also been implicated in Scandinavian families with coeliac 
disease, and probably presents a locus with a small risk to coeliac disease in general. 
These results show that a single large family can provide a unique opportunity for 
mapping complex disease susceptibility genes with small effects in the general patient 
population. 
 Chapter 4 describes the systematic fine-mapping of the 19p13.1 candidate region, 
which has not been performed in any of the candidate regions found in other linkage 
studies in coeliac disease. The initial candidate region of 3 Mb, which contained 92 genes, 
was narrowed-down to 450 kb and only 12 genes by association analysis using 
microsatellite markers. Subsequent typing of single nucleotide polymorphisms (SNPs) in 
this region pinpointed the location of the gene to the final 150 kb of this region, with 
eight possible candidate genes left. Further research is necessary to determine the extent 
of the associated region and the identity of the disease-causing gene. The 19p13.1 region 
is the first candidate region identified by linkage analysis in which association is also 
present, providing the best opportunity so far for identifying a non-HLA susceptibility 
gene for coeliac disease. 
 Three functional candidate genes, located outside the two regions showing linkage 
to coeliac disease in the affected sibpairs, were tested for association (Chapters 5-7). The 
enzyme tissue transglutaminase modifies gluten peptides into epitopes with strong 
affinity for HLA-DQ2 and DQ8, resulting in a greatly enhanced T cell response. The 
gene encoding tissue transglutaminase (TGM2) was tested for association with coeliac 
disease and was excluded as primary factor in coeliac disease pathogenesis, as described 
in Chapter 5. The cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) has been 
implicated as a general susceptibility gene for autoimmunity. Chapter 6 describes the 
association analysis of the functional CTLA4 +49A/G polymorphism in a cohort of 
Dutch patients and controls. The CTLA4 gene was also excluded as a major 
susceptibility gene for coeliac disease, although a small effect of the homozygous GG 
genotype was observed. The cytokine interferon-γ (IFN-γ) plays an important role in the 
pathogenesis of coeliac disease. The CA-repeat in the IFNG gene, of which a certain 
allele was shown to be associated with high expression of IFN-γ, was tested for 
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association. Again, no evidence for a major contribution of this gene to coeliac disease 
risk was found, as described in Chapter 7.  
 Finally, the contribution of the HLA region was evaluated and this is described in 
Chapter 8. An extensive scan of the entire HLA region was performed in simplex coeliac 
disease and control families. Phase-known DQ2-positive haplotypes from patients were 
compared to control DQ2 haplotypes to determine whether there was evidence for the 
presence of an additional HLA risk locus. These results indicated that the contribution of 
the HLA region is mainly attributable to HLA-DQ2 and that a significant contribution of 
other HLA genes is unlikely. In addition, individuals homozygous for DQ2 or 
heterozygous for DQA1*05-DQB1*02/DQA1*0201-DQB1*02 were found to be at 
five-fold increased risk for development of coeliac disease. This risk is conferred by the 
presence of a second DQB1*02 allele next to a DQA1*05-DQB1*02 haplotype, and 
seemed to be independent of the second DQA1 allele.  
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Coeliakie (spreek uit: seuliakíé) is een veelvoorkomende voedselintolerantie met een 
complexe genetische achtergrond. Het wordt veroorzaakt door het eten van gluten 
eiwitten die voorkomen in tarwe, gerst en rogge. De ziekte tast het slijmvlies van de 
dunne darm aan, met afwijkingen variërend van de infiltratie van het darmepitheel door 
lymfocyten tot en met het totaal verdwijnen van de darmvlokken. Deze schade aan de 
dunne darm kan leiden tot diarree en buikpijn, maar ook tot chronische vermoeidheid, 
vermagering, bloedarmoede, botontkalking en een kort postuur. Er bestaat geen medicijn 
voor de behandeling van coeliakie en daarom moeten coeliakiepatiënten de rest van hun 
leven een strikt glutenvrij dieet volgen. Begrip van de genetische factoren die coeliakie 
veroorzaken zal meer inzicht geven in de processen die betrokken zijn bij de ziekte en dit 
zal hopelijk leiden tot nieuwe behandelingsmogelijkheden. 
 Een belangrijke genetische factor die bijdraagt aan coeliakie is het “human 
leukocyte antigen” (HLA) DQ locus. Een grote meerderheid van de coeliakiepatiënten 
draagt hiervan een bepaalde vorm: DQ2. Vrijwel alle DQ2-negatieve patiënten zijn 
positief voor DQ8. De bijdrage van het HLA gebied aan de totale genetische achtergrond 
van coeliakie bedraagt echter maximaal 50%. Daarom moeten er ook niet-HLA genen bij 
coeliakie betrokken zijn, maar er was vrijwel niets over deze genen bekend bij aanvang 
van dit onderzoek. De in dit proefschrift beschreven resultaten leveren een belangrijke 
bijdrage aan het inzicht in de genetische factoren die coeliakie veroorzaken, niet alleen 
voor de Nederlandse patiënten maar ook voor coeliakie in het algemeen.  
 In hoofdstuk 2 wordt de localisatie van de genen die betrokken zijn bij coeliakie 
in de Nederlandse bevolking beschreven. Een dergelijk onderzoek was nog nooit in 
Nederland uitgevoerd. Hiervoor werd een hele genoom screen uitgevoerd bij broers en 
zussen met bewezen coeliakie (“aangedane sibparen”). Broers en zussen delen gemiddeld 
50% van hun erfelijk materiaal, maar als ze beiden coeliakie hebben is het te verwachten 
dat ze 100% van de coeliakie veroorzakende genen zullen delen. Het gebied rondom zo’n 
gen zal ook gedeeld worden tussen de aangedane sibparen en dit gegeven wordt gebruikt 
om de coeliakie veroorzakende genen te localiseren. Een hele genoom screen houdt in 
dat het gehele erfelijke materiaal (genoom) op ongeveer 300 posities, die op een vaste 
afstand van elkaar liggen, wordt onderzocht. Op elke positie wordt dan bekeken of de 
aangedane sibparen meer dan de verwachte 50% van het DNA delen, wat een aanwijzing 
is dat daar een gen dat coeliakie veroorzaakt moet liggen. In de Nederlandse bevolking 
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blijken naast het HLA-DQ locus nog twee belangrijke genen voor te komen die beiden 
een aanzienlijke bijdrage leveren aan het risico op het ontwikkelen van coeliakie. Het 
eerste gen ligt op chromosoom 19 en het bewijs voor de aanwezigheid van een coeliakie 
veroorzakend gen in dit gebied is veel sterker dan voor enig ander gebied dat werd 
gevonden door één van de zeven andere genoom screens die wereldwijd zijn uitgevoerd 
bij families met coeliakie. Het tweede gen ligt op chromosoom 6 (buiten het HLA gebied) 
in een gebied dat ook betrokken is bij andere auto-immuun ziekten en het is daarom 
mogelijk dat dit gen betrokken is bij auto-immuniteit in het algemeen. Een tweede hele 
genoom screen werd uitgevoerd in een familie met 17 coeliakiepatiënten in vier 
generaties. Uit de resultaten, die in hoofdstuk 3 zijn beschreven, blijkt dat de genen op 
chromosoom 19 en 6 geen grote bijdrage leveren aan de ontwikkeling van coeliakie in 
deze uitzonderlijke familie. Het belangrijkste gen bleek op chromosoom 9 te liggen en dit 
gebied is ook betrokken bij coeliakie in Scandinavische coeliakiepatiënten. Dit gebied 
bevat waarschijnlijk een gen met een kleine bijdrage aan de ontwikkeling van coeliakie in 
de algemene bevolking. 
 In hoofdstuk 4 wordt de vervolgstudie van het chromosoom 19 gebied 
beschreven. Na de genoom screen was het kandidaatgebied nog behoorlijk groot en 
bevatte 92 genen, wat teveel is om allemaal te testen. Door middel van associatie analyse 
kon de kandidaatregio worden teruggebracht tot een gebied dat slechts acht genen 
bevatte. Verder onderzoek is noodzakelijk om aan te kunnen tonen welk van deze acht 
genen nu uiteindelijk coeliakie veroorzaakt. Het inperken van een kandidaatgebied voor 
coeliakie door middel van associatie analyse was tot nu toe nog nooit uitgevoerd. De 
behaalde resultaten bieden dan ook de beste kans ooit op het te identificeren van een 
belangrijk niet-HLA gen dat coeliakie veroorzaakt. 
 Drie functionele kandidaatgenen, die niet op chromosoom 6, 9 of 19 liggen, 
werden getest op hun mogelijke betrokkenheid bij coeliakie (hoofdstukken 5 t/m 7). 
Het enzym tissue transglutaminase kan gluten omzetten in een vorm die goed gebonden 
wordt door HLA-DQ2 en DQ8 eitwitten, wat leidt tot een sterk verhoogde T-cel reactie. 
Het gen dat codeert voor tissue transglutaminase werd onderzocht op associatie met 
coeliakie, wat beschreven wordt in hoofdstuk 5. Echter, het bleek dat dit gen kon 
worden uitgesloten als een gen dat coeliakie veroozaakt. Het gen dat codeert voor het 
“cytotoxic T-lymphocyte-associated” eiwit 4 (CTLA4) is betrokken bij verschillende 
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andere auto-immuun ziekten en is daarom ook een aantrekkelijke kandidaat voor 
coeliakie. Helaas bleek ook het CTLA4 gen geen grote rol te spelen in de ontwikkeling 
van coeliakie, wat beschreven wordt in hoofdstuk 6. Interferon-γ speelt in belangrijke rol 
bij de ontwikkeling van de schade aan de dunne darm bij coeliakie. Daarom werd ook het 
gen dat codeert voor interferon-γ getest op associatie met coeliakie en in het bijzonder 
één bepaalde variant die met hoge expressie van het interferon-γ eiwit geassocieerd is. In 
hoofdstuk 7 worden de resultaten beschreven en het bleek dat ook het interferon-γ gen 
niet betrokken is bij het ontstaan van coeliakie.  
 Tot slot werd de bijdrage van het HLA gebied onderzocht, wat beschreven is in 
hoofdstuk 8. Er werd een uitgebreid onderzoek van het HLA gebied uitgevoerd in 
families met één kind met coeliakie en in controle families met één kind zonder coeliakie. 
Het doel was te onderzoeken of er nóg een HLA gen betrokken is bij coeliakie, naast 
HLA-DQ2, maar hier kon geen bewijs voor worden gevonden. Wel bleek dat mensen die 
twee kopiën van DQ2 bezitten, of één DQ2 kopie plus een extra DQB1*02 variant, een 
vijf keer grotere kans hebben om coeliakie te krijgen dan mensen die maar één kopie van 
DQ2 bezitten. 
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